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Summary 
Neuroendocrine tumors of the small intestine (SI-NETs) have experienced a dramatic 
increase in incidence over the last three decades. Although defined by a small 
proliferative index (mostly G1 and G2 tumors), the tumors give frequently and early rise 
to metastases, which often exceed the size of the primary tumor and kill the patients in 
the end. 
SI-NETs are genetically poorly characterized, the frequent loss of one chromosome 18 
(Chr18) being the exception. Therefore, this doctoral thesis focused on this lesion in 
order to investigate potential tumor suppressors located on this chromosome (SMAD2, 
SMAD4, Elongin A3, CABLES, PMAIP1, and DCC). 
SMAD2 and SMAD4 showed retained expression in the 14 SI-NET samples 
investigated (12 with loss of Chr18), leaving only haploinsuffiency as possible 
mechanism in tumor development and progression. 
Elongin A3 and CABLES mRNAs were differentially expressed between the 1xChr18 
and 2xChr18 cohort, suggesting that the loss of Chr18 has an impact on mRNA level. 
However, western blot analysis of 21 SI-NETs revealed preserved protein expression of 
Elongin A3 and CABLES. Interestingly, CABLES western blot depicted – in addition to 
the normal doublet-isoform – an additional isoform at ~55 kDa in the tumor samples, 
which was not present in the HEK293 control. Among alternative splicing, aberrant 
splicing of this protein is known in tumors, which could lead to the loss of the CDK-
binding domain of CABLES, resulting in enhanced cell growth and tumor formation due 
to faster progression through the cell cycle [1].   
PMAIP1 was not expressed in eight samples investigated. Since a 100% loss of a 
tumor suppressor is rare, the hypothesis that the lack of PMAIP1 is a normal feature of 
normal neuroendocrine enterochromaffin cells is favored, rather than the loss being a 
characteristic of neuroendocrine tumor cells. 
Remarkably, the tumor suppressor protein DCC showed total loss or, at least, clearly 
reduced expression in nearly 30% (6/21) of the tumor samples. Abridged DCC function 
can result in reduced apoptosis, giving rise to tumor growth and dissemination. 
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Alternative splicing and mutations in the intronic region of DCC [2] render this gene 
even more interesting.  
Further investigations of our lab will focus on the transcriptome and proteome of SI-
NETs, and thereby on the differential expression of gene transcripts and proteins 
between tumors with and without loss of Chr18; hoping to shed light on the role of DCC 
(and CABLES), which we found to be altered in SI-NETs.  
In 2013, Banck et al. published the genomic landscape of SI-NETs with amplifications of 
the PI3K/AKT/mTOR pathway being the most frequent aberration [3]. Subsequently, we 
analyzed six genes (PDGFRα, PDGFRβ, PIK3CD, AKT1, AKT2, mTOR) involved in this 
pathway by FISH; revealing advanced, metastatic tumors as well as more invasive -
tumors to harbor significantly more copy number (CN) alterations than tumors of early 
stage without metastases and less invasive tumors (UICC and T stage comparison). 
However, no association with protein expression or activation could be identified. One 
possible explanation for the discrepancy between gene and protein expression might be 
that epigenetic events play a role in the transcriptional control of amplified genes, 
thereby preventing protein overexpression. 
Since especially the more aggressive tumors (defined by UICC stage IIIB and IV, as 
well as tumor stage 3 and 4) are lacking effective treatment, the inhibition of the   
PI3K/AKT/mTOR pathway could be a useful new tool in the therapy of SI-NETs. 
Therefore, a similar trial to the RADIANT-4 study [4] with the inclusion of functional 
gastrointestinal neuroendocrine tumors should enlighten the possible effect of 
everolimus or another inhibitor of the PI3K/AKT/mTOR pathway on the tumor 
progression.  
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Zusammenfassung 
Neuroendokrine Tumoren des Dünndarms (Dd-NET) haben über die letzten drei 
Dekaden einen drastischen Anstieg in der Inzidenz erfahren. Obwohl sie durch eine 
geringe Proliferation gekennzeichnet sind (größtenteils G1 und G2 Tumoren), bilden die 
Tumore häufig und früh Metastasen, die den Primärtumor in der Größe oftmals 
übersteigen und den Patienten schließlich töten. 
Dd-NET sind genetisch kaum charakterisiert; nur der häufige Verlust eines 
Chromosoms 18 (Chr18) ist bekannt. Aus diesem Grund beschäftigt sich die 
vorliegende Doktorarbeit mit dieser Läsion, um potentielle Tumorsuppressoren, die auf 
diesem Chromosom lokalisiert sind (SMAD2, SMAD4, Elongin A3, CABLES, PMAIP1 
und DCC), zu untersuchen. 
Die Analyse ergab, dass SMAD2 und SMAD4 in allen 14 untersuchten Dd-NET Proben 
(12 mit Chr18 Verlust) erhalten sind, sodass nur Haploinsuffizienz als möglicher 
Mechanismus in der Tumorentwicklung und –progression in Frage kommt. 
Elongin A3 und CABLES mRNA waren differenziell exprimiert zwischen der 1xChr18 
und der 2xChr18 Kohorte, was darauf hindeutet, dass der Verlust des Chr18 einen 
Einfluss auf das mRNA Level hat. In beiden Fällen zeigte die Western Blot Analyse von 
21 Dd-NET jedoch den Erhalt der Proteinexpression. Interessanterweise war im 
CABLES Western Blot zusätzlich zur normalen Isoform (erscheint als Doppelbande) 
eine Bande von 55 kDa in den Tumorproben nachweisbar, die in der HEK293 Kontrolle 
nicht vorhanden war. Neben alternativem Spleißing ist für dieses Protein auch 
aberrantes Spleißing in Tumoren bekannt, welches zum Verlust der CDK-Bindedomäne 
von CABLES führen und so in verstärktem Zellwachstum und Tumorformation aufgrund 
schnellerer Zellzyklusprogression resultieren kann [1].  
PMAIP1 war in den acht untersuchten Proben nicht exprimiert. Da ein 100%iger Verlust 
eines Tumorsuppressors ein seltenes Ereignis darstellt, wird die Hypothese favorisiert, 
dass die fehlende PMAIP1 Expression eine Eigenschaft einer normalen, 
neuroendokrinen Enterochromaffin-Zelle darstellt, als dass es sich hierbei um ein 
Charakteristikum einer neuroendokrinen Tumorzelle handelt. 
9 
 
Bemerkenswert war, dass das Tumorsuppressor-Protein DCC in fast 30% (6/21) der 
Tumorproben ganz verloren ist oder zumindest eine deutlich verringerte Expression 
zeigte. Die verminderte Funktion von DCC kann sich in verringerter Apoptose-Tätigkeit 
niederschlagen, was wiederum zu Tumorwachstum und Metastasierung führen kann. 
Alternatives Spleißing und Mutationen in der intronischen Region von DCC [2] machen 
das Gen noch interessanter.  
Weitere Untersuchungen unserer Arbeitsgruppe werden sich mit dem Transkriptom und 
Proteom von Dd-NET beschäftigten, genauer gesagt mit der differentiellen Expression 
von Gentranskripten und Proteinen zwischen Tumoren mit und ohne Verlust von Chr18. 
Dies soll näheren Aufschluss über die Rolle von DCC (und CABLES), bringen, für 
welche wir Aberrationen in dieser Tumorart nachweisen konnten. 
2013 wurde von Banck et al. die „genomische Landschaft der SI-NETs“ veröffentlicht, in 
denen Amplifikationen des PI3K/AKT/mTOR Signalwegs als die häufigste Alteration 
beschrieben wurde [3]. Darauffolgend haben wir sechs Gene, die in diesen Signalweg 
involviert sind (PDGFRα, PDGFRβ, PIK3CD, AKT1, AKT2, mTOR), mithilfe der FISH 
Technik analysiert. Fortgeschrittene, mit Metastasen assoziierte Tumoren, als auch 
invasivere Tumoren beinhalten signifikant mehr Kopienzahl-Alterationen als Tumoren 
früherer Stadien ohne Metastasierung und weniger invasive Tumoren (UICC und T 
Stadium Vergleich). Es konnte jedoch keine Assoziation mit Proteinexpression oder 
-aktivierung festgestellt werden. Eine mögliche Erklärung für diese Diskrepanz 
zwischen Gen- und Proteinexpression könnte eine epigenetische Kontrolle der 
Transkription amplifizierter Gene sein, die die Proteinüberexpression verhindert.   
Da vor allem für die aggressiveren Tumoren (durch die UICC Stadien IIIB und IV und 
die Tumorstadien 3 und 4 beschrieben) effektive Behandlungen fehlen, könnte die 
Inhibierung des PI3K/AKT/mTOR Signalwegs ein brauchbares, neues Werkzeug in der 
Therapie der Dd-NET sein. Eine mit der RADIANT-4 vergleichbare Studie [4], die 
funktionelle gastrointestinale neuroendokrine Tumoren einschließt, wäre geeignet um 
den möglichen Effekt von Everolimus oder einem anderen Inhibitor des 
PI3K/AKT/mTOR Signalwegs auf die Tumorprogression zu testen. 
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I. Introduction 
General aspects of neuroendocrine tumors (NETs) 
Neuroendocrine tumors (NETs, formerly known as “carcinoids”) are a heterogeneous 
group of neoplasms arising in the diffuse neuroendocrine system. The term 
neuroendocrine refers to two qualities of these cells: they share structural similarities 
with neurons and can produce hormones like endocrine cells. Although the tumors may 
arise in almost any organ, the majority develops in the pancreas or the gastrointestinal 
tract and are therefore referred to as gastroenteropancreatic NETs (GEP-NETs; Figure 
1) [5]. 
 
Figure 1: Distribution of NETs by anatomical site from the SEER 1973-2007 tumor registry database; modified according to [6] 
(GEP-)NET: (gastroenteropancreatic) neuroendocrine tumor, SEER: Surveillance, Epidemiology and End Results 
 
This work focuses on GEP-NETs; in detail on the small intestinal NETs (SI-NETs), 
which are located in the duodenum, jejunum, or (primarily) the ileum (Figure 2). SI-
NETs represent one-third of all GEP-NETs (Figure 1) and they are the most common 
malignancy in this part of the bowel.  
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Figure 2: Human gastrointestinal tract showing parts where GEP-NETs can arise 
http://www.cancer.gov/images/cdr/live/CDR741567-750.jpg 
 
Classification 
The WHO Classification 2010 of GEP-NETs [7] is based on the histological 
classification, including grading determined by the proliferative behavior of the tumors 
(Table 1) in combination with site-specific staging. Grade 1 (Ki-67 index ≤2%) and 
Grade 2 (Ki-67 index 3-20%) NETs are considered well-differentiated neuroendocrine 
tumors. Grade 3 (Ki-67 index >20%) neoplasms are poorly-differentiated carcinomas. 
The latter are divided in small and large cell neoplasms. Mixed adenoneuroendocrine 
carcinomas (MANECs) consist of both a neuroendocrine and an exocrine glandular 
phenotype (30% of each component at least). The neuroendocrine component may be 
well or poorly differentiated. 
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Table 1: Histopathological grading scale of NETs (WHO Classification 2010) 
The grading scale is based on proliferation. HPF: high-power field, +: positive, NET: neuroendocrine tumor, NEC: 
neuroendocrine carcinoma, MANEC: mixed adenoneuroendocrine carcinoma, ENETS: European neuroendocrine tumor 
society, WHO: World Health Organization 
Grade Mitotic count per 10 HPF % of cells Ki67+ ENETS/WHO definition 
G1 <2 ≤2 NET 
G2 2-20 3-20 NET 
G3 >20 >20 NEC 
   MANEC 
 
The proliferative grading has an important impact on the tumor specific overall survival. 
The 5-year survival rate of jejunoileal NET G1 tumors is 93.8%, of NET G2 83%, and of 
NET G3 50% [8]. 
The TNM (T: primary tumor, N: lymph node involvement, M: distant metastasis) staging 
differs between the different organs/organ parts due to site specific features. A recent 
publication emphasizes the heterogeneity of jejunal NETs, thereby supporting the 
distinction between “upper” and “lower” jejunal tumors [9]. The lower jejunal NETs are 
grouped with ileal NETs, resulting in the TNM classification described in Table 2. This 
grouping has an important prognostic impact since tumors of the lower jejunum and the 
ileum are associated with significant shorter survival than tumors of the upper jejunum 
and duodenum [9]. 
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Table 2: TNM classification of neuroendocrine tumors of the lower jejunum and ileum 
T: primary tumor, N: lymph node involvement, M: distant metastasis, AJCC-UICC: American Joint Cancer Committee-Union 
International Contre le Cancer 
T ENETS/AJCC-UICC classification 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
T1 Tumor invades mucosa or submucosa and has a size <1 cm 
T2 Tumor invades muscularis propria or size >1 cm 
T3 Tumor invades subserosa 
T4 Tumor invades serosa/other organs 
 For any T add (m) for multiple tumors 
N Regional lymph nodes 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastases 
N1 Regional lymph node metastases 
M Distant metastases 
MX Distant metastasis cannot be assessed 
M0 No distant metastases 
M1 Distant metastases 
 
Following the TNM classification, GEP-NETs (except appendiceal NETs) are classified 
into stages depicted in Table 3. The staging includes invasiveness and size of the 
primary tumor, and the involvement of lymph node / distant metastasis. 
Table 3: UICC-staging of GEP-NETs 
Stage Primary tumor Lymph node 
metastasis 
Distant metastasis 
Stage I T1 N0 M0 
Stage IIA T2 N0 M0 
Stage IIB T3 N0 M0 
Stage IIIA T4 N0 M0 
Stage IIIB any T N1 M0 
Stage IV any T N1 M1 
 
Comparable to the influence of the proliferative behavior on the survival rate, the 
staging has an impact on the tumor specific survival. The 5-year survival rate is 100% 
for stages I and II, 97.1% for stage III, and 84.4% for stage IV [8]. 
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Small intestinal NETs (SI-NETs) 
Incidence 
Neuroendocrine tumors of the gastrointestinal tract are considered to be rare tumors, 
representing only 2% of all gastrointestinal neoplasms. However, neuroendocrine 
tumors of the small intestine are the most common tumors of this part of the 
gastrointestinal system (Figure 1) [10], and have experienced a dramatic increase in 
incidence over the past three decades (Figure 3) [5].  
 
Figure 3: Increase in incidence of neuroendocrine tumors over the past three decades [5]  
(US population, Data from SEER database)  
 
2008, the incidence was 1.1/100,000 people per year with a 5-year overall survival (OS) 
of 62-71%, according to SEER data [11]. It is similar in male and female and peaks 
between the sixth and seventh decade.  
General aspects of SI-NETs 
SI-NETs arise mostly sporadic and are not associated with any inherited syndrome, 
(e.g. multiple endocrine neoplasia (MEN) types 1 and 2, von Hippel-Lindau disease, 
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and tuberous sclerosis [12], which can give rise to pancreatic NETs), although familial 
cases have been observed  [13]. 
They are mainly slow-growing tumors (Ki-67 index ≤2%), therefore classified as well 
differentiated G1 or G2 (Ki-67 index 3-20%) tumors. Despite their low proliferation rate, 
SI-NETs often present with lymph node and/or distant metastases at various sites (e.g. 
liver, lung, peritoneum, bones) at the time of diagnosis [13-15].  
Cells of well-differentiated neuroendocrine tumors have eosinophilic and granular 
cytoplasm. The nuclei often depict a typical “salt and pepper” pattern, referring to the 
chromatin. The growth pattern of the tumor cells depends on the site of origin. Ileal 
NETs mostly present with an insular pattern (type A) [16], but can also occur in 
trabecular (type B) or acinar (type C) pattern [17]. 
NETs are divided into functional and non-functional tumors. Functional tumors secrete 
hormones, which cause different clinical symptoms. SI-NETs are mostly functional 
tumors, arising from serotonin-producing enterochromaffin cells (EC) scattered 
throughout the digestive epithelium. The secretion of serotonin leads to the 
development of the so called “carcinoid” syndrome. It comes along with the “carcinoid 
triad” consisting of dry flushing, diarrhea, and cardiac involvement (Hedinger’s 
syndrome) [18]. This syndrome is often due to liver metastases hampering the 
inactivation of the secreted peptides which therefore reach the systemic circulation [19]. 
Figure 4 (A) depicts a neuroendocrine tumor at the ileocecal junction; Figure 4 (B) 
shows an immunohistochemical staining for serotonin in an ileal NET, which infiltrates 
the muscular layer. 
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Figure 4: Depiction of neuroendocrine tumors 
(A) Neuroendocrine tumor at the ileocecal junction (http://www.webpathology.com/). (B) A functional neuroendocrine 
tumor, which infiltrates the muscular layer and produces serotonin (brown IHC staining) [13]. 
 
Biological characteristics of (SI-)NETs 
Biological markers (biomarkers) are disease or patients’ characteristics which have 
prognostic or therapeutic impact. The National Institutes of Health (NIH) Biomarkers 
Definitions Working Group defined a biomarker as “a characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic 
processes, or pharmacologic responses to a therapeutic intervention” [20]. 
The most usable biomarkers are cell surface and/or secreted proteins. Other potential 
biomarkers which are expressed in the nucleus or cytoplasm are of limited use due to 
poor accessibility to clinical assays. The following markers are frequently used for 
prognostic or predictive implications in SI-NETs. 
a) Expression of chromogranin A 
One of the most widely used biomarkers in NETs is chromogranin A (CgA). CgA is a 
member of the chromogranin/secretogranin family of neuroendocrine secretory proteins. 
It is expressed in secretory vesicles of neurons and endocrine cells. The level of CgA 
correlates with tumor burden, indicating a worse prognosis [21]. CgA has a medium to 
high diagnostic sensitivity (60-90%), varying among different primary tumor locations 
[22]. However, it is not very specific for it is also elevated in a wide variety of benign 
diseases as well as other malignant tumors of non-neuroendocrine origin [23]. In the 
pathological diagnostics of NETs immunohistochemical staining of CgA, synaptophysin 
(b) and haematoxylin-eosin is routinely used [24]. 
a b 
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b) Expression of synaptophysin  
Synaptophysin is an integral membrane protein of small synaptic vesicles in endocrine 
cells [25]. Synaptophysin is regarded as the most specific marker of neuroendocrine 
differentiation, with a much higher sensitivity than CgA [26]. 
c) Secretion of serotonin and 5-HIAA 
Serotonin and its metabolite 5-HIAA are widely explored biomarkers for functional SI-
NETs. For a long time, the urinary levels were measured. Recently, a plasma-based 
method was developed, making the analysis faster and more convenient for the patients 
[27]. 5-HIAA shows a high specificity (100%), but only low sensitivity (35%) due to 
diverse expression [28]. Nuclear immunohistochemical positivity for serotonin is 
supportive for NETs of intestinal origin [24]. 
d) Expression of CDX2 
CDX2, a nuclear transcription factor, plays a crucial role in the regulation of intestine-
specific genes involved in cell growth and differentiation. It was found to be a useful 
marker for intestinal-type differentiation, rarely seen in other tumor types [29]. 
Furthermore, CDX2 is overexpressed in SI-NETs, independent of clinical stage or 
phenotype, suggesting it to be an early event in tumor development [30]. 
e) Expression of Somatostatin receptors (SSTR) 
Somatostatin receptors belong to the G-protein coupled receptor 1 family. Up to now, 
five subtypes of SSTR have been cloned and characterized (SSTR1, 2A, 3, 4, 5). 
SSTR2A seems to play a pivotal role in low grade NETs of the gastrointestinal tract 
[31]. The determination of SSTR expression is important for therapeutic considerations 
(see chapter Therapy). 
f) CD56 
CD56 (or Neural cell adhesion molecule – NCAM) is a glycoprotein expressed on 
neurons, natural killer cells and skeletal muscle cells; as well as on cells of the 
neuroendocrine system. It can be used as marker for tumors of the foregut or midgut 
with neuroendocrine phenotype [17]. However, CD56 is not specific for the 
neuroendocrine differentiation [32]; therefore it should always be used in combination 
with other neuroendocrine markers, such as CgA or synaptophysin.  
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g) Circulating tumor cells 
Recently, circulating tumor cells (CTCs) have become of increasing interest as 
biomarkers since the development of technology allows for detection in small samples 
of blood. The technology is based on the expression of the epithelial cell adhesion 
molecule (EpCAM). In 2013, Khan and colleagues reported 47% of patients with midgut 
NETs to have ≥2 detectable CTCs [33]. Their results were confirmed by another group 
[34]. However, since no significant association with therapeutic response could be 
found, the applicability of CTCs as effective biomarker in neuroendocrine tumors 
remains to be seen. 
Genetic characteristics 
a) Chromosomal aberrations 
The underlying genetic causes for the development of SI-NETs are still not fully 
understood. About 70% of SI-NETs display a (partial) loss of chromosome 18 [15, 35-
38]. Due to its high frequency it has been postulated that the loss of heterozygosity 
(LOH) / loss of chromosome 18 represents an early event in tumorigenesis. Other 
chromosomal aberrations such as gains of chromosome 4, 5, 7, 14, and 20 as well as 
(partial) loss of chromosome 3, 11, and 13 have been reported in SI-NETs (reviewed in 
[39]). Gain of chromosome 14 has been shown to be significantly associated with 
shorter survival [37]. Comparative analysis of the different studies led to the proposal of 
a molecular progression model for SI-NETs, subdividing the tumors in two groups 
(Figure 5) [39]. Following this model, most tumors arise from cells which have lost 
chromosome 18 (Chr18). In a subsequent step these tumors can also loose (parts) of 
chromosome 3, 11 or 13 and become metastatic (Figure 5, upper illustration). A smaller 
group of tumors is characterized by different chromosomal gains (Figure 5, lower 
illustration).  
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Figure 5: Subgrouping of SI-NETs by their chromosomal aberrations  [39] 
The majority of tumors is characterized by loss of Chr18, followed by additional losses of e.g. Chr3p, 11q, and 13 (upper 
illustration). In another, somehow smaller, group gains of Chr4, 5, 7, 14, and 20 were observed (lower illustration) 
 
The role of these frequent genetic aberrations for the tumor progression of SI-NETs has 
not yet been clarified.  
b) Chr18-associated tumor suppressors 
The loss of one Chr18 allele could possibly result in the partial loss of tumor suppressor 
genes located on Chr18, such as the well-known tumor suppressors SMAD2, SMAD4, 
DCC, and SERPINB5.  
SMAD2 and SMAD4 (both located on 18q21.1) encode important signal transduction 
molecules in the TGFβ pathway [40]. SMAD2 (together with SMAD3) is a receptor 
regulated SMAD molecule (so-called R-SMADs) which regulates this pathway. R-
SMADs become phosphorylated, thereby dissociating from the receptor. Due to 
phosphorylation these SMADs have a high affinity to so-called “Co-SMADs”, e.g. 
SMAD4. A complex of R-SMAD and Co-SMAD enters the nucleus, binds to 
transcription factors, subsequently promoting gene transcription. One main function of 
TGFβ signaling is the inhibition of cell proliferation and induction of apoptosis, 
identifying TGFβ as tumor suppressor. In contrast, a disturbed TGFβ signaling pathway 
can result in promotion of tumorigenesis by induction of epithelial-mesenchymal 
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transition (EMT), angiogenesis, and suppression of the immune system [41]. SMAD2 
and SMAD4 are known to be functionally inactivated in different types of cancers [42-
46].  
In 1990, DCC (18q21.3) was identified to be frequently deleted in colorectal carcinoma 
[47], a cancer, in which LOH on 18q is a frequent event in tumor progression. DCC 
encodes a netrin-1 receptor, which induces caspase-9-dependent apoptosis in the 
absence of netrin-1 [48]. Since SI-NETs are characterized by frequent metastases 
despite of a low proliferation index, reduced apoptosis could be an explanation for the 
progression of these tumors. 
Maspin (encoded by the gene SERPINB5, which is located on 18q21.33) has been 
shown to be deregulated (up- or downregulated) in a myriad of cancers. Intensive 
studies have shed light on the tumor suppressor function of Maspin by detecting 
reprogramming of the tumor proteome via Maspin expression, particularly of protein 
pathways involved in tumor cell extravasation [49]. To evaluate the role of Maspin in SI-
NETS, we did western blot analysis in eight tumor samples. No expression of Maspin 
could be detected in these tumors. However, double immunofluorescence staining with 
synaptophysin revealed that Maspin is also not expressed in neuroendocrine cells of 
the normal ileal mucosa ruling out this suspect [50]. 
Single point mutations or deletions/insertions in genes, especially tumor suppressors, of 
Chr18 regions that depict a LOH could result in a total loss of function. However, up to 
now, no mutations were found in SMAD2, SMAD4, DCC, as well as in other genes, 
located on Chr18 regions (e.g. SMAD7, ONECUT2, NEDD4L) which are frequently 
deleted in SI-NETs [35, 36, 38].  
Other proteins such as PMAIP1 (18q21.32) and CABLES (18q11.2) have been 
postulated to be candidate Chr18 encoded tumor suppressors. In 2008, PMAIP1 was 
identified as a potential tumor suppressor gene in pancreatic cancer by comparative 
cDNA microarray analysis [51]. PMAIP1 is a pro-apoptotic gene whose protein functions 
in a p53-dependent manner [52]. Therefore, loss of PMAP1 could result in a similar 
outcome as loss of DCC; namely deregulated apoptosis which could give rise to tumor 
progression due to the development of metastases.   
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CABLES is a cell cycle regulatory protein that plays a role in proliferation and 
differentiation [53]; the encoding gene was found to be silenced in ovarian, colorectal, 
endometrial, and non-small lung cancer [54-57]. In 2013, Zukerberg et al. reported that 
the (partial) loss of CABLES (detected by IHC) is also a frequent aberration in SI-NETs 
[58]. Interestingly, alternative as well as aberrant splicing has been described for 
CABLES, resulting in the expression of different isoforms, which can result in abridged 
protein function due to loss of important protein-protein interacting domains [59].  
Imprinted genes requiring only one mutational hit for inactivation are of special interest 
regarding potential tumor suppressor genes. TCEB3C (18q21.1), a maternally imprinted 
gene [60], functions as a transcription elongation factor and is hence an interesting 
tumor suppressor candidate [61]. TCEB3C encodes the protein Elongin A3, which is 
known to stimulate the rate of transcription elongation by RNA polymerase II. It was 
shown that the majority of SI-NETs harbor only one copy of TCEB3C and that this 
results in frequent downregulation of the protein in immunohistochemical experiments. 
However, some tumor samples with loss of one copy of TCEB3C depicted retained 
protein expression and three samples with two copies showed no protein expression 
[62].  
Taken together, the frequent loss of Chr18 is a suspicious event in the development of 
SI-NETs. It could result in downregulation of tumor suppressors located on Chr18. A 
second mutational hit (substitutions, InDels, LOH) then could lead to the loss of tumor 
suppressor function and thereby to tumor development and progression.     
c) PI3K/AKT/mTOR pathway 
Members of the PI3K/AKT/mTOR pathway (Figure 6) are known to be frequently altered 
in tumors, e.g. lung carcinomas, brain tumors, and colorectal cancer [63-65]. Banck and 
colleagues found that this is also true for SI-NETs with copy number changes in 29% of 
the analyzed cases [3]. They could show that PIK3CD, PDGFRα/β, AKT1/2, and mTOR 
were amplified in 8 to 17% of the tumors, using whole exome sequencing and array-
comparative genomic hybridization (aCGH). Amplifications in the PI3K/AKT/mTOR 
pathway could lead to constant activation, resulting in enhanced cell proliferation and 
survival, giving rise to tumor development and progression [66]. 
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Figure 6: A simplified overview of the PI3K/AKT/mTOR pathway [66] 
Platelet-derived growth factor receptors, alpha and beta polypeptide (PDGFRα and   
PDGFRβ) encode for cell surface tyrosine kinase receptors, which upon binding of its 
ligands spur a signaling cascade including activation of Phosphoinositide-3-kinases 
(PI3K), leading to cell proliferation and growth. Amplifications of PDGFRα have primarily 
been described in glioblastomas [64], but also in lung adenocarcinomas and lung 
squamous cell carcinomas [67]. PDGFRβ amplification has been described in choroid 
plexus carcinomas [68] and in sarcomatoid non-small cell lung cancer the amplifications 
have been linked to elevated protein expression [69]. 
PI3Ks phosphorylate PftdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to 
generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 is a key role player, 
which recruits PH domain containing proteins such as AKT1 to the membrane, thereby 
activating signaling cascades involved in cell growth, proliferation, survival, and motility. 
PIK3CD encodes the p110δ catalytic subunit belonging to the class I PI3Ks. mRNA 
overexpression of PIK3CD, but no amplification was reported in glioblastomas [70]. A 
second study also focusing on glioblastomas detected low level copy number gains of 
PIK3CD and PIK3CA without gene amplifications [71].  
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AKT1 and AKT2 are related genes encoding serine-threonine kinases, which are 
phosphorylated by PI3K at Thr308. AKT1 is ubiquitously expressed, whereas AKT2 is 
predominantly expressed in insulin-responsive tissues such as the liver [72]. Upon 
activation, the AKT proteins translocate to different subcellular compartments and the 
nucleus, where they regulate numerous cellular functions such as survival, growth, and 
cell cycle progression through phosphorylation of their target genes. 
Amplification/overexpression of AKT2 has been reported in different cancers such as 
non-Hodgkin’s lymphoma [73], pancreatic cancer [74], and hepatocellular carcinomas 
[75]. More recently, amplifications and, more commonly, polysomy of AKT genes were 
described in lung cancer [63].  
mTOR belongs to a family of phosphatidylinositol kinase-related kinases. mTOR builds 
complexes with other proteins, termed mTORC1 (with RPTOR and MLST8), which can 
be inhibited by the immunosuppressive drug rapamycin and mTORC2 (with RICTOR, 
MLST8, and mSIN1), which is resistant to rapamycin [76]. mTORC1 is responsible for 
the activation of S6K1 and 4E-BP1, which are two main downstream targets of mTOR. 
They function as translation enhancer and repressor, respectively. Activated S6K1 
phosphorylates ribosomal protein S6, which initiates protein synthesis. 
Unphosphorylated 4E-BP1 binds to eIF4E, thereby preventing the protein from docking 
to the mRNA with subsequent inhibition of the translation-initiation-complex. By 
phosphorylation, 4E-BP1 releases eIF-4E, which induces translation. It has been 
shown, that eIF-4E cooperates with other cancer genes to induce tumor formation, 
identifying the encoding protein as potential oncoprotein [77, 78]. Amplifications of 
mTOR have not been reported in cancers until now. However, it was recently shown, 
that another component of the mTOR complex mTORC2, RICTOR, is amplified in a 
subset of patients with lung cancer [79]. These patients might benefit from treatment 
with dual mTORC1/2 or PI3K/mTOR inhibitors, such as AZD2014 and BEZ235, as was 
shown by in vitro experiments.  
The constitutive activation of the PI3K/AKT/mTOR survival pathway by amplifications 
represents an attractive therapeutic target for many different cancers. Everolimus (RAD-
001) and temsirolimus (CCI-779) are two approved PI3K/AKT/mTOR inhibitory drugs, 
which target mTOR. Through the inhibition the synthesis of proteins involved in tumor 
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cell growth, proliferation, and survival is impaired. Many other anti-cancer drug targeting 
kinases of this and other pathways are in pre-clinical development [80]. Figure 7 shows 
the PI3K/AKT/mTOR pathway with the target sites of different inhibitory drugs. The 
identification of amplifications in SI-NETs could give rise to new possibilities for the 
treatment of these tumors. 
 
Figure 7: PI3K/AKT/mTOR pathway and the target sites for inhibitory drugs [81]  
PI3K, Akt, and mTOR can be inhibited (reversible or irreversible, indicated in red) by different drugs and mechanisms; PI(4)P, 
PI(4,5)P2, PI(3,4)P2, PI(3,4,5)P3: different phosphoinositides 
 
Epigenetic characteristics 
a) MicroRNAs 
MicroRNAs (miRNAs) are small (19-25 nt), non-coding RNAs, which function as gene 
regulators. They can act as oncogenes or tumor suppressors [82]. Li and colleagues 
found, that five miRNAs (miR-96, -182, -183, -196a, and -200a) are upregulated during 
tumor progression, whereas four miRNAs (miR-31, -129-5p, -133a, and -215) are 
downregulated [83]. 
The loss of Chr18 may result in downregulation of Chr18-related microRNAs involved in 
tumor progression. Similar effects on miRNA expression by chromosome loss have 
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been described for gastrointestinal stromal tumors in which the partial loss of 
chromosome 14 went hand in hand with the downregulation of 38 chromosome 14-
related miRNAs [84]. Therefore, we investigated 27 miRNAs located on Chr18 in a 
cohort of 20 SI-NETs (ten with, ten w/o loss of Chr18), revealing no significant 
difference in expression between the two cohorts [50]. 
b) Methylation 
Inactivation through methylation is another possible mechanism by which the tumor 
suppressor function can be lost. Intensive studies revealed methylation of CpG islands 
(covalent attachment of a methyl group at the 5’ position of cytosine residues in CG 
dinucleotides [85]) in the promoter region to result in downregulation of gene expression 
[86]. DNA methylation, leading to physical conformation changes, thereby preventing 
binding of regulatory proteins, works together with histone modifications and chromatin 
remodeling. The outcome of this interaction is transcriptionally repressed 
heterochromatin [86, 87]. 
In 2003, Chan et al. studied the CpG islands of 14 genes and loci (known to be 
frequently methylated in other gastrointestinal tumors) in seven SI-NETs (and other 
GEP-NETs) and associated normal mucosa [88]. They found that the CDKN2A gene 
isoform coding for p14ARF was methylated in 57% (4/7) of cases; in contrast, the 
adjacent normal mucosa was unmethylated. Liu and colleagues confirmed these 
results; in their cohort 69% (11/16) of ileal tumors were methylated. They also found the 
alternate isoform of CDKN2A, coding for p16INK4a, and RASSF1A to be methylated in 
25% (4/16) and 69% (11/16), respectively, whereas the adjacent normal tissue (if 
available) was not methylated [89]. Similar findings were reported by Fotouhi et al. [90]. 
p16INK4a functions as CDK4 kinase inhibitor, whereas p14ARF stabilizes p53 by 
interacting with the E3 Ubiquitin Ligase MDM2, which is responsible for the degradation 
of p53. RASSF1A normally inhibits accumulation of Cyclin D1, resulting in cell cycle 
arrest. Hence, all proteins described above play important roles in the cell cycle G1 
control and loss of their function will eventually result in abnormal cell cycle progression 
and thereby in enhanced cell proliferation and growth. 
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SERPINB5 is a controversial discussed tumor suppressor gene (see Genetic 
characteristics b) Chr18-associated tumor suppressors). Verdugo and colleagues 
reported SERPINB5 to be methylated in NETs, however, methylation status in the 
corresponding normal tissue was not applied [91]. 
Whereas hypermethylation is mostly a local phenomenon, hypomethylation is a global 
event in cancers [92]. Hypomethylation arises predominantly on highly repetitive DNA 
sequences, such as Alu and long interspersed elements (LINE)-1 [93, 94]. Choi and 
colleagues found that these two repetitive sequences are hypomethylated in a subset of 
“carcinoid” neuroendocrine tumors. LINE-1 methylation was associated with Chr18 loss, 
methylation of RASSF1A, and lymph node metastases [95]. 
A recent integrative genomic study, published by Karpathakis et al., identified molecular 
distinct subgroups of SI-NETs [96]. The biggest group comprised SI-NETs with loss of 
Chr18 and associated CpG island methylator phenotype (CIMP) negativity, whereas 
CIMP positivity was associated with absence of copy number variations (CNVs); 
indicating that aberrant global methylation and CNVs are mutually exclusive mutations 
in SI-NETs. 
Although the number of methylome studies rises, the translation to protein expression is 
often still missing.  
Therapy 
The only curative therapy for SI-NETs is removal of the primary tumor and the regional 
lymph node metastases. Unfortunately, this is only possible with 20% of patients [97]. 
Since SI-NETs are slow-growing tumors systemic chemotherapy is not applicable for 
most of the patients. 
Somatostatin analogues (SSA) can be given to patients with tumors expressing SSTRs. 
The highest affinity of SST analogues is to SSTR2A [98]. These drugs can help reduce 
the symptoms of the carcinoid syndrome. In addition, they can inhibit growth of NETs; 
only in rare cases the reduction of the tumor volume is seen [99]. For octreotide, a 
widely used SSA, the inhibitory function could be shown in the human midgut carcinoid 
tumor cell line CNDT2.5 [100]. However, patients may develop resistance to treatment 
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over time which is partially explained by upregulation of truncated SSTR5 variants in 
tumors [101].  
Radiolabeled SSA therapy or peptide receptor-mediated radiotherapy (PRRT) is 
another treatment possibility for inoperable and/or metastatic tumors which overexpress 
SSTR. Radionuclides target the SSTR-expressing tumor cells, get internalized, and 
thereby inhibit the growth of the tumor by destroying the cells through β- or γ-radiation. 
The most common used agents are 90Y-DOTATOC and 177Lu-DOTATAE. The side 
effects of PRRT are mostly mild and self-limiting [102].  
The RADIANT-2 study evaluated the effect of the mTOR inhibitor everolimus on 
progressive SI-NETs [103]. The median progression-free survival (PFS) was 16.4 
months with everolimus + octreotide in contrast to 11.3 months with placebo + 
octreotide. However, no statistical significance was reached (which was probably due to 
imbalanced informative censoring). Despite this, the study showed that a subgroup of 
patients with progressive SI-NETs may benefit from treatment with everolimus. The 
recently published RADIANT-4 study showed that 10 mg everolimus per day leads to 
significantly prolonged median progression-free survival by 7.1 months compared to the 
placebo control group in neuroendocrine tumors of the lung or gastrointestinal tract [97]. 
However, no functional NETs were included, so that the explanatory power for SI-NETs 
is still a minor one. 
In summary, the only curative therapy for SI-NETs, surgery, is only feasible in 1/5 of the 
patients. All other treatments can reduce the symptoms and prolong the overall survival, 
but unfortunately do not cure the patients and development of resistance can occur. In 
this regard, the necessity of new drugs which target tumor specific aberrations or 
pathways is obvious.    
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Preliminary work (working group Prof. Sipos) 
In preliminary experiments of the working group of Prof. Sipos the effect of the common 
loss of Chr18 in SI-NETs was addressed.  
In order to investigate the protein expression of the well-known tumor suppressors 
SMAD2, SMAD4, DCC, and Maspin immunohistochemical analyses were performed. 
DCC and SMAD2 were expressed in all 87 tumors investigated. SMAD4 was expressed 
in 97% (84/87) of the analyzed cases. However, since the staining results for these 
proteins were not perfectly convincible due to imperfect antibodies, the results have to 
be interpreted carefully. Therefore, western blot analysis was the method of choice for 
the protein investigation in my doctoral thesis, since more reliable antibodies were 
available for this method. 
Maspin was not expressed in any of the 87 tumor samples. Subsequent double 
immunofluorescence stainings of Maspin and synaptophysin of normal small intestine 
tissues adjacent to SI-NETs revealed neuroendocrine cells of the ileal mucosa to not 
express Maspin. This suggests that the lacking Maspin expression in neoplastic SI-NET 
cells does not reflect an oncogenic event but the phenotype of the non-neoplastic 
neuroendocrine cells of the mucosa of the small intestine. 
My master thesis focused on Chr18-related microRNAs (miRNAs) and their expression 
in SI-NETs. Therefore, we analyzed the expression of 27 miRNAs coded by regions on 
Chr18 in quantitative Real-time PCR experiments in an explorative cohort of 20 SI-
NETs (with and without loss of Chr18). As no expression differences between the two 
cohorts could be detected, one allele seems to be sufficient for the expression of the 
encoded miRNAs. 
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Aim 
Part 1: Alterations of Chr18-related tumor suppressors in SI-NETs 
The first part of my doctoral thesis addresses the frequent loss of Chr18 in SI-NETs. 
Therefore, protein expression of the Chr18-related tumor suppressors DCC, SMAD2, 
SMAD4, PMAIP1, Elongin A3, and CABLES was analyzed by western blot in a cohort of 
8-21 SI-NETs. In addition, mRNA expression of DCC, PMAIP1, TCEB3C (encoding 
Elongin A3), and CABLES was analyzed. The aim of this study was to investigate all 
known candidate tumor suppressors on Chr18 in view of tumor development. Next 
generation sequencing and SNP array analysis were performed to investigate 
alterations on DNA level, which could identify potential (new) tumor suppressors and 
oncogenes in SI-NETs. In summary, this comprehensive approach to define Chr18-
associated genetic alterations should help to improve the understanding of the 
molecular biology of SI-NETs. 
Part 2: Alterations of the PI3K/AKT/mTOR pathway in SI-NETs 
The second part of my doctoral thesis focuses on the PI3K/AKT/mTOR pathway in SI-
NETs. Since this pathway can be targeted by different FDA approved drugs, it is of 
special interest for tumor research. Banck and colleagues showed that this pathway is 
affected by copy number alterations in 29% of SI-NETs by performing next generation 
sequencing on 48 patients [3]. To take a deeper look at these alterations, Fluorescence-
in-situ-hybridization (FISH) analysis was applied to a greater cohort of 217 SI-NETs. Six 
genes belonging to the PI3K/AKT/mTOR pathway (PIK3CD, PDGFRα, PDGFRβ, AKT1, 
AKT2, and mTOR) were investigated in order to detect potential gene amplifications 
and the results were correlated with protein expression and activation of (p-)AKT, p-
mTOR, and the downstream signaling proteins p-S6 and p-4EBP1. Gene amplification 
and/or protein overexpression can be targeted by protein kinase inhibitors such as 
everolimus (an mTOR inhibitor), which is already approved for treatment of advanced 
and metastasized pancreatic NETs. 
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II. Material 
2.1 Equipment 
Table 4: Equipment 
Equipment Manufacturer 
Biofuge primoR (Heraeus) Thermo Fisher Scientific (Waltham, MA, US) 
CM1900 Leica Biosystems, Nussloch, DE 
Curix60 (X-ray film processor) Agfa (Stuttgart, DE) 
FlexCycler Analytik Jena AG (Jena, DE) 
Fluorescence microscope Axioplan 2 Carl Zeiss (Jena, DE) 
Genesis RSP 100 (Automated liquid handling 
system) 
Tecan Trading AG (Männedorf, CH) 
GeXP – Genetic Analysis System Beckman Coulter (Brea, CA, US) 
HybEZ oven Advanced Cell Diagnostics (Hayward, CA, US) 
Hyrax M55 (Microtom) Carl Zeiss (Jena, DE) 
Incubator NuAire-5510E Integra Biosciences (Fernwald, DE) 
Infinity (Gel documentation system) Vilber Lourmat (Eberhardzell, DE) 
Inverse Microscope for Cell culture Nikon Europe (Düsseldorf, DE) 
LightCycler 480 II Roche (Mannheim, DE) 
Microplate Reader Biorad (Hercules, CA, US) 
Microscope Carl Zeiss (Jena, DE) 
Microwave Severin (Sundern, DE) 
MiraxDesk (Scanner) Carl Zeiss (Jena, DE) 
Minispin Eppendorf (Hamburg, DE) 
NanoDrop2000 Thermo Fisher Scientific (Waltham, MA, US) 
Pipettes (10, 100,200, 1000) Eppendorf (Hamburg, DE) 
ThermoBrite Stat Spin Abbott Molecular (Abbott Park, IL, US) 
Thermomixer Comfort Eppendorf (Hamburg, DE) 
Tissue-Tek® slide stainer Sakura (Alphen aan den Rijn, NL) 
Tissue Microarrayer Beecher Instruments (Sun Prairie, WI, US) 
Ventana BenchMark System Ventana Medical Systems (Tucson, AZ, US) 
Vortex Genius 3 IKA (Staufen im Breisgau, DE) 
Waterbath GFL (Burgwedel, DE) 
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Table 5: Consumables 
Consumables Manufacturer 
Cell culture flasks T75 Sarstedt (Nümbrecht, DE) 
Centrifuge tubes (15 and 50 ml) Greiner (Frickenhausen, DE) 
Cover slips Menzel (Braunschweig, DE) 
Mini-PROTEAN® TGX™ Precast Polyacrylamide 
Gels 
Biorad (Hercules, CA, US) 
Pasteur pipettes Roth (Karlsruhe, DE) 
PCR Reaction tubes 0,2ml Sarstedt (Nümbrecht, DE) 
Pipette tips Starlab (Blakelands, UK) 
Reaction Tubes 0,5; 1,5 and 2 ml Eppendorf (Hamburg, DE) 
Serological pipettes 5; 10; 25; 50 ml  Sarstedt (Nümbrecht, DE) 
Feather Disposable Scalpels pfm medical (Köln, DE) 
SuperFrost Plus slides R.Langenbrinck (Emmendingen, DE) 
 
2.2 Software and Databases 
Table 6: Software and Databases 
Software Manufacturer 
Chromosome Analysis Suite Affymetrix (Santa Clara, CA, US) 
COSMIC http://cancer.sanDE.ac.uk/cosmic 
dbSNP http://www.ncbi.nlm.nih.gov/projects/SNP/ 
Ensembl http://www.ensembl.org/index.html 
Exome Variant Server http://evs.gs.washington.edu/EVS/ 
Genetic Analysis Software Beckman Coulter (Brea, CA, US) 
GraphPad Prism 4 GraphPad (La Jolla, CA, US) 
KEGG http://www.kegg.jp/ 
Pathway Maps http://lsresearch.thomsonreuters.com/maps/ 
PolyPhen-2 http://genetics.bwh.harvard.edu/pph2/ 
Primer-BLAST http://www.ncbi.nlm.nih.gov/tools/primer-
blast/ 
Primer3Plus http://primer3plus.com/cgi-
bin/dev/primer3plus.cgi 
PubMed http://www.ncbi.nlm.nih.gov/pubmed/ 
SIFT/PROVEAN http://sift.jcvi.org/ 
SPSS Statistics IBM (Armonk, NY, US) 
The Human Protein Atlas http://www.proteinatlas.org/ 
Tissue Studio XD 2.3.0 Definiens (München, DE) 
TMA Designer 2  Alphelys (Plaisir, Fr) 
UniProt http://www.uniprot.org/ 
 
45 
 
2.3 Chemical and biological reagents 
Table 7: Chemical and biological reagents 
Reagent Manufacturer 
0,25% Trypsin/EDTA Solution (1x) Gibco, Thermo Fisher Scientific (Waltham, MA, 
US) 
6x Loading Dye Fermentas (St. Leon-Rot, DE) 
Albumin Fraction V Roth (Karlsruhe, DE) 
Agarose Biozym (Hessisch Oldendorf, DE) 
Agencourt AMPure XP Beads Beckman Coulter (Brea, CA, US) 
Agencourt CleanSEQ Beckman Coulter (Brea, CA, US) 
Aqua Phenol pH 4,5 – 5 Roth (Karlsruhe, DE) 
BCA Protein Assay Reagent (bicinchoninic acid) Thermo Fisher Scientific (Waltham, MA, US) 
Boric acid Merck (Darmstadt, DE) 
Bovine Serum Albumine (BSA) Standards Thermo Fisher Scientific (Waltham, MA, US) 
β-Mercapthoethanol Merck Millipore (Darmstadt, DE) 
CAS block Thermo Fisher Scientific (Waltham, MA, US) 
CEP hybridization buffer Abbott Molecular (Abbott Park, IL, US) 
Chloroforme / IAA Roth (Karlsruhe, DE) 
Citric acid monohydrate Merck Millipore (Darmstadt, DE) 
cOmplete Tablets EDTA-free, EASYpack 
(Protease Inhibitor) 
Roche (Basel, CH) 
Cot-1 DNA (human) Invitrogen, Life Technologies, Thermo Fisher 
Scientific (Waltham, MA, US) 
Disodium phosphate Merck Millipore (Darmstadt, DE) 
DMEM, high glucose Gibco, Thermo Fisher Scientific (Waltham, MA, 
US) 
Dulbecco’s PBS (1x) GE Healthcare (Little Chalfont, UK) 
Ethylenediaminetetraacetic acid (EDTA) Merck Millipore (Darmstadt, DE) 
Ethanol Merck Millipore (Darmstadt, DE) 
Fetal calf serum (FCS) Invitrogen, Life Technologies, Thermo Fisher 
Scientific (Waltham, MA, US) 
F-12 Nutrient Mix Gibco, Thermo Fisher Scientific (Waltham, MA, 
US) 
GelRed Nucleic Acid Stain Biotium (Hayward, CA, US) 
GeneRuler 1kb DNA Ladder Fermentas (St. Leon-Rot, DE) 
Glycin Roth (Karlsruhe, DE) 
Glycogen Roche (Basel, CH) 
Immobilon Western Chemiluminescent HRP 
Substrate 
Merck Millipore (Darmstadt, DE) 
Isopropanol Merck Millipore (Darmstadt, DE) 
Methanol Merck Millipore (Darmstadt, DE) 
Monopotassium phosphate Roth (Karlsruhe, DE) 
Nonidet P 40 Substrate (NP-40) Sigma-Aldrich (St. Louis, MO, US) 
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Normal goat serum Cell Signaling (Danvers, MA, US) 
Papanicolaous Solution 1a Harris’ 
Haematoxylinsolution 
Merck Millipore (Darmstadt, DE) 
PageRuler prestained Protein Ladder Thermo Fisher Scientific (Waltham, MA, US) 
Papanicolaou Solution 1A Merck Millipore (Darmstadt, DE) 
Penicillin/Streptomycin Solution Lonza (Basel, AT) 
Pepsin Sigma-Aldrich (St. Louis, MO, US) 
Potassium chloride (KCl) Merck Millipore (Darmstadt, DE) 
ProLong® Gold Antifade mountant with DAPI Invitrogen, Life Technologies, Thermo Fisher 
Scientific (Waltham, MA, US) 
ProSieve QuadColor Protein Marker Lonza (Basel, CH) 
Proteinase K (50 mg/ml) Qiagen (Hilden, DE) 
Restore Western Blot Stripping Buffer Thermo Fisher Scientific (Waltham, MA, US) 
RNaseOUT™ Recombinant Ribonuclease 
Inhibitor 
Invitrogen, Life Technologies, Thermo Fisher 
Scientific (Waltham, MA, US) 
RnaseZap Invitrogen, Life Technologies, Thermo Fisher 
Scientific (Waltham, MA, US) 
RPMI1640 Gibco, Thermo Fisher Scientific (Waltham, MA, 
US) 
Skim Milk BD (Franklin Lakes, NJ, US) 
Sodium actetate 3M (NaAc) pH 5,2 Invitrogen, Life Technologies, Thermo Fisher 
Scientific (Waltham, MA, US) 
Sodium azide Sigma-Aldrich (St. Louis, MO, US) 
Sodium chlorid (NaCl) Merck Millipore (Darmstadt, DE) 
Sodium desoxycholat Roth (Karlsruhe, DE) 
Sodium dodecyl sulfate (SDS) Merck Millipore (Darmstadt, DE) 
Sodium fluorid (NaF) Merck Millipore (Darmstadt, DE) 
Sodium hydroxide (NaOH) Merck Millipore (Darmstadt, DE) 
Trisodium citrate dihydrate Roth (Karlsruhe, DE) 
Trizma Base Sigma-Aldrich (St. Louis, MO, US) 
Tween 20 Merck Millipore (Darmstadt, DE) 
Xylol BDH ProLabo (Darmstadt, DE) 
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2.4 Antibodies and FISH probes 
Table 8: Primary Antibodies 
 M: monoclonal, p: polyclonal, rb: rabbit, ms: mouse, g: goat, IHC: immunohistochemistry, WB: western blot 
Antibody Clone Dilution Manufacturer 
AKT2 (m, ms) F-7 1:100 (IHC) Santa Cruz (Dallas, TX, US) 
Anti IK3-1 / Cables1 (p, rb)  1:200 (WB) Biozol (Eching, DE) 
β-Actin (m, ms) AC-15 1:40.000 (WB) Sigma-Aldrich (St. Louis, MO, US) 
CDX2 (m, rb) EPR2764Y 1:25 (IHC) Zytomed (Berlin, DE) 
DCC (p, gt)  1:100 (WB) Santa Cruz (Dallas, TX, US) 
DCC (p, rb)  1:500 (WB) Biorbyt (Cambridge, UK) 
Elongin A3 (p, rb)  1:200 (WB) Santa Cruz (Dallas, TX, US) 
Ki-67 Antigen (m, ms) MIB-1 1:200 IHC Dako, Agilent Technologies 
(Santa Clara, CA, US) 
pHH3 (p, rb)  1:250 (IHC) Zytomed (Berlin, DE) 
PMAIP1 (p, rb)  1:250 (WB) Sigma-Aldrich (St. Louis, MO, US) 
p-AKT1 (Thr308) (p, rb)  1:200 (IHC) Santa Cruz (Dallas, TX, US) 
p-mTOR (Ser2448) (m, rb) 49F9 1:100 (IHC) Cell Signaling (Danvers, MA, US) 
p-S6 (Ser240/244) (m, rb) D68F8 1:138 (IHC) Cell Signaling (Danvers, MA, US) 
p-4E-BP1 (Ser65/Thr70) (p, 
gt) 
 1:400 (IHC) Santa Cruz (Dallas, TX, US) 
Serotonin (m, ms) SHT-H209 1:30 (IHC) Dako, Agilent Technologies 
(Santa Clara, CA, US) 
SMAD2 (m, rb) 86F7 1:1000 (WB) Cell Signaling (Danvers, MA, US) 
SMAD4 (m, ms) B-8 1:100 (WB) Santa Cruz (Dallas, TX, US) 
SSTR2 (p, rb)  1:100 (IHC) Zytomed (Berlin, DE) 
Synaptophysin (m, ms) Snp88 1:200 (IHC) DCS-Diagnostics (Hamburg, DE) 
 
Table 9: Secondary Antibodies  
IgG: Immunoglobulin G, HRP: Horseradish peroxidase, H+L: heavy + light chains 
Antibody Conjugation Dilution Manufacturer 
Streptavidin Alexa Fluor594 Streptavidin 1:500 Thermo Fisher Scientific (Waltham, 
MA, US) 
Goat anti rabbit IgG (H+L) HRP 1:3000 Thermo Fisher Scientific (Waltham, 
MA, US) 
Goat anti mouse IgG (H+L) HRP 1:3000 Thermo Fisher Scientific (Waltham, 
MA, US) 
Rabbit anti goat IgG (H+L) HRP 1:3000 Thermo Fisher Scientific (Waltham, 
MA, US) 
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Table 10: FISH probes 
Cen: Centromere, CEP: centromere enumeration probe 
FISH probe Fluorophore/Labeling Manufacturer 
AKT1/Cen14q Texas Red/FITC Abnova (Taipei, RC) 
AKT2/Cen19p Texas Red/FITC Abnova (Taipei, RC) 
Cen1 SpectrumGreen Metasystems (Altlussheim, DE) 
CEP18 SpectrumGreen Abbott Molecular (Abbott Park, IL, US) 
mTOR Biotin-labeled Custom made (CeGaT, Tübingen, DE) 
PDGFRA/Cen4p Texas Red/FITC Abnova (Taipei, RC) 
PDGFRB/PDGFRB (Split) Texas Red/FITC Abnova (Taipei, RC) 
PIK3CD Red 5’-ROX dUTP Empire Genomics (Buffalo, NY, US) 
 
2.5 Oligonucleotides 
Table 11: Oligonucleotides for the validation / falsification of mutations found by exome sequencing  
The product sizes incl. M13 primers are listed in parentheses 
Name Sequence Size 
ADCY5 M13 for 
ADCY5 M13 rev 
tgtaaaacgacggccagCTGGAAAGCCTGTCTCTGGG 
caggaaacagctatgacGCTGAGGGCTTCATGCTTTG 
165 bp (200 bp) 
ATF7IP M13 up 
ATF7IP M13 lo 
tgtaaaacgacggccagTTGGACAATGTACAGTCTAAACGTCGTCGATA 
caggaaacagctatgacAAGCTCAACCACTTTCTTCAAGTTCTTTCTTTC 
251 bp (286 bp) 
AUTS2 M13 for 
AUTS2 M13 rev 
tgtaaaacgacggccagGACATTCACCGGAGAGACCC 
caggaaacagctatgacGAGGGTCCACAGACAGCG 
172 bp (207 bp) 
BDP1 M13 for 
BDP1 M13 rev 
tgtaaaacgacggccagTGGTCAAGATGCCATGGGTT 
caggaaacagctatgacCCTCAGTGGTATATTCTTGACAGT 
182 bp (217 bp) 
CABYR for 
CABYR rev 
TGTGCCTGTGACTGAAGGAG 
TTGGGACTAACTCGTGGTGA 
138 bp 
CACNA1E M13 for 
CACNA1E M13 rev 
tgtaaaacgacggccagTTCCCTTAGTCATGGCCCTG 
caggaaacagctatgacTTTGTCTATCCAGGCACGGT 
168 bp (203 bp) 
CBLL1 for 
CBLL1 rev 
TAAAGGGGGTGAGCTGTTTG 
TGTGCATTACTCCAATAAAACATT 
150 bp 
CORO2A M13 for 
CORO2A M13 rev 
tgtaaaacgacggccagTGGTGTTGAAGGACATGGAGAG 
caggaaacagctatgacGCATCCTGGCCAGCATGTAA 
181 bp (216 bp) 
CYP3A5 M13 for 
CYP3A5 M13 rev 
tgtaaaacgacggccagCACCACCATTGACCCTTTGG 
caggaaacagctatgacTCTGTTTCTTTCCTTCCAGGC 
178 bp (213 bp) 
C1RL M13 for 
C1RL M13 rev 
tgtaaaacgacggccagTTAGCCAGCCCATCTCCATG 
caggaaacagctatgacACCGTCAGAATGAGTCCCAT 
174 bp (209 bp) 
C3ORF20 M13 for 
C3ORF20 M13 rev 
tgtaaaacgacggccagCATTTTTGGGGGCCGTGTTT 
caggaaacagctatgacCCTCATCCTGCGTGTTTCCT 
150 bp (185 bp) 
ERCC4 for 
ERCC4 rev 
GCTCGAGCAAGGGTTTATCA 
TGCACTTTAAATTTCCATACCAAA 
157 bp 
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FLNA for 
FLNA rev 
CTCCGAGTCTCTCCCAACTG 
CCTGTGTCCTGACTGGGACT 
161 bp 
HECTD4 for 
HECTD4 rev 
ACAGCAGCAAAGCCAAGTTT 
CATGGCCCTGCTCAATATCT 
160 bp 
ITGA7 for 
ITGA7 rev 
AGGTTGGTGACCATCAGCTC 
AATGGTAGGGGGAGGTGTTC 
131 bp 
ITGA9 for 
ITGA9 rev 
CACCAAAGGCAGATTCCAAA 
GCAGTAATGGTCACCCACCT 
132 bp 
KPNA1 for 
KPNA1 rev 
GCACCTGCAGTGTACAATTCTC 
TGGGGAAACAGAACCTAACC 
110 bp 
LAMA3 for 
LAMA3 rev 
CTACCAGCATTTGCCAGTGA 
ATGACAGGGTGTGCAGGTGT 
109 bp 
LAMA5 M13 for 
LAMA5 M13 rev 
tgtaaaacgacggccagCTCAGACGGGCAGTGAAGAG 
caggaaacagctatgacGTTCCCTGTCCAGTCACCTG 
191 bp (226 bp) 
LARP4 M13 for 
LARP4 M13 rev 
tgtaaaacgacggccagGGCTTAACATTACTAGTAAACAAACCA 
caggaaacagctatgacTCTGTGTCTGACTGGAAAGTGA 
189 bp (224 bp) 
MS4A14 M13 for 
MS4A14 M13 rev 
tgtaaaacgacggccagAGCTGCGTCACTCCAAGTTT 
caggaaacagctatgacTTGAGGGGGCAGGTCATTAG 
184 bp (219 bp) 
MTOR M13 for 
MTOR M13 rev 
tgtaaaacgacggccagAAGAGGTCCTGATGCAGTGC 
caggaaacagctatgacAGATGCTGCCTTTAGCCCAA 
165 bp (200 bp) 
MUC16 M13 for 
MUC16 M13 rev 
tgtaaaacgacggccagACTCATGGGTGAACTTGGACT 
caggaaacagctatgacCCTCCCCTACCATTGGAAGC 
185 bp (220 bp) 
MUM1L1 M13 for 
MUM1L1 M13 rev 
tgtaaaacgacggccagTGAGGCAAACATGAATTCTGAAAA 
caggaaacagctatgacCCGTGAAAGAACCACAACCTATTC 
185 bp (220 bp) 
MYO10 M13 for 
MYO10 M13 rev 
tgtaaaacgacggccagAGCTGCAGGGACTTGTTCTC 
caggaaacagctatgacTCGCCACAAAATGCAATCCA 
174 bp (209 bp) 
NFATC1 for 
NFATC1 rev 
AGGAAGAACACACGGGTACG 
ACGAACGAAAAGCTGAGAGC 
188 bp 
NFYA for 
NFYA rev 
AGGCTTCCGTCTCTCTCCTC 
CACTACCTGGAGGGTCTGGA 
190 bp 
 
OR1A1 M13 for 
OR1A1 M13 rev 
tgtaaaacgacggccagCCTAAGATGCTGGCCAACCA 
caggaaacagctatgacTTGTGTAGTGAAGTGGGCGG 
166 bp (201 bp) 
OR5T3 M13 for 
OR5T3 M13 rev 
tgtaaaacgacggccagTCCAGCTATGCTTCAGACCA 
caggaaacagctatgacTGTGAACTCTGACACTCAACA 
200 bp (235 bp) 
PIEZO2 for 
PIEZO2 rev 
CATTGTCTCTGGTGAGCGATA 
TGGGAAATTTGTCCGTGAAT 
187 bp 
PIK3C3 for 
PIK3C3 rev 
TTTCCTTGCTTGTGTAATAATTGTA 
TGGTTGGTGGATAACTCACA 
150 bp 
PML for 
PML rev 
AGCAGCAGTGAGTCCAGTGA 
TTAGAAAGGGGTGGGGGTAG 
166 bp 
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PRKCH M13 for 
PRKCH M13 rev 
tgtaaaacgacggccagGGTTCTCCCGCTGCGAAG 
caggaaacagctatgacTCACCGTCAGATAGGGGTCC 
197 bp (232 bp) 
RAD54B M13 for 
RAD54B M13 rev 
tgtaaaacgacggccagACCTGAATGTCAGTGGCTGG 
caggaaacagctatgacGCAGCAGATTGTTGATGGCT 
153 bp (188 bp) 
RB1CC1 M13 for 
RB1CC1 M13 rev 
tgtaaaacgacggccagTACAGACCTGTTGTTCCGCA 
caggaaacagctatgacGTCCTGCCATTGACTCTACCA 
174 bp (209 bp) 
RFC4 M13 for 
RFC4 M13 rev 
tgtaaaacgacggccagCTTACCCCGGCAATGTCTGT 
caggaaacagctatgacACAACTCTTTTCTCTTCAGGGAA 
150 bp (185 bp) 
SEMA3F for 
SEMA3F rev 
GCCACCCACTCATGTACCA 
CCCAGGAAAAGCACCTCATA 
142 bp 
SLC27A3 for 
SLC27A3 rev 
GGTGTCCACCAGGAAGATGT 
TACCCTGGAGGACTCACACC 
174 bp 
SMG5 M13 for 
SMG5 M13 rev 
tgtaaaacgacggccagTGTCCTTCAGGTGGAGACCA 
caggaaacagctatgacTCAGCATTGCCCAGTCTGAG 
165 bp (200 bp) 
SPANXN3 M13 for 
SPANXN3 M13 rev 
tgtaaaacgacggccagTCCCCACTGTCCTGTGAAGA 
caggaaacagctatgacACTCCATCAATCCAATCCAAAAG 
193 bp (228 bp) 
SVEP1 M13 for 
SVEP1 M13 rev 
tgtaaaacgacggccagGTGAGTTTTGGAGCACCGTG 
caggaaacagctatgacCGGGTTTGTCTTGCCAATGG 
179 bp (214 bp) 
SVIL M13 for 
SVIL M13 rev 
tgtaaaacgacggccagAGGCAGCCTGCTGGAAAAT 
caggaaacagctatgacAAGAAAGAATTGCCAGGCGC 
192 bp (227 bp) 
SYNPR M13 for 
SYNPR M13 rev 
tgtaaaacgacggccagCCCCAGACCAGTTCCCTGAT 
caggaaacagctatgacCCAGTGGCTGCTCAGTATTACA 
192 bp (227 bp) 
USP44 for 
USP44 rev 
GTAACCACGAAAGGCAGGAA 
GTGGTGGAGCATCAAAAGGT 
188 bp 
USP48 for 
USP48 rev 
TGGAAAACTGCTTTACCTGGA 
CCAAGTGTGGCAAAGGAACT 
115 bp 
XBP1 M13 for 
XBP1 M13 rev 
tgtaaaacgacggccagACCCTCATCTGTCTAGTTAGGGA 
caggaaacagctatgacCAGCACTCAGACTACGTGCA 
196 bp (231 bp) 
ZNF280B M13 for 
ZNF280B M13 rev 
tgtaaaacgacggccagACATGTTCCACACCAACAAAGA 
caggaaacagctatgacGAAGCATTGGGACTTGTGGC 
163 bp (198 bp) 
ZNF555 M13 for 
ZNF555 M13 rev 
tgtaaaacgacggccagGCAAACAGTGTGGGAAGACC 
caggaaacagctatgacCAGTGTGCACCCTCATGTGT 
150 bp (185 bp) 
M13 for 
M13 rev 
tgtaaaacgacggccag 
caggaaacagctatgac 
35 bp 
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Table 12: Oligonucleotides for the sequencing of all functional regions of the PML gene 
Name Sequence Size 
PML Ex 1 for 
PML Ex 1 rev 
TCCCCTTCAGCTTCTCTTCA 
CCATCATCCCCTAACCCAAT 
219 bp 
PML Ex 2.1 for 
PML Ex 2.1 rev 
GACTTCTCCAGGCCTCACCT 
GCTGCAGACTCTCGAAAAAGA 
249 bp 
PML Ex 2.2 for 
PML Ex 2.2 rev 
CATGCAGTGCCCCATCTG 
CTCGTGCTTGAGGAACCACT 
232 bp 
PML Ex 2.3 for 
PML Ex 2.3 rev 
CTCTGCGCCAAGTGCTTC 
CGCCCTCTACCTGGTACTTG 
218 bp 
PML Ex 3.1 for 
PML Ex 3.1 rev 
GAGTCCTAACCCAGGCCAAC 
CCAAAGGCACTATCCTGCTC 
197 bp 
PML Ex 3.2 for 
PML Ex 3.2 rev 
ACATCAGCGCAGAGATCCAG 
GTCCACAGCCTCCAGCAG 
224 bp 
PML Ex 3.3 for 
PML Ex 3.3 rev 
GCCAGGTGGTAGCTCACG 
AGGAAACCGTGCATGTCC 
205 bp 
PML Ex 3.4 for 
PML Ex 3.4 rev 
CAGAGGATGAAGTGCTACGC 
TTCCCTAGGGTGCAGCAG 
240 bp 
PML Ex 4 for 
PML Ex 4 rev 
TGCCTGTGACCTTCTTTGTG 
ACTCACAACCTGCCTGACCT 
163 bp 
PML Ex 5 for 
PML Ex 5 rev 
GGCTGCTGCCTAGTCATTTC 
GGAACTCAGGCCTTCAGGAG 
237 bp 
PML Ex 6.1 for 
PML Ex 6.1 rev 
ACCTGACCTGGCTCTGTGAC 
GTGAGACTGCCTTGGAGGTG 
190 bp 
PML Ex 6.2 for 
PML Ex 6.2 rev 
GGAAGGTCATCAAGATGGAGTC 
CCACTGCCCTACCCACCT 
225 bp 
PML Ex 7 for 
PML Ex 7 rev 
AGCATGCATCCTAGGCAGTT 
CTGAGAGTCACCTGCTGTGG 
188 bp 
PML Ex 8 for 
PML Ex 8 rev 
TGACGCTTGGTTTTTCTGTG 
TTAGAAAGGGGTGGGGGTAG 
213 bp 
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Table 13: Oligonucleotides for the analysis of potential Chr18-associated tumor suppressor genes by quantitative Real-time 
PCR (qRT-PCR) 
ACTB is a housekeeper gene and served as normalization control for qRT-PCR analysis. 
Name Sequence Size 
ACTB for 
ACTB rev 
accagcttttctgcaagtgc 
gtttgaggcctgttgctgtg 
116 bp 
CABLES Ex4 for 
CABLES Ex5 rev 
tgccgtatcgcgacagtac 
ctttcaaactcactgcaccagt 
81 bp 
DCC Ex3 for 
DCC Ex4 rev 
acaggaaatgaagcagaagtcag 
acattggatggtctttgcaga 
83 bp 
DCC Ex17 for 
DCC Ex18 rev 
accagcttttctgcaagtgc 
gtttgaggcctgttgctgtg 
76 bp 
PMAIP1 Ex1 for 
PMAIP1 Ex2 rev 
gcaagaacgctcaaccgag 
tgtctccaaatctcctgagttg 
84 bp 
TCEB3C for 
TCEB3C rev 
gcaaggggcacaaatcgtc 
ctgcagcctctctgactgg 
80 bp 
 
2.6 Kits 
Table 14: Commercial Kits 
Kit Manufacturer 
DAB Substrate Kit Zytomed (Berlin, DE) 
Goat-on-rodent HRP Polymer Kit Zytomed (Berlin, DE) 
High-Capacity cDNA Reverse Transcription Kit Thermo Fisher Scientific (Waltham, MA, US) 
iView DAB Detection Kit Ventana Medical Systems (Tucson, AZ, US) 
QIAamp DNA FFPE Tissue Kit Qiagen (Hilden, DE) 
QuantiTect SYBR Green PCR Kit Qiagen (Hilden, DE) 
ZytoChemPlus HRP Polymer Kit Zytomed (Berlin, DE) 
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2.7 Buffer 
Table 15: Buffer  
Buffer Composition 
Ammonia-ethanol 400 ml 70 % EtOH 
12 ml NH3 
Citrate Buffer (10x, pH 6) 29,4 g Trisodium citrate dihydrate  
ad 1 l ddH2O 
Denaturation Solution (FA/2xSSC, pH 7-8) 70 ml Formamide 
10 ml 20xSSC, pH 5,3 
ad 100 ml ddH2O 
PBS (10x, pH 7,4) 80 g NaCl 
2 g KCl 
14,2 g Disodium phosphate 
2 g Monopotassium phosphate 
ad 1 l ddH2O 
Pepsin Buffer (0,9% NaCl pH 2) 0,9 g NaCl 
ad 100 ml ddH2O 
RIPA Buffer 15 ml NaCl (5 M) 
5 ml NP-40  
2,5 g Sodium desoxycholat (0,5%) 
0,5 g SDS (0,1%) 
25 ml Tris (1M) 
2 ml EDTA (0,5M) 
1,05g NaF 
ad 500 ml ddH2O 
Running Buffer (5x) 15 g Tris 
72 g Glycin 
5 g SDS 
TBS Buffer (10x, pH 7,6) 24,2 g Tris 
80 g NaCl 
ad 1 l ddH2O 
TEC Buffer (10x, pH 9) 2,5 g Tris 
5g EDTA 
3,2 g Trisodium citrate dihydrate 
ad 1 l ddH2O 
Transfer Buffer (10x) 30,3 g Tris  
144 g Glycin 
ad 1 l ddH2O 
Transfer Buffer (1x) 100 ml 10x Transfer Buffer 
200 ml Methanol 
700 ml ddH2O 
Tris-Borate-EDTA-(TBE-) Buffer (1x) 54 g Tris 
28,4 g Boric acid 
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3,7 g EDTA 
ad 5 l ddH2O 
TS-TMBSA 5 ml Tris-HCl 
15 ml NaCl 
500 µl Tween 20 
25 g Skim Milk 
10 g BSA 
5 ml Sodium azide 
ad 0,5 l ddH2O 
SDS Loading Buffer Leammli (2x) 2 ml Tris-HCl 
400 mg SDS 
20 mg Bromphenol blue 
2 ml Glycerol 
ad 10 ml ddH2O 
SDS-Lysis Buffer (5x) 2,5 ml 1 M Tris/HCL pH 8,0 
50 µl 0,5 M EDTA 
25 ml 20 % SDS 
22,45 ml RNase/Dnase free H2O 
Saline Sodium Citrate (SSC) Buffer (20x, pH 
7,4) 
175,32 g NaCl 
88,23 g Na-Citrat 
ad 1 l ddH2O 
Wash Buffer for FISH in general 100 ml 20xSSC, pH 5,3 
ad 1 l ddH2O 
Wash Buffer for Post-Hybridization (0,3% NP-
40/2xSSC) 
100 ml 20xSSC, pH 5,3 
3 ml NP-40 
ad 1 l ddH2O 
Wash Buffer for Western Blot 1x TBS Buffer 
0,05% Tween 20 
 
Table 16: Cell lines/tissues used as controls for western blot analysis 
Kit Control for Manufacturer 
BxPC-3 SMAD4 (negative) NCI-60 
HEK293 CABLES (positive) ATCC 
IMR-32 DCC (positive) ATCC 
K562 SMAD2 (positive) NCI-60 
Kidney tissue Elongin A3 (positive) Institute of pathology, 
Tuebingen 
NIH/3T3 SMAD4 (positive) ATCC 
U251 PMAIP1 (positive) NCI-60 
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III. Methods 
 
3.1 Clinical Samples 
Formalin-fixed, paraffin-embedded (FFPE) tumor specimens of 217 SI-NETs (135 
patients) were retrieved from the surgical pathology files of the Institutes of Pathology of 
Tuebingen, Munich, Duesseldorf, and Marburg. Ethical approval was obtained from the 
local ethics committee at the University Hospital, Tuebingen (469/2010BO2). The 
collective comprised 128 primary tumors, 73 lymph node metastases, and 16 distant 
metastases. For 60 patients, primary tumors and matching lymph node metastases 
were available. Matching triplets of primary tumors, lymph node, and distant metastases 
as well as matching pairs of primary tumors and distant metastases were available for 
seven patients, respectively. For one patient lymph node and distant metastasis were 
available, but no primary tumor. 
Nine fresh frozen tumors (five primary tumors, two matching metastases, and two non-
matching metastases from the Institutes of Pathology of Munich and Kiel were used for 
Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, US). Five of these 
samples (two primaries and three non-matching metastases and corresponding normal 
tissue) were further used for exome sequencing (CeGaT, Tuebingen, DE). For western 
blot analysis up to 21 fresh frozen samples from the Institutes of Pathology of 
Tuebingen, Bad-Berka, Graz, and Marburg were used.  
3.1.1 Staging of neuroendocrine tumors of the ileum  
The SI-NET samples were staged following the TNM criteria defined by the AJCC-UICC 
and grouped into defined UICC-stages (Appendix Table 26). In addition, the patients 
were grouped into cohorts, depending on the absence/presence of lymph node/distant 
metastases at time of diagnosis: 
Cohort 1: no lymph node or distant metastases at time of diagnosis 
Cohort 2: lymph node metastases at time of diagnosis 
Cohort 3: lymph node and distant metastases at time of diagnosis 
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3.2 HE staining 
Hematoxylin and eosin (HE) staining of a representative section was carried out using 
an automated Tissue-Tek® slide stainer (Sakura, Alphen aan den Rijn, NL) and 
histologically characterized by a pathologist (Prof. Bence Sipos) to determine the tumor 
areas of interest. 
3.3 Tissue Microarray  
Eight tissue microarrays (TMAs) were designed using the FFPE samples described in 
3.1 Clinical Samples.  
The construction of TMAs was performed as described elsewhere [104]. In short, 1 mm 
sized tissue biopsies were extracted from the paraffin donor blocks and transferred into 
pre-punched holes as duplicates (TMA 6-8) / triplicates (TMA 11-14) on recipient 
paraffin blocks with a tissue microarrayer (Beecher Instruments, WI, US) equipped with 
a TMA booster (Alphelys, Plaisir, France). Grid layouts for the TMAs were designed 
with the TMA Designer 2 software (Alphelys, Plaisir, France). The recipient blocks were 
sealed for 10 min at 56°C and 30 min at 4°C. This procedure was repeated twice. The 
TMA blocks were cut into 3/3.5 µm sections and placed on SuperFrost Plus slides 
(Langenbrinck, Emmendingen, DE) for immunohistochemical and fluorescence-in-situ-
hybridization analyses, respectively. 
TMA 6-8 comprised only primary tumors. TMA 6 consisted of cohort 1 tumors, TMA 7 of 
cohort 2 and TMA 8 of cohort 3 tumors, respectively. TMA 11.1 and 11.2 comprised 
mostly primary tumors - but also some metastases - of patients with follow up data. 
TMA 12 included lymph node metastases corresponding to primary tumors of cohort 2 
(TMA 7). TMA 13 included lymph node and distant metastases corresponding to 
primary tumors of cohort 3 (TMA 8). Finally, TMA14 consisted of metastases (and some 
primary tumors) corresponding to the tumors on the follow up TMAs 11.1 and 11.2. 
3.4 DNA Extraction 
For the extraction of DNA, fresh frozen and FFPE tissue samples of SI-NET specimens 
were cut into 8 µm slices using the CM1900 (Leica Biosystems, Nussloch, DE) and the 
microtome Hyrax M 55 (Zeiss, Esslingen, DE), respectively. Tumor areas were macro 
dissected manually from the sections with a sterile scalpel (pfm medical, Cologne, DE) 
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and further processed for DNA extraction. DNA was extracted using the QIAamp DNA 
Mini Kit or the QIAamp DNA FFPE Tissue Kit (both Qiagen, Hilden, DE) following the 
manufacturer’s instructions. DNA quantification was performed with the NanoDrop ND-
2000 spectrophometer (NanoDrop Technologies, Wilmington, US). 
3.5 RNA Extraction 
Preparations for RNA extraction were the same as for DNA extraction. RNA was 
extracted manually with the chloroform/phenol extraction method. Therefore, the tumor 
sections were deparaffined and macro dissected, followed by proteolysis in 1x SDS-
Lysis-buffer over-night. The following day, RNA was extracted through chemical 
precipitation (chloroform/phenol), washed with 70% ethanol and dissolved in 
DNase/RNase free water. RNA quantification was performed as described above. 
3.6 Polymerase chain reaction (PCR) 
For the PCR, the reaction mixture (25 µl in total) included 2.5 µl buffer, 0.5 µl dNTPs, 1 
µl of each Primer, 0.25 µl of Gold Taq Polymerase, 17.75 µl of DNase/RNase free 
water, and 2 µl cDNA (100 ng).  
The reaction mixtures were initially heated at 95°C for 5 min to activate the polymerase, 
followed by 40 cycles including a denaturation step at 94°C for 45 s, an annealing step 
at 53°C for 45 s and an elongation step at 72°C for 45 s. A final elongation step at 72°C 
for 5 min was added [105]. 
The PCR products were illustrated by gel electrophoresis and UV irradiation.  
After verification of PCR products (right size of the bands and no band in the negative 
control), the products were purified with magnetic Agencourt AMPure XP Beads 
(Beckman Coulter, Brea, CA, US). The purified products were eluted in dH2O und 
stored at -20°C until further use.  
3.7 Sequencing PCR 
For the Sequencing PCR, 2 µl DTCS-Mix, 1 µl Primer (forward/reverse) and 7 µl purified 
PCR product were mixed together (10 µl reaction mixture in total). The DTCS Mix 
includes a Thermo Sequenase DNA polymerase I, a pyrophosphatase, dNTPS, dye 
terminators (ddNTPs), and buffer. The sequencing PCR was carried out for 40 cycles 
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including a denaturation step at 96°C for 20 s, an annealing step at 50°C for 20 s and 
an elongation step at 60°C for 4 min. Afterwards the PCR products were purified with 
Agencourt CleanSEQ (Beckman Coulter, Brea, CA, US), eluted in Sample Loading 
Solution (SLS) and covered with an oil layer. 
3.8 Sanger sequencing 
Sanger sequencing was performed with a GenomeLab GeXP machine (Beckman 
Coulter, Brea, CA, US). Thereby, the single DNA fragments with their fluorescence-
labelled ddNTPs become separated by gel electrophoresis. The four different ddNTPs 
emit light of different wavelengths, which is detected by the instrument and shown as 
different colored peaks by the software. 
3.9 cDNA synthesis and quantitative Real-time PCR (qRT-PCR) 
Total RNA (1 µg) was used for reverse transcription with the High-Capacity cDNA RT 
Kit with RNA Inhibitor (Thermo Fisher Scientific, Waltham, MA, US) for mRNA analysis 
in a total volume of 20 µl. 
QRT-PCR was carried out on 96-well reaction plates in a LightCycler 480 II (Roche, 
Basel, CH). The reaction mixture included 10 µl of Real-time SYBR Green PCR master 
mix, 1 µl of each Primer (forward and reverse), 7 µl of DNase/RNase free water and 1 µl 
of diluted reverse transcription product (20 ng). Each reaction was carried out in 
triplicates. A negative (water) control was included. 
The reaction mixtures were initially heated at 95°C for 15 min to activate the 
polymerase, followed by 40 cycles including a denaturation step at 94°C for 15 s, an 
annealing step at 55°C for 30 s, and an elongation step at 70°C for 30 s. A melting 
curve analysis was carried out with temperatures increasing from 60 to 97°C at 0.11°C 
interval after the Real-time PCR to assess the specificity of the amplified PCR product 
[105]. 
3.10 Immunohistochemistry (IHC) 
Immunohistochemical staining was performed on 3 µm thick FFPE-sections mounted on 
Superfrost® Plus Slides (R. Langenbrinck, Emmendingen, DE). 
59 
 
3.10.1 IHC staining 
Immunohistochemical staining of Ki-67 (MIB-1) and pHH3 was performed to 
characterize the SI-NET samples regarding their proliferative and mitotic status. It has 
been shown that phosphorylation of histone H3 is a reliable marker for mitotic activity. 
To verify expression of neuroendocrine markers, the tumors were stained against 
Somatostatin receptor 2 (SSTR2), synaptophysin, as well as the intestine specific 
transcription factor CDX2. Since SI-NETs are mostly functional tumors which secrete 
hormones, the samples were also stained for serotonin. 
Immunohistochemical staining of pHH3, Ki-67 (MIB-1), serotonin, synaptophysin, 
SSTR2, and CDX2 was carried out with the iView DAB Detection Kit on the Ventana 
BenchMark system (Ventana Medical Systems, Tucson, AZ, US). The antibodies are 
listed in Table 8 and 9. Cell conditioning solution 1 (CC1) pre-treatment (1 hour) of the 
tissues was applied for all primary antibodies, except serotonin. For synaptophysin, 
SSTR2, and pHH3 a Biotin block was applied prior to the staining procedure. Incubation 
of primary antibodies took place at 37°C for 32 min, incubation of secondary antibodies 
at 37°C for 8 min. The slides were counterstained with Hematoxylin solution. 
In order to determine the involvement of the PI3K/AKT/mTOR pathway in our SI-NET 
samples, the following proteins were analyzed by immunohistochemical staining: 
AKT2, phospho-AKT1 (Thr308), phospho-mTOR (Ser2448), phospho-S6 Ribosomal 
Protein (Ser240/244), and phospho-4E-BP1 (Ser65/Thr70). The IHC staining against 
these (phospho-) proteins was performed with the respective antibodies (Table 8) with 
the ZytoChemPlus Horseradish-peroxidase (HRP) Polymer Kit (Zytomed, Berlin, DE) 
and the DAB Substrate Kit (Zytomed, Berlin, DE) on the Tecan Genesis RSP 100 
system (Tecan Trading, CH). Slides were deparaffined and boiled for 5 min in TEC 
buffer pH9 (p-AKT, p-4E-BP1) or citrate buffer pH6 (AKT2, p-mTOR, p-S6) for heat-
induced antigen-retrieval. The antibodies were diluted in Antibody Diluent (Zytomed, 
Berlin, DE). The slides were incubated at 4°C over-night. The following day the slides 
were incubated with the secondary antibody (Table 9) and then with the HRP Polymer 
for 30 min each at room temperature (RT). The HRP Polymer consists of several 
molecules of secondary antibody which are covalently attached to several molecules 
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horseradish peroxidase. After a washing step the slides were incubated with a 
substrate/chromogen solution two times for 5 min each (16 µl chromogen (DAB) + 200 
µl Substrate Buffer per slide). The enzymatic reaction forms a brown staining at the site 
where the primary antibody has bound. The tissue slides were counterstained with 
Papanicolaou solution (Merck, Darmstadt, DE) and dehydrated in an ascending ethanol 
sequence. Finally, the slides were sealed with cover slips for microscopy. 
3.10.2 IHC evaluation 
pHH3 and Ki-67 (MIB-1) staining were analyzed with the Tissue Studio XD 2.3.0 
software (Definiens, Munich, DE). Therefore, whole tumor samples as well as three 
hotspots (squares à 250 µm2) were analyzed per slide. The parameter “Nucleus 
Classification” was chosen to differentiate between low and medium staining as well as 
between medium and high staining. The results were imported into Excel (Microsoft, 
Redmond, US). Nuclei, which were called “medium” and “high” by the software were 
determined positive and therefore summed up and divided through all detected nuclei. 
The results represent the percentage of pHH3/Ki-67 positive cells in the respective 
tumor sample/hotspot.   
AKT2, p-AKT, as well as p-mTOR, p-4E-BP1, and p-S6 immunohistochemical staining 
was evaluated using the immunoreactive score (IRS) resulting in staining values 
ranging between 0 and 12 (Table 17).  
Table 17: Immunoreactive Score (IRS) 
Staining intensity # of positive cells IRS 
0 no reaction 0 no 0-2 negative 
1 weak reaction 1 less than 10% 3-4 weakly positive 
2 moderate reaction 2 between 10 and 50% 6-8 moderately positive 
3 strong reaction 3 between 50 and 80% 9-12 highly positive 
  4 more than 80%   
 
Synaptophysin and serotonin were scored 0 for negative staining, 1 for weak staining, 2 
for moderate staining, and 3 for strong staining. CDX2 expression was valued with + for 
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positive staining and - for negative staining. Finally, SSTR2 staining was evaluated with 
0 for negative staining, 1 for partial staining, 2 for incomplete membrane staining, and 3 
for >10% of the cells showing strong membranous staining. 
3.11 Fluorescence-in-situ-hybridization (FISH) 
3.11.1 FISH processing 
For all FISH analyses, deparaffined slides were heated in sodium citrate buffer and 
proteins were enzymatically digested with pepsin (Sigma-Aldrich, St. Louis, MO, US). 
Chr. 18 FISH 
To determine how many samples of our cohort exhibit loss of chromosome 18, a Chr18 
centromere FISH probe was used (Table 10). 
For Chr18 centromere FISH, whole tissue slides as well as TMAs were used. With a HE 
stained slide of the same sample the tumor area was determined and the FISH slide 
was marked on the back side with a diamond pen (~25 mm2). The slides were 
denatured for 10 min in 70% formamide/2x SSC at 72°C. The CEP 18 FISH probe was 
diluted in CEP hybridization buffer (# 07J36-001, Abbott Molecular Inc., Abbott Park, IL, 
US) and distilled water in a 1:2:7 ratio (probe:dH2O:CEP hybridization buffer) and the 
mix was denatured for 5 min at 72°C. The hybridization was carried out at 42°C for at 
least 15 h. All hybridizations were carried out with a ThermoBrite hybridizer (Abbott 
Molecular Inc., Abbott Park, IL, US). The following day the slides were washed in 2x 
SSC Buffer as well as in 2x SSC with 0.3% NP-40 at 72°C for 5 min to wash away non-
specific hybrids which are less stable than specific bindings. After slides were air-dried 
in darkness, they were counterstained and mounted with ProLong® Gold Antifade 
mountant with DAPI (Life Technologies, Waltham, MA, US) and a cover slip was placed 
over the target area. 
PI3K/AKT/mTOR-pathway FISH 
For the evaluation of amplifications in the PI3K/AKT/mTOR-pathway, commercial 
probes for PIK3CD, AKT1, AKT2, PDGFRα, and PDGFRβ, and a custom made probe 
for mTOR were used (see Table 10). The FISH analysis for these six genes was carried 
out on the eight TMAs described in 3.3 Tissue Microarray. 
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AKT1/2, PDGFRα/β FISH 
The probes for AKT1/Cen14q, AKT2/Cen19p, PDGFRα/Cen4p, and PDGFRβ (split 
probe) were ready to use (all Abnova, Taipei, RC). The slides and probes were co-
denatured for 5 min at 75°C and the hybridization was carried out at 37°C for 15 h at 
least. The post-hybridization wash and the DAPI counterstaining were carried out as 
described above. 
PIK3CD FISH 
The PIK3CD FISH (Empire Genomics, Buffalo, NY, US) was used together with the 
Cen-1 probe (Metasystems, Altlussheim, DE). The hybridization mix included 2 µl 
PIK3CD probe, 2 µl Cen-1 probe, and 10 µl hybridization buffer. The mix and the slides 
were co-denatured at 83°C for 3 min. Hybridization, post-hybridization wash, and the 
DAPI counterstaining took place as described above. 
mTOR FISH 
The mTOR FISH probe was a customized probe which was developed by CeGaT 
(Tuebingen, DE) in cooperation with Prof. Dr. Perner (Institute of Pathology, University 
Hospital Bonn).  
The probe mix for the mTOR detection included 2 µl mTOR probe, 2 µl CEP1 probe, 
1 µl Cot-1 (Thermo Fisher Scientific, Waltham, MA, US), and 10µl CEP hybridization 
buffer. Cot-1 is used to suppress non-specific hybridizations to probes derived from 
BAC clones, resulting in improved signal-to-background-ratio. The slides and the probe 
were co-denatured at 84°C for 6 min. The hybridization was carried out as described 
above. 
Post-hybridization wash was performed with 2x SSC for 6 min at 75°C and 0.5x SSC at 
RT. Afterwards the slides were blocked with CAS block (Thermo Fisher Scientific, 
Waltham, MA, US) including 10% normal goat serum (Cell Signaling, Danvers, MA, 
US). The secondary antibody Streptavidin Alexa Fluor 594 (Thermo Fisher Scientific, 
Waltham, MA, US) (Table 9) was used for the detection of mTOR (Biotin labelled). It 
was diluted 1:1000 in CAS block before it was applied to the slides. The detection took 
place for 1 h at RT in a humidified chamber. After another washing step, the nuclei were 
counterstained with DAPI.  
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3.11.2 FISH evaluation 
The evaluation of the FISH assays was achieved with a Zeiss Axioskop fluorescent 
microscope (Zeiss, Jena, DE).  
Chr. 18 FISH 
To determine whether an SI-NET sample has lost one Chr18 at least 100 cells were 
counted. If >80% cells showed two signals, the sample was considered to have a 
normal set of two Chr18, and vice versa (if >80% of the cells showed only one signal, 
the sample was considered to have a loss of Chr18). If the count of one (two) signal(s) 
was between 20% and 80% of cells, the sample was considered to have a mosaic 
pattern of Chr18. 
PI3K/AKT/mTOR-pathway FISH 
The number of specific signals per cell as well as the number of the respective 
centromeric probe was counted. At least 30 cells per tumor were counted and a gene-
reference-ratio was established. The ratio and the average number of gene and 
centromere specific signals were taken into account for statistical analyses. The gaps 
between the target specific and the centromere probe were of different size for each 
gene.  
PDGFRα (69 kb) is located on 4q12, whereas the chromosome reference probe is 
located on 4p13, leaving a gap of 9,200 kb. AKT1 (26 kb) is located on 14q32.33, the 
chromosome reference probe on 14q11.2, resulting in a gap of 71,800 kb. AKT2 (55kb) 
is located on 19q13.13, the chromosome reference probe on 19p13.11, resulting in a 
gap of 17,800 kb. Since a split probe was used for PDGFRβ (42 kb, located on 5q33.1) 
no gap was present between the two probes. mTOR (155 kb) and PIK3CD (77 kb) are 
located both on 1p36.2. The centromere enumeration probe, which was used for Chr1, 
was located on the long arm of Chr1, at position 1q12.  
Gene amplifications are defined as an increase in the copy number of a specific 
chromosomal region, that is commonly linked to overexpression of the respective gene 
[106]. Polysomy, however, describes the condition when extra copies of a whole 
chromosome are present. The centromere probes, included in every gene specific FISH 
analysis, were used as reference for the presence of polysomy. These basic definitions 
in mind, we grouped our samples into the following three categories: 
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Samples were defined as “amplified”, when the centromere signal count was ≤72 and 
target/centromere signal ratio >1.2, counting 30 cells. “Amplified + polysomy” refers to 
samples with a centromere signal count >72 and target/centromere signal ratio >1.2. 
Samples defined as “polysomy” had a target signal count >72, but a target/centromere 
signal ratio ≤1.2. 
The ratio of 1.2 for the amplification threshold was based on evaluation of 
target/centromere signal counts in normal neuroendocrine cells, since this ratio was 
significantly different from the signal ratios in the non-tumorigenic cells. 
For PDGFRβ, only one parameter was available, resulting in the conditions “not 
amplified” (target/reference signal ≤72) and “amplified” (target/reference signal >72) for 
statistical analysis. 
3.12 Statistical analysis 
Pearson’s Chi-square test was applied (SPSS, IBM, Armonk, NY, US) for FISH and IHC 
results and Kaplan-Meier estimation for survival were performed with SPSS (IBM SPSS 
Statistics for Windows, Version 22.0). For multivariate analyses Bonferroni correction 
was applied. 
For statistical analysis of association between FISH results and immunohistochemical 
stainings, two cut offs were chosen for IHC: a) no/weak staining (Remmele score 0-3) 
against moderate/strong staining (Remmele score 4-12) and b) dichotomic distribution 
(0-6 vs. 7-12). 
3.13 Protein extraction 
Frozen tissues of SI-NET samples were cut into 15x10 µm slices for protein isolation. 
100-150 µl RIPA-buffer (charged with protease inhibitor (Roche, Basel, CH)) was added 
to the tissues. Tissues were homogenized by pipetting up and down on ice. After 
centrifugation at 4°C and 13.000 rpm the supernatants containing the protein lysates 
were used for further processing. BCA reaction was carried out to determine protein 
concentration using Bovine Serum Albumin (BSA) Standards (Thermo Fisher Scientific, 
Waltham, MA, USA). Absorption was measured at 560 nm with the Microplate Reader 
(Biorad, Hercules, CA, US). 
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3.14 Western blot 
20 µg protein were charged with 1 Vol of 2x Laemmli Sample Buffer (Biorad, Hercules, 
CA, US) and 1/10 Volume of β-mercaptoethanol (Merck, Darmstadt, DE) and denatured 
at 95°C for 10 min.  
For western blotting the protein lysates were separated on 7.5%, 10% or 12% SDS gels 
(Biorad, Hercules, CA, US), depending on the predicted protein size, at 200 V. Proteins 
were transferred to a PVDF membrane at 100 V for 1 h. Membranes were blocked with 
5% Skim Milk (BD, Franklin Lakes, NJ, US) diluted in 1x TBS/Tween 0.05% buffer for 1 
h at RT. After an over-night incubation at 4°C with the primary antibody (SMAD2 (86F7) 
Rabbit mAb (1:1000), #3122, Cell Signaling, MA, US; SMAD4 (B-8) Mouse mAb 
(1:100), #sc-7966, Santa Cruz, CA, US; PMAIP1 Rabbit pAb (1:250), #HPA051063, 
Sigma, MO, US;  Anti-IK3-1 / CABLES1 Antibody (Lys588), Rabbit pAb (1:1000), #LS-
C176874, Biozol, DE; Elongin A3 (S-16) Rabbit pAB (1:200), #sc-84811, Santa Cruz, 
CA, US; DCC, Rabbit pAb (1:500), #orb10519, Biorbyt, Cambridge, UK; 2. DCC (A-20), 
Goat pAb (1:100), #sc-6535, Santa Cruz, CA, USA with Blocking Peptide sc-6535 P) 
the membranes were washed with 1x TBS/Tween 0.05% buffer for 3x 10 min and 
incubated with the secondary antibody at RT for 1 h (Goat anti-mouse (1:3000) IgG 
(H+L) HRP conjugated, #G-21040 or Goat anti-rabbit (1:3000) IgG (H+L) HRP 
conjugated, #G-21234, both from Life Technologies, Carlsbad, CA, US). All antibodies 
are listed in Table 8 and 9. The membranes were washed for 3x 10 min and Immobilon 
Western Chemiluminescent HRP Substrate (Merck Millipore, Darmstadt, DE) was 
added. Darkroom development techniques were used for image acquiring.  
To ensure that the gels were properly loaded with equal amounts of protein, the 
membranes were stripped with Stripping Buffer (Thermo Fisher Scientific, Waltham MA, 
US), washed, blocked, and incubated with an antibody against β-Actin (clone AC-15 
(1:40000), # A5441, Sigma-Aldrich, St.-Louis, MO, US). The blotting procedure was 
carried out as explained above.  
As positive controls for western blot analysis K562 and NIH/3T3 cell line for SMAD2 and 
SMAD4 were used, respectively. The human pancreatic carcinoma cell line BxPC-3 
lacking expression of SMAD4 [44] was used as a negative control in SMAD4 western 
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blots. As positive controls for western blot analysis of Elongin A3, PMAIP1, and 
CABLES kidney tissue, U-251 cell line, and HEK293 cell line were used, respectively. 
The neuroblastoma cell line IMR-32 served as positive control for DCC western blot. 
The cell lines K562, BxPC-3, and U251 were retrieved from the NCI-60 cell line panel. 
NIH/3T3, HEK293, and IMR-32 were bought from ATCC (Middlesex, UK). 
Due to difficulties in distinguishing the bands between 180 and 250 kDa of the second 
DCC western blot, a competition with the matching peptide was performed.  
Since the β-Actin expression of the samples varied slightly between the samples, a 
semi-quantitative analysis of the western blot results was done. Therefore, the western 
blot pictures were loaded into Adobe Photoshop (Mountain View, CA, USA), inverted 
and analyzed with the histogram setting. The background noise was subtracted from 
the protein bands. Then, the specific bands of the tumor suppressor proteins were 
normalized to the respective β-Actin band, resulting in a percentage value. A value 
<20% was determined as lost/reduced expression of the protein. 
3.15 Cell culture 
For western blot analyses different cell lines were used as positive/negative controls 
(3.14 Western blot). NIH/3T3 and HEK293 were maintained in DMEM plus 10% FCS 
and 1% Penicillin/Streptomycin. IMR-32, K562, BxPC-3, and U251 were maintained in 
RPMI plus 10% FCS and 1% Penicillin/Streptomycin. All cell lines were cultured at 37°C 
and 5% CO2. For protein extraction cells were trypsinized, washed in 1x PBS, and 
pelleted through centrifugation. Protein extraction was performed as explained in 3.12 
Protein extraction. 
3.16 Exome sequencing & SNV calling 
Exome sequencing of five SI-NET samples (tumor content between 70% and 90%) and 
the corresponding normal tissues was performed by CeGaT (Tuebingen, DE) using the 
SOLiD 5500xl machine (Thermo Fisher Scientific, Waltham, MA, US). For the 
sequencing performance DNA was enriched with the Agilent SureSelect ExomeKit v.4. 
Mapping was done by LifeScope v2.5.1 (Thermo Fisher Scientific, Waltham, MA, US). 
SNV/InDel calling was performed with diBayes in LifeScope v2.5.1 (Thermo Fisher 
Scientific, Waltham, MA, US) as well as with samtools mpileup 0.1.18 with bcftools and 
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vcfutils.pl [107]. Annotation was achieved with dbSNP137, ESP6500 (Exome Variant 
Server), Ensembl v69, and the inhouse database of CeGaT. The comparison between 
tumor and normal sample output was done with the following settings: in tumor 
samples, SNVs with a coverage >10 and a minimal novel allele frequency of 1% were 
considered for further analysis, when the SNVs in the normal tissue samples (coverage 
>20) showed a maximal novel allele frequency of 1%. Minimum distance between the 
novel allele frequencies was set to 0.3 (min. 3x normal allele frequency < tumor 
frequency). Lists of “real” somatic mutations were achieved by filtering SNVs and InDels 
according to the following four steps. 
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1) SNVs with bad quality 
2) SNV function (non-synonymous, (essential) splice site, stop gain/loss) 
3) SNVs and InDels with rs-number (dbSNP database) 
4) SNVs and InDels against SNVs and InDels found in the corresponding normal 
tissue 
3.17 Validation by Sanger sequencing 
High value somatic SNVs (achieved by the steps laid out above) were validated by 
Sanger sequencing with the GeXP – Genetic Analysis System (Beckman Coulter, Brea, 
CA, US).  
3.18 Oligonucleotides 
High value somatic SNVs (achieved by the steps laid out above) were validated by 
Sanger sequencing. PCR primers were designed using the program Primer3Plus 
(http://primer3plus.com/cgi-bin/dev/primer3plus.cgi) generating amplicons between 110 
bp and 250 bp.  
Two targets [PML (Chr15) and NFATC1 (Chr18)] were further analyzed (sequencing of 
all functional regions) in a set of 30 SI-NETs (including 15 primaries, eight matching 
distant metastases and seven non-matching lymph node metastases). (The sequencing 
of NFATC1 was subject of the doctoral thesis of Dr. Laura Stoß). 
For the potential tumor suppressor genes DCC, PMAIP1, TCEB3C, and CABLES 
primers were designed which were used for qRT-PCR. The specificity of all primers was 
tested with Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). All primers 
are listed in tables 11-13. 
3.19 SNP array & Data analysis 
The SNP array analysis (Atlas Biolabs, Berlin, DE) was performed to identify 
chromosomal aberrations in SI-NETs.  The data was analyzed and interpreted with the 
Chromosome Analysis Suite (Affymetrix, Santa Clara, CA, US). To evaluate additional 
smaller losses, the parameter “copy number marker count” was set to 10 and the 
“sizes” to 100, 50, and 40kb, respectively. Nine fresh frozen tissues (five primary tumors 
and four metastases of SI-NETs) from Kiel and Munich were used for SNP Array 
analysis (named Tu1, Tu1 Met, Tu2, Tu3, Tu4, Tu5 Met, Tu6 Met, Tu7, and Tu7 Met). 
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3.20 Liquid chromatography – Mass spectrometry (LC-MS) 
All steps for the Liquid chromatography – Mass spectrometry analysis were carried out 
by the Clinical Proteomics workgroup of Jun.-Prof. Barbara Sitek (Medical Proteom-
Center, Bochum, DE). 
Sample preparation 
Cell lysis was performed in lysis buffer (7 M urea, 2 M thio-urea, 0.1 % SDS, 30 mM 
Tris-HCl, pH 8.5) by sonication on ice for 10 min. Protein concentration was carried out 
using Bradford assay. Subsequently, 40 µg of cell lysate were loaded on ProGel Tris 
Glycin 18%, 1 mm gel two times. Samples were allowed to run for 1 h. After Coomassie 
staining, three gel bands were cut between 150-250 kDa and in-gel digestion was 
performed with trypsin (37°C, 16 h). The resulting tryptic peptides were extracted from 
the gel by sonication in 50% acetonitrile in 0.1% trifluoroacetic acid (TFA) two times. 
Fractions of the same molecular weight were pooled together and dried in vacuum. 
Peptides were reconstituted in 40 µl 0.1% TFA. 
LC-MS/MS analysis 
LC-MS analysis was performed on Ultimate 3000 RSLCnano system online coupled to 
an Orbitrap Elite instrument (Thermo Fisher Scientific, Waltham, MA, US). 15 µl of the 
reconstituted samples were loaded onto a trap column and the peptides were then 
separated on an analytical C18 column using a 90 min gradient from 5–40% solvent B 
at a flow rate of 300 nl/min (solvent A: 0.1% formic acid, solvent B: 0.1% formic acid 
84% acetonitrile). 
Protein Identification 
Thermo Scientific Proteome Discoverer™ version 1.4 was used to search MS/MS 
spectra against UniProtKB/Swiss-Prot human database using Mascot® search engine. 
Mascot parameters were set as: Tryptic digestion with up to one missed cleavage, 
precursor ion mass tolerance of 5 ppm and fragment ion mass tolerance of 0.4 D with 
Oxidation (M) and prominamide (C) as dynamic modification. To estimate the 
confidence of peptide identifications a decoy database search was performed. Peptides 
with false discovery rate (FDR) > 1% were discarded. 
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IV. Results - General characterization 
 
Clinicopathological data of the patients 
Clinical characteristics 
The clinical characteristics of the patients are summarized in Appendix Table 26. For 
the 135 patients, whose tissues were used for TMA design, IHC, FISH, qRT-PCR, and 
Sanger sequencing, the mean age at the time point of diagnosis was 60.5 (range 20-
87). 51 were female, 50 were male, and for 32 patients the sex was not available. The 
patients’ samples were classified according to TNM stage and UICC stage. The UICC 
classification is summarized in Table 18. 
Table 18: Distribution of UICC stages in the patients’ cohort 
TMA: Tissue micro array, FFPE: formalin-fixed, paraffin embedded, NA: not available 
Sample 
group 
Stage I Stage 
IIA 
Stage 
IIB 
Stage 
IIIA 
Stage 
IIIB 
Stage IV NA 
FFPE 9 6 8 1 52 46 4 
Cryo 3 1 1 0 11 8 1 
 
The grading was determined by Ki-67 staining, which was evaluated with the Hotspot 
method by using the Tissue Studio software (Definiens, Munich, DE). Most of the 
samples were G1 tumors, which is in line with the literature concerning ileal NETs; few 
were G2. Additionally, pHH3 was analyzed, which ranged between <0.00 and 2.14, 
indicating that the mitotic activity is really low in these tumors (Appendix Table 26). 
Concerning the cryo samples used for western blot and SNP analysis, as well as 
sequencing, the mean age of the patients was 61.2 and ranged between 26 and 85 (for 
three patients the age was not available). 15 patients were female, seven were male, 
and for three the sex was not available. Again, UICC classification is shown in Table 18. 
Expression of immunohistochemical markers 
Seven potential tumor samples were excluded before evaluating the 
immunohistochemical results of the neuroendocrine tumor markers (Appendix Table 27, 
indicated in grey), due to lacking tumor tissue or detachment of the tissue from the 
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slide. 95% (198/208) of the tumor samples expressed synaptophysin (for 2/210 samples 
the staining was not applicable). Hereof, 87 samples exhibited strong, 78 moderate, and 
33 weak expression. 5% (10/208) showed no expression of synaptophysin. The 
samples with no synaptophysin expression are rare examples of tumors, for which the 
diagnosis of a SI-NET is confirmed by the immunohistochemical marker CgA alone. 
The nuclear transcription factor CDX2 was expressed in 91% (181/198) of SI-NETs (for 
12 samples no evaluation was feasible). 9% (18/198) did not express CDX2. 
Somatostatin receptor 2 (SSTR 2) was expressed by 76% (155/203) of SI-NETs (for 
seven samples the analysis was not feasible). Hereof, 100 samples showed strong, 26 
moderate, and 29 weak expression. 24% (48/203) showed no expression of SSTR2. 
86% (179/208) of the tumors were positively stained for serotonin, indicating that the 
majority of the SI-NET cohort comprises functional tumors, as expected (for two 
samples the staining was not applicable). Only 17% (36/208) were negative for 
serotonin. 
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IV. Results – Genetic characterization 
 
Parts of the results described on page 71-91 are already published in [50]. 
Chr18 is commonly lost in SI-NETs 
Focusing on this characteristic lesion, FISH analysis with a Chr18 centromeric 
enumeration probe was performed in 121 SI-NET samples. The analysis revealed that 
64% of the tumor samples (77/121) had suffered loss of one Chr18 (Appendix Table 
26). 12% showed mosaicism regarding their Chr18 status (14/121); 18% exhibited the 
normal count of two copies of Chr18 (22/121). In 7%, it was not possible to determine 
the Chr18 status. In the three cohorts, 57% of cohort 1, 65% of cohort 2, and 65% of 
cohort 3 showed a loss of Chr18.  
SNP Array analysis 
Nine SI-NET samples (including five primary tumors and four metastases with two 
matching primary-metastasis pairs) were analyzed by SNP array 6.0 technology 
(Affymetrix, Santa Clara, CA, US). One sample (Tu6 Met) was of bad quality and 
therefore excluded from further analysis. In Table 19 the results of the remaining eight 
samples are shown. 
Table 19: SNP array analysis of five primary tumors and three metastases (two matching)  
Chr: Chromosome, CN: Copy number, -: no gain/loss 
Chromosome Tu1 Tu1 Met Tu2 Tu3 Tu4 Tu5 Met Tu7 Tu7 Met 
Chr4 CN3 CN3 CN3 - - - CN3 CN3 
Chr5 CN3 CN3 - - - - CN3 CN3 
Chr9 - - CN1: 
p11.2-
q13 
- - - - - 
Chr10 CN3 CN3 - - - - - - 
Chr12 CN1: 
p.13.31-
p11.1 
CN1: 
p.13.31-
q11 
- - - - - - 
Chr14 - - CN3 - - - - - 
Chr17 CN3: 
q21.32-
q25.3 
CN3: 
q21.32-
q25.3 
- - - - - - 
Chr18 CN1 CN1 - Mosaic CN1 CN1 CN1 CN1 
Chr20 CN3 CN3 CN3 - - -  CN3 CN3 
 
Tu1 and its matching metastasis showed copy number gain of Chr4, 5, 10, 20, and part 
of the long arm of Chr17. Both samples depicted loss of Chr18 and partial loss of 
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Chr12. Remarkably, in the metastasis the partial loss of Chr12 comprised both the short 
and the long arm of the chromosome, whereas in the primary tumor only the short arm 
was affected. Tu7 and the matching metastasis also showed CN gain of Chr4, 5, and 20 
and loss of Chr18. Tu2 shared the CN gain of Chr4 and 20, but depicted additionally 
gain of Chr14. In this tumor a partial loss of Chr9 was present, which was not found in 
any of the other tumors. Tu2 was the only tumor with a normal count of two for Chr18. 
Finally, Tu4 and Tu5 Met depicted loss of Chr18 as sole chromosomal aberration. In 
Tu3 a mosaic pattern regarding Chr18 was present without additional alterations. 
Exome sequencing 
Exome sequencing was performed with five different SI-NETs and corresponding 
normal tissue samples. Statistics concerning the mean coverage on target and 
underrepresented bases (total and in percent) are shown in Appendix Table 28.  
Appendix Table 29 gives an overview over the alterations detected by exome 
sequencing, but were not included in the further analysis (e.g. intergenic, intronic, 
synonymous, etc.).  
Only stop-gained and non-synonymous variants were included in the further analysis 
and evaluation. The following table (Table 20) shows the workflow and the type 
(transition vs. transversion) of substitutions. The filtering for adjacent SNVs was 
necessary, because the detection of these artifacts is a known problem of the SOLiD 
5500xl machine. 
Table 20: Stop-gained and non-synonymous somatic variants found by exome sequencing of five SI-NET samples and 
corresponding normal tissue  
w/o: without, rs-number: dbSNP database entry 
Sample All SNVs  
(w/o rs-
number) 
Coverage 
≥20 
Filtering for 
adjacent SNVs 
Transitions 
(A/G – C/T) 
Transversions 
(A/C, A/T, G/C, G/T) 
1 118 (95) 81 (67) 63 (49) 27 36 
2 100 (76) 68 (53) 49 (35) 16 33 
3 129 (91) 85 (66) 76 (57) 26 50 
4 122 (94) 83 (66) 68 (51) 22 46 
5 55 (36) 54 (35) 38 (23) 17 21 
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Validation by Sanger sequencing 
The selection of target genes for validation by Sanger sequencing was achieved by 
extensive review of the literature concerning cancer context and pathways. Additionally, 
the SNVs had to be determined “deleterious” or “damaging” by the protein variation 
prediction programs PROVEAN and SIFT (http://provean.jcvi.org/index.php), 
respectively plus “probably/possibly damaging” by Polyphen-2, a tool for annotating 
coding non-synonymous SNVs (http://genetics.bwh.harvard.edu/pph2/bgi.shtml). In 
contrast to the other prediction tools, PROVEAN can also predict impacts of InDels.  
PolyPhen-2 predicts the functional significance of an allele substitution by Naïve Bayes 
classifier trained using supervised machine-learning. It consists of two dataset pairs. 
The first pair is called HumDiv and includes all damaging alleles with known effects on 
the molecular function causing human Mendelian diseases, present in the UniProtKB 
database, together with differences between human proteins, which are assumed to be 
non-damaging. The second pair, HumVar, consists of all human disease-causing 
mutations from UniProtKB, together with common human ns-SNVs (MAF>1%) without 
known involvement in disease and which are therefore treated as non-damaging 
(http://genetics.bwh.harvard.edu/pph2/dokuwiki/overview). 
All primers for validation/falsification of NGS data were designed using the program 
Primer3Plus (http://primer3plus.com/cgi-bin/dev/primer3plus.cgi). The list of primers is 
shown in Table 11-13. (Some primers had an additional gene-unspecific tail, called 
“M13”, attached to the gene-specific sequence for easing of the sequencing PCR.) 
Firstly, the focus lay on variations which were found in more than one patient. This 
basic approach was soon to be discarded, because Sanger sequencing revealed that 
none of these “common” alterations were “true” mutations, but artifacts (Table 21).  
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Table 21: Sanger validation of absence of mutations 
Chr: chromosome, Ref: reference base, Mut: mutated base, Aa: amino acid 
Chr Position Type Ref Mut Aa1 Aa2 Aa 
pos. 
Gene Sample PROVEAN/SIFT PolyPhen-2 
(HumDiv/HumVar) 
Chr1 11206838 SNV G C D E 1527 MTOR 3 neutral/tolerated probably 
damaging 
Chr1 153749658 SNV C G S C 380 SLC27A3 5 deleterious/damaging probably 
damaging 
Chr3 37512566 SNV T G F C 85 ITGA9 1,2,3,4 deleterious/damaging probably 
damaging 
Chr3 122180112 SNV A C F V 131 KPNA1 1,2,3,4 deleterious/damaging probably/possibly 
damaging 
Chr3 122180113 SNV C A R S 130 KPNA1 1,2,3,4 deleterious/damaging probably/possibly 
damaging 
Chr3 50222175 SNV C A R S 462 SEMA3F 1,2,3,4 neutral/tolerated benign 
Chr5 16877777 SNV G C P A 21 MYO10 4 deleterious/tolerated possibly damaging 
Chr7 107393921 SNV C G R G 83 CBLL1 1,2,3,4 neutral/damaging probably 
damaging 
Chr8 95392469 SNV C A L F 717 RAD54B 5 deleterious/damaging probably 
damaging 
Chr10 29843781 SNV T C T A 31 SVIL 1 neutral/tolerated probably 
damaging 
Chr12 50834274 SNV A T E V 237 LARP4 5 deleterious/damaging probably 
damaging 
Chr12 56088728 SNV A C F C 676 ITGA7 1,2,3,4 deleterious/damaging probably 
damaging 
Chr16 14026096 SNV T A S R 352 ERCC4 5 neutral/damaging benign 
Chr18 39576604 SNV T A . (splice 
site) 
. 298 PIK3C3 5 neutral/tolerated - 
Chr18 39576605 SNV A T I F 299 PIK3C3 5 deleterious/damaging probably 
damaging 
Chr18 21407328 SNV C G A G 907 LAMA3 1,2,3,4 neutral/tolerated benign 
Chr19 2853229 SNV C T T I 389 ZNF555 1 deleterious/tolerated benign 
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Chr22 22843692 SNV G T P H 11 ZNF280B 1 neutral/damaging benign 
ChrX 105450788 SNV G A V M 455 MUM1L1 1 neutral/tolerated probably 
damaging 
ChrX 142596781 SNV T G N H 97 SPANXN3 1 neutral/damaging possibly 
damaging/benign 
ChrX 153596042 SNV C T M I 229 FLNA 1 deleterious/damaging probably 
damaging 
ChrX 153596044 SNV T C M V 229 FLNA 1 deleterious/damaging probably 
damaging 
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Next, the focus lay on mutations in genes located on Chr18. Three somatic mutations in 
Chr18-associated genes could be identified and verified by Sanger sequencing (Table 
22). The SNVs in CABYR and NFATC1 were found in one patient (Tu5) whereas the 
deletion in PIEZO2 was found in another patient (Tu3). 
NFATC1 had a mutational count of 66% in the exome sequencing of the respective 
tumor. The SNV in NFATC1, which results in an amino acid change from arginine to 
cysteine at position 552 (p.R552C, c.1720G>A), was predicted to be 
deleterious/damaging (PROVEAN/SIFT) and probably damaging (PolyPhen-2). The 
database COSMIC (Catalogue of Somatic Mutations) revealed p.R552C not to be 
described in any tumor type. However, this SNV could be a unique feature of SI-NETs. 
The mutation in CABYR (p.I318V, c.1104T>C) showed a allele frequency of 46% in the 
tumor sample. This SNV was predicted to have no damaging effect on protein 
structure/function (neutral/tolerated/benign). Isoleucine and valine are both essential 
amino acids with hydrophobic side chains. The similar chemical features reduce the 
possibility, that the substitution has a negative impact on the protein function. This 
prediction is in line with the finding that this mutation is not listed in the COSMIC 
database.  
The deletion of three bases in PIEZO2 (p.E2727del, c.8181_8183del) was present in 
nearly 19% of the tumor sample. Prediction with the program PROVEAN revealed a 
deleterious effect on protein structure/function, but since the deletion of three bases 
does not result in a frameshift the protein function will probably be preserved 
nonetheless. This mutation is also not reported in COSMIC. Additionally, no distinct 
protein features, such as phosphorylation/acetylation/etc. sites, are described for this 
amino acid position and the mutation is positioned at the very end of the gene, 
indicating that the damaging impact on the whole protein is probably small.  
The remaining three SI-NETs did not show any SNVs or InDels in Chr18-related genes. 
Thereafter, mutations affecting Chr18 independent genes with relation to tumor 
development and/or progression and classification as “damaging” were investigated by 
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Sanger sequencing. Table 21 (falsified SNVs) and Table 22 (validated SNVs) include all 
genes/mutations which were subject of this approach.  
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Table 22: Sanger-validated somatic mutations 
Chr: chromosome, Ref: reference, Mut: mutated base, Aa: amino acid, *germ line 
Chr Position Type Ref Mut Aa1 Aa2 Aa 
pos. 
Gene Sample PROVEAN/SIFT PolyPhen-2 
(HumDiv/HumVar) 
Chr1 22056254 SNV T C M V 415 USP48 5 deleterious/damaging probably 
damaging 
Chr1 156228800 SNV C T R Q 813 SMG5 1 neutral/tolerated benign 
Chr1 181680146 SNV G A R Q 371 CACNA1E 5 deleterious/damaging probably 
damaging 
Chr3 14803089 SNV T C M T 821 C3orf20 1 deleterious/damaging benign 
Chr3 63437756 SNV T A F Y 11 SYNPR 4 deleterious/NA - 
Chr3 123071419 SNV T G N H 382 ADCY5 4 deleterious/damaging probably 
damaging 
Chr3 186509587 SNV G A T I 243 RFC4 2 deleterious/damaging probably 
damaging 
Chr5 70849070 SNV G A D N 2375 BDP1 3 neutral/tolerated benign 
Chr6 41048582 SNV G T Q H 36 NFYA 1 neutral/damaging possibly damaging 
Chr7 70255539 SNV G T D Y 1113 AUTS2 5 deleterious/damaging probably 
damaging 
Chr7 99250323 SNV A G V A 369 CYP3A5 1 deleterious/tolerated benign 
Chr8 53558307 SNV A T N K 1314 RB1CC1* 5 neutral/tolerated probably 
damaging 
Chr9 100895449 SNV C T M I 173 CORO2A 1 neutral/tolerated benign 
Chr9 113169164 SNV C T D N 2906 SVEP1 5 neutral/tolerated possibly damaging 
Chr11 56020625 SNV C T P L 317 OR5T3 1 deleterious/damaging probably 
damaging 
Chr11 60183406 SNV C T S F 322 MS4A14 4 neutral/damaging probably/possibly 
damaging 
Chr12 7249343 SNV C T G S 370 C1RL 4 deleterious/tolerated probably/possibly 
damaging 
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Chr12 14589163 SNV A T D V 590 ATF7IP 1 deleterious/damaging probably 
damaging 
Chr12 95926819 SNV A G M T 405 USP44 1 deleterious/damaging benign/possibly 
damaging 
Chr12 112632704 SNV C G A P 2490 C12orf51 5 neutral/damaging probably/possibly 
damaging 
Chr14 61788886 SNV C T Q * 23 PRKCH* 5 NA/NA - 
Chr15 74335379 SNV T A L Q 587 PML 1 neutral/damaging probably 
damaging 
Chr17 3119215 SNV A G M V 101 OR1A1 4 neutral/damaging benign 
Chr18 21736417 SNV A G I V 318 CABYR 5 neutral/tolerated benign 
Chr18 77211057 SNV C T R C 552 NFATC1 5 deleterious/damaging probably 
damaging 
Chr18 10671600-10671602 Del GAG  - E - 2727 PIEZO2 2 deleterious/NA - 
Chr19 9087465 SNV C A Q H 1450 MUC16 1 neutral/damaging probably 
damaging/benign 
Chr20 60886124 SNV G A P L 3372 LAMA5 5 neutral/tolerated benign 
Chr22 29192093 SNV A C S A 181 XBP1 4 neutral/tolerated possibly 
damaging/benign 
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After 29 of the 51 genes chosen for re-sequencing by Sanger sequencing could be 
validated, two genes were picked for further analysis; PML (promyelocytic leukemia) 
and NFATC1 (Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1). 
Sanger-sequencing of PML 
Next generation sequencing and subsequent Sanger sequencing revealed tumor 
sample 1 to have a p.L587Q (c.1760T>A) mutation in PML. This mutation was predicted 
to be (probably) damaging by the programs PolyPhen-2 and SIFT, respectively 
(whereas PROVEAN predicted the substitution to be tolerated). 
Therefore, and since PML is a well-known tumor suppressor gene, it was chosen to be 
object of further sequencing analysis in a cohort of 30 SI-NET samples. The cohort 
consisted of 15 primary tumors, eight matching distant metastases, and seven non-
matching lymph node metastases. Primers were designed for Exon 1-8 of the gene, 
including all important domains (e.g. coiled coil domain, essential for core assembly of 
PML Nuclear Bodies (PML-NBs), Nucleus localization signal, Sumo interaction motif, 
and different Zinc finger motifs). 
In one distant metastasis the somatic mutation p.T130I (c.389C>T) could be detected, 
whereas the primary tumor depicted the wild type allele, as did both matching normal 
tissues. This variation was predicted to be benign by PolyPhen-2; the SIFT result was in 
agreement (tolerated). Only the PROVEAN prediction suggested a deleterious effect on 
protein function. 
No further mutations in PML could be found in our cohort of SI-NETs. The p.L587Q 
mutation is not located in any important domain. p.T130I is located within the B box-
type binding domain which mediates the interaction with PIAS1, together with the coiled 
coil domain. 
Sanger-sequencing of NFATC1 
The somatic mutation in NFATC1 (p.R552C, c.1720G>A) was of great importance for 
our research, because the gene is located on Chr18 and the mutation was predicted to 
be deleterious/damaging for the function of the altered protein. It is positioned in the 
Rel-homology domain (RHD), which is found in a family of eukaryotic transcription 
factors (incl. NFAT). Dr. Laura Stoß (former doctoral student) sequenced all important 
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domains of NFATC1 (phosphorylation sites, DNA-binding sites, Calcineurin-binding site, 
and transactivation domain A, nucleus localization signal and nucleus export signal) in 
the same cohort of 30 SI-NET samples described above. A germ line mutation 
(p.L344V, c.1030C>G) in a primary tumor as well as in the matching distant metastasis 
(and the matching normal tissue) was detected. This mutation is not located in any 
distinct domain and since it was also present in the normal tissue, no tumor-specific 
background of the SNV was expected.  
Data comparison with external data set 
During the preparation of my doctoral thesis, Banck et al. published the first study 
concerning the genomic landscape of SI-NETs. They detected 197 somatic alterations 
in 48 patients [3].  
The only gene bearing mutations in both the cohort of Banck et al. and ours was 
ADCY5 (Adenylate cyclase 5). Both mutations lie in the Adenylyl cyclase N-terminal 
extracellular and transmembrane region. Partridge et al. pointed out that primarily the 
loss of polar residues in transmembrane domains (TMD) can lead to severe protein 
malfunction, since these residues are able to form membrane-inserted H-bonds, 
thereby stabilizing the α-helices of TMDs [108].  
The mutation found in our sample (p.N382H, c.1144A>C, 19%) lead to an amino acid 
substitution from asparagine (polar) to histidine (basic), which therefore could result in a 
destabilized protein structure. The mutation found by Banck et al. (p.V312I) is a valine 
to isoleucin substitution (both hydrophobic amino acids), meaning that amino acids with 
similar chemical functionalities are replaced by another, diminishing the potential 
disadvantageous impact of this mutation. 
Concerning Chr18 Banck and colleagues identified only one SNV. The gene 
ANKRD30B (Ankyrin repeat domain 30B) depicted a T>A substitution at genomic 
position 14796361 (p.V625D, predicted to be benign). No Pfam annotations are known 
for this gene (http://cancer.sanger.ac.uk/cosmic). The tumor, in which the mutation was 
found, showed no loss of Chr18. 
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Our exome sequencing of five patients with SI-NETs revealed two SNVs and one 
deletion in genes on Chr18 in two patients. Patient Tu5, which had one mutation in 
NFATC1 and CABYR, respectively, also showed loss of one Chr18 (FISH and SNP 
array analysis). Patient Tu3 (with a 3-base pair-deletion in PIEZO2) showed a mosaic 
pattern concerning Chr18 status. 
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IV. Results – Chr18-associated tumor suppressors 
 
Western blot analysis of Chr18-associated putative tumor suppressors 
In order to analyze, whether Chr18 loss is accompanied with loss of protein expression 
of the known putative tumor suppressors located on this chromosome, western blot 
analysis was performed with protein lysates from up to 21 SI-NET samples. 
SMAD2 and SMAD4 are strongly expressed in SI-NETs 
First, the protein expression of the two tumor suppressors SMAD2 and SMAD4 was 
investigated by western blot analysis with protein lysates from 14 SI-NET samples (ten 
with loss of Chr18, confirmed by Chr18 centromere FISH, two without loss of Chr18 and 
two samples with mosaicism regarding Chr18 status). Both tumor suppressor proteins 
were detected in varying amounts in all samples investigated (SMAD2: 60 kDa, 
SMAD4: 61 kDa, β-actin: 42 kDa; Figure 8).  
SMAD2 
SMAD2 could be detected in varying amounts in all samples investigated (Figure 8, 
upper panel). SMAD2 appears as double band in western blot analysis; one band at 
~55 kDa, one at ~70 kDa. To determine if either bands or only one band is specific for 
SMAD2, the CML cell line K562 was used as positive control. The protein lysate of this 
cell line showed a single band at ~55 kDa in western blot analysis; therefore, this band 
was defined as specific for SMAD2 (Figure 8, indicated by the red arrow). Although no 
loss of expression was detected in the SI-NET samples, the tumor samples showed 
differences in strength of expression of SMAD2, whereas the β-Actin expression only 
varied slightly between the samples. The quantitative western blot analysis revealed 
one sample to be negative for SMAD2 (sample 6, <20% of β-Actin, Figure 9). This 
sample depicted loss of Chr18.  
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Figure 8: Western blot of the tumor suppressors SMAD2 and SMAD4 in 14 SI-NETs  
The samples show variable strength of expression of SMAD2 and SMAD4 (SMAD2: 60 kDa, indicated by the red arrow, 
SMAD4: 61 kDa, β-actin: 42 kDa). P: positive control, N: negative control, M: mosaic, 1: 1xChr18, 2: 2xChr18, numbers below 
indicate tumor content (%) 
 
  
Figure 9: Quantitative western blot analysis for SMAD2 and SMAD4  
The ratio of the distinct protein expression (SMAD2/SMAD4) to the respective β-Actin expression per sample is shown (%). P: 
positive control; red bar indicates protein expression <20% of β-Actin 
 
SMAD4 
Western blot analysis of SMAD4 revealed a similar result: all 14 SI-NET samples 
showed strong expression of this protein, regardless of the count of Chr18 (Figure 8, 
lower panel). Half of the samples showed (slightly) higher SMAD4 expression than 
expression of the housekeeping protein β-Actin (>100% of β-Actin expression), whereas 
the other half of the samples showed similar expression for both proteins (Figure 9). 
NIH/3T3 was used as positive control for this Western blot, whereas the pancreatic 
carcinoma cell line BxPC-3 was used as negative control for SMAD4 [44].  
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Elongin A3 and CABLES show strong expression in SI-NETs, whereas PMAIP1 is not 
expressed 
Western blot analyses of the two tumor suppressors Elongin A3 and CABLES were 
performed with 21 fresh frozen tissues. CABLES was detected in varying amounts in all 
analyzed samples (Figure 10, upper panel, Figure 11, first picture; only the first eight 
samples are shown). For CABLES multiple isoforms are described, which often show as 
doublets in western blot analyses. Whereas the positive control (HEK293 T cell lysate) 
only depicts the upper doublet band at ~67 kDa, all NET samples showed an additional 
aberrant band of varying strength at ~55 kDa. 
Since two different bands were visible in the Elongin A3 western blot (but only one 
isoform is known), a competition analysis with a peptide was performed, identifying the 
upper band to be the specific one (Figure 10, middle panel, Figure 11, second picture; 
only the first eight samples are shown). Elongin A3 exhibited distinct positive results in 
20 of the 21 samples; one sample was negative (not shown). 
Western blot analysis of PMAIP1 revealed negativity (<20% of β-Actin expression) of 
the first eight samples, whereas the protein lysate of U251 showed a distinct band 
(Figure 10, lower panel, Figure 11, third picture); therefore, no further samples were 
tested. 
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Figure 10: Western Blot analysis of the putative tumor suppressors CABLES, Elongin A3, and PMAIP1 in 8 (of 21) SI-NETs 
CABLES and Elongin A3 are mostly strongly expressed, whereas PMAIP1 is negative in all samples (CABLES: 67 kDa, indicated 
by the red arrow, Elongin A3: 60 kDa, with and without competing peptide, indicated by the red arrow, PMAIP1: 15 kDa) P: 
positive control, M: mosaic, 1: 1xChr18, 2: 2xChr18, numbers below indicate tumor content (%) 
88 
 
 
Figure 11: Quantitative western blot analysis for CABLES, Elongin A3, and PMAIP1 
The ratio of the distinct protein expression (SMAD2/SMAD4) to the respective β-Actin expression is shown (%). P: positive 
control; red bars indicate protein expression <20% of β-Actin; Sample 1, 3, 5, 7, and 8 depicted no band at all for PMAIP1. 
 
DCC expression is lost/reduced in nearly 30% of SI-NET samples 
Western blot analysis of DCC using the first antibody was performed with 21 tumor 
samples. The evaluation of the western blot results revealed total loss or reduced DCC 
expression (<20% of β-Actin expression) in 29% (6/21) of samples (Figure 12A, Figure 
13: DCC 1A, 2, 3).  
With the first eight tumor samples a second western blot was performed, using another 
antibody (Figure 12B, Figure 13: DCC 1B). Due to difficulties in distinguishing the bands 
between 180 and 250 kDa, a competition with the matching peptide was applied. In 
addition, a label-free identification of DCC-specific peptides in the positive control IMR-
32 by mass spectrometry was performed. The mass spectrometry confirmed DCC to be 
present in the gel bands at ~190 kDa. 
The second western blot analysis revealed sample 5 and 7 to have lost DCC 
expression. This result is supported by the first western blot: sample 7 has lost DCC 
expression as well and sample 5 exhibits reduced expression of DCC. Since the 
background signal was very high, sample 3 and 6 were not analyzable in the second 
89 
 
western blot. All samples with lost/reduced expression of DCC depicted only one copy 
of Chr18. 
 
Figure 12: Western blot of the Chr18-associated tumor suppressor DCC in 21 SI-NETs 
A) DCC is lost in sample 7 and 12. The samples 3, 5, 11, and 16 show greatly reduced expression of DCC (158 kDA). B) DCC 
western blot of the first eight tumor samples, using a second antibody (190 kDa). A competition analysis with matching 
peptide was carried out to determine the right protein band (indicated by the red arrow). DCC is lost in sample 5 and 7. Due 
to strong background, the samples 3 and 6 are not analyzable. P: positive control, M: mosaic, 1: 1xChr18, 2: 2xChr18, 
numbers below indicate tumor content (%) 
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Figure 13: Quantitative western blot analysis for DCC 
Red bars indicate protein expression <20% of β-Actin. Sample 3 and 6 of DCC western blot 1B (second antibody) were not 
analyzable due to high background, therefore no bar is shown. 
 
Quantitative Real-time PCR (qRT-PCR) analysis reveals TCEB3C and CABLES to 
be differentially expressed between sample cohorts with and without loss of 
Chr18 
Since only one cryo-conserved sample with the normal count of Chr18 was available for 
western blot analyses of Elongin A3, PMAIP1, DCC, and CABLES, an additionally qRT-
PCR was performed to further investigate the influence of the Chr18 loss on these 
tumor suppressors. qRT-PCR for TCEB3C (coding for Elongin A3), PMAIP1, DCC, and 
CABLES was done in a greater cohort of 69 FFPE samples.  
The Cp-values ranged between 22 (high expression) and 35 (low expression). The raw 
Cp-values were normalized to β-Actin, resulting in ΔCp values. The statistical setup was 
designed that lower ΔCp values indicate an upregulation, whereas higher ΔCp values 
display a downregulation.  
Four samples depicted Cp values >30 for the normalization control β-Actin and were 
therefore excluded from further analysis (the high Cp values of the ubiquitously 
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expressed housekeeping gene β-Actin suggest that the RNA of the respective samples 
is somehow degraded). Of the remaining 65 samples, 38 exhibited the loss of one 
Chr18, 13 samples depicted the normal count of two chromosomes 18, and 12 tumors 
showed mosaicism regarding their Chr18 status, determined by FISH analysis (it was 
not possible to ascertain the Chr18 status for two samples). For the comparative 
analysis of cohorts with/without loss of Chr18, the mosaic samples were excluded. 
DCC seems to be weakly expressed in SI-NETs: DCC Ex3-4 exhibited average Cp 
values of 34.29 and 34.65 for samples with 1xChr18 and 2xChr18, respectively. Similar 
results were achieved, when comparing the mRNA coding for the exon boundary 
between Ex17 and Ex18 of the DCC gene: average Cp value of 33.51 and 34.02 for 
1xChr18 and 2xChr18, respectively. The mean ΔCp values were 10.41 (1xChr18) and 
9.86 (2xChr18) for DCC Ex3-4 and 9.59 (1xChr18) and 9.22 (2xChr18) for DCC Ex17-
18 (Figure 14, upper panel). The difference of expression between the two cohorts were 
not significant for DCC (p=0.22 for Ex3-4 and p=0.31 for Ex17-18, respectively). 
TCEB3C (the gene coding for Elongin A3) exhibited strong expression in SI-NETs with 
average Cp values of 24.62 (1xChr18) and 24.71 (2xChr18). Although the Cp values 
were nearly the same for both cohorts, the normalization revealed a significant 
downregulation of this gene in the cohort with loss of Chr18 (p=0.01, with average ΔCp 
values of 0.9 for 1xChr18 and 0.07 for 2xChr18; Figure 14, middle panel, first picture). 
CABLES was weakly expressed in SI-NETs with average Cp values of 34.2 (1xChr18) 
and 34.38 (2xChr18). However, comparative analysis revealed significantly different 
mRNA expression between the two cohorts (ΔCp values of 10.47 and 9.68 for 1xChr18 
and 2xChr18, p=0.03; Figure 14, middle panel, second picture). 
Finally, PMAIP1 expression was analyzed by qRT-PCR. Since western blot analysis 
revealed negativity for eight tested SI-NETs, weak mRNA expression was to be 
expected regarding this gene. This was confirmed by the Cp values: mean Cp values 
were 34.37 (1xChr18) and 34.75 (2xChr18). The normalization resulted in average ΔCp 
values of 10.52 (1xChr18) and 9.97 (2xChr18). The difference between the two cohorts 
showed a tendency towards higher PMAIP1 expression in the cohort with preserved 
Chr18 status, but was not significant (p=0.07; Figure 14, lower panel). 
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In summary, only TCEB3C mRNA seems to be strongly expressed in SI-NETs, all other 
genes exhibited high Cp values, suggesting a weak expression. However, all genes 
investigated showed a trend towards lower ΔCp values in the cohort with two Chr18 
compared to the cohort with loss of Chr18, meaning higher expression. This difference 
was significant concerning TCEB3C and CABLES.  
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Figure 14: ΔCp values of the four tumor suppressor genes DCC, TCEB3C, CABLES, and PMAIP1 
The Cp values of the genes were normalized to β-actin. For DCC, two primer pairs amplifying different exon boundaries of 
the gene were tested (exon 3-4 and exon 17-18). TCEB3C and CABLES were significantly downregulated (p=0.01 and p=0.03, 
respectively) in the cohort with loss of Chr18 compared to the cohort with a normal count of Chr18.  
p=0.22 p=0.31 
 
p=0.01 
p=0.03 
p=0.07 
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IV. Results - PI3K/AKT/mTOR pathway 
FISH analysis of the PI3K/AKT/mTOR-pathway 
Copy number gains of PIK3CD, AKT1, AKT2, PDGFRα, PDGFRβ, and mTOR 
Eight TMAs with 217 SI-NETs (comprising 135 patients) were analyzed for 
amplifications of the PI3K/AKT/mTOR-pathway. To cover the whole pathway, the 
tyrosine kinase receptors PDGFRα and PDGFRβ, the PI3K delta isoform PIK3CD, and 
the serine/threonine kinases AKT1 and AKT2, and mTOR were analyzed. 
Evaluation of FISH results revealed low level amplifications in a subset of SI-NETs, 
meaning that most of the nuclei showed 3-6 gene specific signals per cell (Figure 15). 
No high level amplifications with >9 signals per cell could be detected. These 
amplifications were sometimes associated with additional signals for the reference 
chromosome probes, indicating chromosome polysomy. (The ratios of gene specific 
signals to reference chromosome signals ranged between 1.03 and 1.6. This evaluation 
was not achieved for PDGFRβ since only a split probe was available for this gene.)  
Henceforth, the term copy number (CN) variation is used for the variations found in the 
tumors, since single gene amplifications (centromere signal count ≤72, 
target/centromere ratio >1.2), amplifications in combination with polysomy (centromere 
signal count >72, ratio target/centromere signals >1.2), or polysomy (target signal count 
>72, ratio target/centromere signals ≤1.2) occurred in our samples. 
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Figure 15: Exemplary fluorescent pictures of SI-NETs harboring CN gains 
(A) AKT1, (B) AKT2, (C) PDGFRβ, (D) PDGFRα, (E) mTOR, and (F) PIK3CD; magnification: 1000x; red: gene specific signals, 
green: reference chromosome signals 
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The percentage of CN variations in our cohort ranged between 12% (PDGFRα) and 
24% (PDGFRβ). PIK3CD and AKT1 depicted CN variations in 18% each, AKT2 in 14% 
and mTOR in 16% (Table 23 last line). Table 23 gives a detailed overview over the 
variations found in the SI-NETs. 
Table 23: Results of FISH analysis of PIK3CD, AKT1/2, PDGFRα/β, and mTOR 
The upper panel shows the number of samples which were applicable for FISH analysis. In the lower panels the percentage 
and total number of samples with gene CN variations are given. P: primary tumor, LN: lymph node metastasis, DM: distant 
metastasis, CN: copy number, any: any CN variation for the gene, amplified: centromere signal count ≤72, ratio 
target/centromere signals >1.2, amplified+polysomy: centromere signal count >72, ratio target/centromere signals >1.2, 
polysomy: target signal count >72, ratio target/centromere signals ≤1.2 
  PIK3CD AKT1 AKT2 PDGFRα PDGFRβ mTOR 
Applicable 
cases 
P: 94 P: 91 P: 96 P: 83 P: 96 P: 95 
  LN: 57 LN: 56 LN: 58 LN: 59 LN: 63 LN: 58 
  DM: 13 DM: 13 DM: 10 DM: 12 DM: 14 DM: 12 
  any: 113 any: 110 any: 112 any: 104 any: 112 any: 110 
Amplified cases 
[%] 
P: 7% 
(7/94) 
P: 9% (8/91) P: 2% (2/96) P: 1% (1/83) P: 14% 
(13/96) 
P: 7% (7/95) 
  LN: 19% 
(11/57) 
LN: 14% 
(8/56) 
LN: 9% (5/58) LN: 3% (2/59) LN: 27% 
(17/63) 
LN: 7% (4/58) 
  DM: 15% 
(2/13) 
DM: 23% 
(3/13) 
DM: 10% 
(1/10) 
DM: 0% DM: 36% 
(5/14) 
DM: 8% 
(1/12) 
Amplified + 
polysomy [%] 
P: 0% P: 1% (1/91) P: 1% (1/96) P: 0%  - 
 
P: 1% (1/95) 
  LN: 0% LN: 4% (2/56) LN: 0% LN: 0% -  LN: 0% 
  DM: 0% DM: 0% DM: 0% DM: 0%  - DM: 0% 
Polysomy [%] P: 0% P: 0% P: 4% (4/96) P: 2% (2/83)  - P: 4% (4/95) 
  LN: 2% 
(1/57) 
LN: 0% LN: 3% (2/58) LN: 10% 
(6/59) 
 - LN: 2% (1/58) 
  DM: 0% DM: 0% DM: 10% 
(1/10) 
DM: 17% 
(2/12) 
 - DM: 0% 
All CN 
variations 
P: 7% 
(7/94) 
P: 10% (9/91) P: 7% (7/96) P: 4% (3/83) P: 14% 
(13/96) 
P: 13% 
(12/95) 
  LN: 21% 
(12/57) 
LN: 18% 
(10/56) 
LN: 12% 
(7/58) 
LN: 14% 
(8/59) 
LN: 27% 
(17/63) 
LN: 9% (5/58) 
  DM: 15% 
(2/13) 
DM: 23% 
(3/13) 
DM: 20% 
(2/10) 
DM: 17% 
(2/12) 
DM: 36% 
(5/14) 
DM: 8% 
(1/12) 
  any: 18% 
(20/113) 
any: 18% 
(20/110) 
any: 14% 
(16/112) 
any: 12% 
(12/104) 
any: 24% 
(27/112) 
any: 16% 
(17/110) 
 
The distribution of CN alterations in the PI3K/AKT/mTOR pathway between primary 
tumors, lymph node metastases, and distant metastases is depicted in Figure 16. For 
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five of the six genes, CN alterations were more abundant in metastases (lymph node 
and distant metastases combined) than in primary tumors, with mTOR being the 
exception. This observation was statistically significant for AKT1 (p=0.005), AKT2 
(p=0.014), PDGFRα, and PDGFRβ (both p<0.000). Additionally, the percentage of 
amplified genes was mostly slightly higher in distant than in lymph node metastases, 
but statistical significance was not reached. The values of lymph node/distant 
metastases for the different genes were: PIK3CD 21/15%, AKT1 18/23%, AKT2 
12/20%, PDGFRα 14/17%, PDGFRβ 27/36%, and mTOR 9/8%. 
 
 
Figure 16: Distribution of CN alterations in the PI3K/AKT/mTOR pathway between primary tumors and metastases  
Blue: primary tumors, red: lymph node metastases, green: distant metastases 
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Comparative analysis of primary tumor and metastases 
The FISH analysis showed that metastases mostly harbor more CN variations than 
primary tumors. To take a closer look at the time point of this event, we did a 
comparative analysis of primary tumors and matching metastases.  
For the comparison, 37 to 50 analyzable samples were available. The evaluation 
revealed AKT1, AKT2, and PDGFRα CN gains to occur more often in metastases than 
in matching primary tumors (Figure 17). PIK3CD and PDGFRβ CN gains were present 
fifty-fifty either in primary tumors or metastases. Interestingly, gains of PDGFRα were 
predominantly seen in both primary tumors and matching metastases (60%); in contrast 
no overlap of gains could be observed in matching primary-metastases pairs for 
PIK3CD.  
 
Figure 17: Comparison of amplifications between primary tumors and matching metastases  
P: primary tumor, M: metastasis 
 
Advanced tumors harbor significantly more CN gains than tumors of earlier stage 
The next step was a comparative evaluation of the distribution of gains in different 
tumor stages. Advanced tumors (UICC stage IIIB and IV) depicted significantly more 
gains in the PI3K/AKT/mTOR pathway than earlier tumors (UICC stage I-IIIA grouped 
together, p=0.014, Figure 18).  
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Figure 18: Distribution of gains by UICC stages 
Advanced tumors (UICC stage IIIB and IV) show significantly more CN gains in the PI3K/AKT/mTOR pathway in contrast to 
tumors of earlier stages (p=0.014). 
 
Furthermore, when comparing early T stages (T1+T2) with higher T stages (T3+T4) 
concerning their amplification status, a significant association was seen between gains 
and higher T stages (p=0.028, Figure 19). 
 
Figure 19: Distribution of gains by T stages 
Higher T stages (T3+T4) depicted significantly more CN gains than T1 and T2 stages (p=0.028). 
 
p=0.014 
p=0.028 
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These results indicate that the CN variations are prevalent in tumors with advanced 
stage (with lymph node / distant metastases) and invasion in the (sub-)serosa / other 
organs. 
Comparison of FISH results with SNP array results  
In order to get a better understanding of the events underlying the CN variations 
received by FISH analysis, the SNP array samples Tu1 und Tu7, and their matching 
metastases, as well as Tu2 (samples showing multiple CNVs), were analyzed in regard 
of the PI3K/AKT/mTOR signaling pathway gene variations.  
Therefore, SNP array data was compared with the exact chromosomal locations of the 
genes investigated by FISH.  
PDGFRα, which is located on Chr4, was affected by a huge CN gain, comprising the 
region 4p11-q12 and 4p11-q13.2, in Tu1(Met) and Tu7(Met) respectively. Comparable 
results were achieved for PDGFRβ, located on Chr5: the regions 5q32-q33.1 and 
5q31.1-q33.1 were affected in the respective tumors. For both regions, CN gains of 3 
were detected. Tu2, which also depicted CN of 3 for Chr4 and Chr14, showed no 
amplification of PDGFRα and AKT1, indicating that the amplified regions were dissimilar 
to the locations of these two genes. 
mTOR, PIK3CD (both located on Chr1), and Akt1 (Chr14) were not affected by CN 
gains in any of the samples investigated. Akt2 (Chr19) was amplified (CN=3) within a 
region of 3,642 kb (19q13.2) in Tu1(Met), but not in Tu7(Met) or Tu2. 
Comparison of FISH results with data from Banck et al. [3] 
Banck and colleagues’ publication, stating gene alterations in the PI3K/AKT/mTOR 
pathway to be the most frequent with 29% (14/48) of patients affected, prompted us to 
verify their findings in a greater cohort of 135 patients (217 tumor samples) and with 
another method, the Fluorescence-in-situ-hybridization. Subsequently, a comparison of 
the results, achieved by the different methods and in the different cohorts, is performed. 
The exact locations of the six genes of the PI3K/AKT/mTOR pathway were compared 
with the data of Supplemental Table 12 of Banck et al., which depicted “1013 Somatic 
Copy Number Variations (SCNA) in 48 SI-NET” (adjusted in Table 25, fold change was 
not given by Banck et al., but calculated by us). 
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Table 24: Comparison of FISH results with raw data from Banck et al. 
Table adapted after Supplemental Table 12 of Banck et al. [3] 
Pt-ID: Patients identification, Chr: Chromosome, m.log2: ratios between tumor and normal tissue reads per exon, normalized to mean ratio and log(2) transformed, 2x: fold 
change, calculated on basis of m.log2, bp: base pairs, pval: p-value. 
Pt-ID Chr Start End Exons m.log2 (x) Fold 
change 
(2^x) 
Event size 
[bp] 
Call pval Gene 
13 1 6.488.285 28.843.236 3066 0.2686 1.205 22.354.951 amp 1.34E-09 mTOR/PIK3CD 
17 1 14.362 11.710.001 1539 0.2662 1.203 11.695.639 amp 7.77E-22 mTOR/PIK3CD 
35 1 14.362 13.182.960 1818 0.2571 1.195 13.168.598 amp 8.21E-50 mTOR/PIK3CD 
45 1 14.362 28.843.236 4011 0.3777 1.299 28.828.874 amp 5.23E-19 mTOR/PIK3CD 
4 4 53.226 190.947.538 7842 0.3628 1.286 190.894.312 amp NA PDGFRα 
7 4 53.226 190.947.538 7844 0.402 1.321 190.894.312 amp NA PDGFRα 
20 4 678.271 190.947.538 7783 0.256 1.194 190.269.267 amp NA PDGFRα 
36 4 40.058.650 190.947.538 5983 0.341 1.267 150.888.888 amp NA PDGFRα 
2 5 94.982.582 180.687.001 4944 0.4715 1.387 85.704.419 amp NA PDGFRβ 
4 5 140.372 180.687.001 8828 0.3525 1.277 180.546.629 amp NA PDGFRβ 
7 5 140.372 180.687.001 8816 0.3881 1.309 180.546.629 amp NA PDGFRβ 
9 5 140.372 180.687.001 8783 0.3219 1.25 180.546.629 amp NA PDGFRβ 
20 5 34.684.611 180.687.001 7773 0.2831 1.217 146.002.390 amp NA PDGFRβ 
22 5 140.372 180.687.001 8760 0.319 1.247 180.546.629 amp NA PDGFRβ 
34 5 6.651.954 180.687.001 8430 0.329 1.256 174.035.047 amp NA PDGFRβ 
4 14 50.175.876 106.950.170 4314 0.3994 1.319 56.774.294 amp NA Akt1 
7 14 89.029.994 106.950.170 1714 0.3538 1.278 17.920.176 amp NA Akt1 
14 14 103.998.918 106.950.170 355 0.7003 1.625 2.951.252 amp NA Akt1 
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20 14 19.377.593 106.950.170 6164 0.3067 1.237 87.572.577 amp NA Akt1 
21 14 77.679.788 106.950.170 2007 0.4777 1.393 29.270.382 amp NA Akt1 
35 14 104.037.959 106.950.170 355 0.3055 1.236 2.912.211 amp NA Akt1 
41 14 104.640.484 106.950.170 237 0.3641 1.287 2.309.686 amp NA Akt1 
42 14 103.801.989 106.950.170 401 0.3866 1.307 3.148.181 amp NA Akt1 
13 19 30.018.117 59.092.611 6103 0.4087 1.327 29.074.494 amp NA Akt2 
16 19 110.678 59.092.611 11624 0.4449 1.361 58.981.933 amp NA Akt2 
22 19 110.678 59.092.611 11496 0.3157 1.245 58.981.933 amp NA Akt2 
45 19 17.598.268 43.967.277 3274 0.4959 1.41 26.369.009 amp 2.11E-26 Akt2 
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PIK3CD and mTOR were co-amplified in the patients 13, 17, 35, and 45, resulting in a 
frequency of 8% (4/48). PDGFRα and AKT2 were amplified in four out of 48 samples, 
as well. AKT1 was the most amplified gene in 17% (8/48) of the samples, PDGFRβ the 
second most amplified gene in 14.5% (7/48). 
Figure 20 summarizes the different frequencies of CN gains, which were found in the 
study of Banck et al. [3] and by us. 
 
Figure 20: Percentage of CN gains in SI-NETs 
Percentages over the blue bars depict the results of the FISH evaluation in our cohort of 217 tumor samples. Values under 
the gene names refer to the percentage of amplified cases (raw data analysis) detected by Banck et al. [3] in 48 tumor 
samples. 
 
The frequencies achieved by FISH are slightly higher than the ones achieved by NGS 
and array CGH, which is probably due to the different collectives and sample sizes.  
In our cohort, the majority of the variations were defined as “amplified” (Table 23), 
indicating that, albeit increased reference centromere signals occasionally occurred 
(Appendix Table 30), these additionally signals did not exceed the threshold of 72 
signals per cell (see Methods 3.11.2 FISH evaluation).  
In order to evaluate, if this was also true for the gains found by Banck et al., we again 
looked at the raw data of the CNVs (Table 24). The event size and number of exons 
give an impression of the regions which were affected by these CN gains. At least, 237 
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exons were affected and the smallest event size was 2,310 kbp (patient 41, AKT1 
amplification). One gene includes an average of 8.8 exons [109], so that the mentioned 
region might statistically  comprise 27 different genes. This result suggests that Banck 
et al. did not identify single gene amplifications, but CN variations, which are due to 
(partial) chromosomal gains. 
The last part of the data set comparison regarding gene amplifications in the 
PI3K/AKT/mTOR pathway focused on the level of amplifications, because our FISH 
results revealed predominant low-level amplifications of 3-6 signals per cell. Banck and 
colleagues provided an m.log2 value, which was calculated by counting the reads per 
exon in tumor and in normal tissue and determining the ratio between counts from 
normal tissue to tumor tissue. The ratios were then normalized to the mean ratio and 
log2-transformed (Supplemental data of Banck et al. [3]). All samples with an m.log2 
≥0.25 were defined as “amplified”. For easing of the interpretation, the m.log2 values 
were converted to fold changes (2x) by us. m.log2 ≥0.25 results in a fold change of 
1.189. The fold changes of the regions, in which the six signaling genes are located, 
ranged between 1.194 and 1.625; meaning that these huge CN gains depicted only low 
amplification amplitudes (the authors describe that only small/focal amplifications, which 
included mostly only two exons, depicted higher amplitudes up to 16-fold). To sum up, 
Banck et al. observed gene gains in conjunction with gains of larger chromosomal 
regions, comparable to our SNP array results. Our FISH results, however, revealed 
mostly gene specific amplifications, in contrast to polysomy or combined occurrence of 
amplification and polysomy, according to our definition of the different CN statuses. All 
detected amplifications/gains (by Banck et al., as well as our SNP array and FISH 
results) were defined as “low-level”.   
Copy number variations are not associated with poorer overall survival 
To test whether single CN gains are associated with reduced overall survival, a Cox-
Regression analyses for all six genes was performed. For patients with CN gains no 
significant differences in survival were seen compared to patients without any gains. 
Figure 21 depicts the Kaplan Meier plots for A) AKT1, B) AKT2, C) PDGFRα, D) 
PDGFRβ, E) mTOR, and F) PIK3CD. The analysis included all CN variations 
(amplification, amplification + polysomy, polysomy) in any tumor sample of a patient 
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(primary tumor, lymph node, and/or distant metastasis). The p-values are given in the 
legends. 
In addition, investigation of all CN variations involved in the PI3K/AKT/mTOR pathway 
did not reveal any significant association with reduced overall survival (no amplification 
vs. amplification p=0.218, no amplification vs. 1xamplification vs. multiple amplifications 
p=0.458, no amplification vs. 1xamplification vs. 2xamplification vs. 3x+amplification 
p=0.598, no amplification vs. 1xamplification vs. 2xamplification vs. 3xamplification vs. 
4x+amplification p=0.755, no amplification vs. 1xamplification vs. 2xamplification vs. 
3xamplification vs. 4xamplification vs. 5x+amplification p=0.841, high amplifications (3-
6) vs. low amplifications (0-2) p=0.455; no figures shown). 
To sum up, CN gains in the PI3K/AKT/mTOR pathway do not seem to have a negative 
(or positive) impact on overall survival of the patients. 
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Figure 21: Kaplan Meier curves for the six genes of the PI3K/Akt/mTOR pathway investigated 
A) AKT1 p=0.77, B) AKT2 p=0.90, C) PDGFRα p=0.60, D) PDGFRβ p=0.85, E) mTOR p=0.30, F) PIK3CD p=0.22; green: CN gain, 
blue: no CN gain, overall survival in months 
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Protein expression and activation of AKT, mTOR, and its downstream targets 
and its association with copy number gains in the PI3K/AKT/mTOR pathway 
Activation of AKT, mTOR, and its downstream targets 
The last aim was to determine if there is an association between gains of the above 
mentioned genes and expression of the encoded proteins. Therefore, a statistical 
analysis of gene gains with subsequent protein expression was performed. The protein 
expression was evaluated according to the immunoreactive score (see Table 17).  Two 
cut offs were chosen for immunohistochemical staining: a) no/weak staining (Remmele 
score 0-3) against moderate/strong staining (Remmele score 4-12) and b) dichotomic 
distribution (0-6 vs. 7-12). 
AKT2 was moderately to strongly expressed in 69% of primary tumors, 56% of lymph 
node metastases, and 79% of distant metastases. p-AKT showed moderate to strong 
expression in 42.5%, 37%, and 58% of primary tumors, lymph node, and distant 
metastases, respectively (Table 25, line 3). Dichotomic evaluation revealed strong 
expression of AKT2 in only 16, 11, and 7% of primary tumors, lymph node, and distant 
metastases, respectively. For p-AKT, the values were even lower with 9% (primary), 2% 
(lymph node), and 0% (distant metastases) (Table 25, line 5).  
Moderate to strong (0-3 vs. 4-12) activation of mTOR was seen in 47% of primary 
tumors, 44% of lymph node, and 58% of distant metastases for p-mTOR. p-S6 was 
moderately to strongly expressed in only 8% of primary tumors and lymph node 
metastases, and 33% of distant metastases. In contrast, p4E-BP1 depicted strong 
expression in 69% of primary tumors, 23% and 30% of lymph node and distant 
metastases, respectively. However, when applying the dichotomic cut off (0-6 vs. 7-12), 
only 4% of primary tumors, 7% of lymph node, and 0% of distant metastases showed 
strong expression for p-mTOR. All samples showed only weak staining for p-S6, when 
using the dichotomic evaluation. p-4E-BP1 was strongly expressed in 12.5% of primary 
tumors; the metastases depicted only weak expression in this setting.  
When looking at protein expression of the AKT/mTOR pathway in any tumor sample of 
one case (primary or lymph node or distant metastases), moderate to strong expression 
(4-12) of AKT2 and p-AKT was seen in 74% and 48%, respectively. In contrast, strong 
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expression was only detected in 21 and 8.5%, respectively. p-mTOR was moderately to 
strongly expressed in 55% of the SI-NET samples. Only 6.5% showed expression with 
staining scores of 6-12. Similar results were achieved for p-4E-BP1 with 67% (4-12) and 
11% (6-12) moderate to strong expressed samples. For p-S6 both cut offs resulted in 
14% of moderately to strongly expressed samples.  
The difference of the results achieved with the two different cut-off values indicate that 
most of the samples showed moderate staining with scores of 4-6 for the different 
(phosphor-)proteins evaluated. 
Table 25: Expression profile of AKT2, p-AKT, p-mTOR, and its downstream signaling molecules (IHC) 
  AKT2 p-AKT 
(Thr308) 
p-mTOR 
(Ser2448) 
p-S6 
(Ser240/244) 
p-4E-BP1 
(Ser65/Thr70) 
Applicable cases P: 98 P: 87 P: 89 P: 88 P: 88 
  LN: 61 LN: 54 LN: 43 LN: 60  LN: 39  
  DM: 14 DM: 12 DM: 12 DM: 12  DM: 10  
 any: 113 any: 106 any: 107 any: 108 any: 104 
No/weak stained cases 
[0-3] 
P: 31% 
(30/98) 
P: 57.5% 
(50/87) 
P: 53% 
(47/89) 
P: 92% 
(81/88) 
P: 31% (27/88) 
  LN: 44% 
(27/61) 
LN: 63% 
(34/54) 
LN: 56% 
(24/43) 
LN: 92% 
(55/60) 
LN: 77% 
(30/39) 
  DM: 21% 
(3/14) 
DM: 42% 
(5/12) 
DM: 42% 
(5/12) 
DM: 67% 
(9/12) 
DM: 70% 
(7/10) 
 any: 26% 
(29/113) 
any: 52% 
(55/106) 
any: 45% 
(48/107) 
any: 86% 
(93/108) 
any: 33% 
(34/104) 
Moderate/strong stained 
cases [4-12] 
P: 69% 
(60/98) 
P: 42.5% 
(37/87) 
P: 47% 
(42/89) 
P: 8% (7/88) P: 69% (61/88) 
  LN: 56% 
(34/61) 
LN: 37% 
(20/54) 
LN: 44% 
(19/43) 
LN: 8% (5/60) LN: 23% (9/39) 
  DM: 79% 
(11/14) 
DM: 58% 
(7/12) 
DM: 58% 
(7/12) 
DM: 33% 
(4/12) 
DM: 30% 
(3/10) 
 any: 74% 
(84/113) 
any: 48% 
(51/106) 
any: 55% 
(59/107) 
any: 14% 
(15/108) 
any: 67% 
(70/104) 
No-to-moderate stained 
cases [0-6] 
P: 84% 
(82/98) 
P: 91% 
(79/87) 
P: 96% 
(85/89) 
P: 100% 
(88/88) 
P: 87.5% 
(77/88) 
  LN: 89% 
(54/61) 
LN: 98% 
(53/54) 
LN: 93% 
(40/43) 
LN: 100% 
(60/60) 
LN: 100% 
(39/39) 
  DM: 93% 
(13/14) 
DM: 100% 
(12/12) 
DM: 100% 
(12/12) 
DM: 100% 
(12/12) 
DM: 100% 
(10/10) 
 any: 79% 
(89/113) 
any: 91.5% 
(97/106) 
any: 93.5% 
(100/107) 
any: 86% 
(93/108) 
any: 89% 
(93/104) 
Strong stained cases [6-
12] 
P: 16% 
(16/98) 
P: 9% (8/87) P: 4% (4/89) P: 0% (0/88) P: 12.5% 
(11/88) 
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  LN: 11% 
(7/61) 
LN: 2% 
(1/54) 
LN: 7% 
(3/43) 
LN: 0% (0/60) LN: 0% (0/39) 
  DM: 7% 
(1/14) 
DM: 0% 
(0/12) 
DM: 0% 
(0/12) 
DM: 0% 
(0/12) 
DM: 0% (0/10) 
 any: 21% 
(24/113) 
any: 8.5% 
(9/106) 
any: 6.5% 
(7/107) 
any: 14% 
(15/108) 
any: 11% 
(11/104) 
 
In Figure 22, exemplary stainings of AKT2, p-AKT (Thr308), and p-mTOR are shown. 
Figure 23 shows immunohistochemical staining of the mTOR downstream signaling 
proteins p-4E-BP1 (with and without complementary peptide) and p-S6.
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Figure 22: Immunohistochemical stainings of AKT2, p-AKT, and p-mTOR in SI-NETs 
Picture (A) depicts an AKT2 negative, (B) an AKT2 positive, (C) a p-AKT negative, (D) a p-AKT positive, (E) a p-mTOR negative, 
and (F) a p-mTOR positive case. Magnification: 200x
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Figure 23: Immunohistochemical stainings of mTOR downstream molecules in SI-NETs 
Picture (A) depicts a p-4E-BP1 positive case with use of a complementary peptide and (B) without peptide. (C) shows a p-S6 
negative and (D) a p-S6 positive case. Magnification: 200x 
 
Copy number gains of the PI3K/AKT/mTOR pathway are not associated with protein 
expression or activation  
In order to identify possible associations between copy number gains and the protein 
expression and activation status, Pearson’s Chi-square test was applied. Copy number 
gains in primary tumors, lymph node, and distant metastases alone or together were 
analyzed against immunohistochemical stainings of p-mTOR, p-S6, and p-4E-BP1 (both 
cut-offs), as well as against any activation of the three proteins. Finally, multivariate 
analysis was performed to address the association between any gains in the pathway 
and the protein expression achieved by IHC (Appendix Table 31). 
No significant association between gene gains and subsequent protein expression 
could be determined. In some cases, even the opposite event occurred, so that the 
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protein expression was inversely correlated with the amplification of the gene, 
suggesting that the amplifications do not result in enhanced protein expression.   
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V. Discussion 
 
Parts of the discussion described on page 111-118 are already published in [50]. 
Part 1: Chromosome 18 
Neuroendocrine tumors of the gastroenteropancreatic system (GEP-NETs) comprise a 
multiplicity of different neoplasms that differ in tumor biology and prognosis [5]. What 
they have in common, however, is their origin in single neuroendocrine cells or 
neuroendocrine islets of the diffuse neuroendocrine system. Although SI-NETs are 
slow-growing neoplasms, they are nevertheless tumors with a morbidity rate that cannot 
be neglected (23.5% after 10 years for G1 and 30.3% for G2, respectively [8]).  
Loss of (a part) of Chr18 found in approximately 70% of SI-NETs has been shown in 
several previous studies to be a common event in SI-NETs, and seems to be an early 
event of tumorigenesis. No other frequent genetic alterations or putative affected 
pathways have been implicated in the tumorigenesis of SI-NETs as yet. A number of 
studies (reviewed in [39]) investigated the possible effect of Chr18 loss. However, there 
is no comprehensive data on Chr18-related alterations at transcriptional level in SI-
NETs. One conceivable possibility is the loss of tumor suppressor activity of Chr18-
related tumor suppressors. The first part of my doctoral thesis focused on the 
investigation of six putative tumor suppressors on Chr18 using RNA or protein-based 
assays, comparing SI-NETs with and without Chr18 losses.  
First, the most relevant Chr18-related tumor suppressors, SMAD2 and SMAD4, which 
are important signal transduction molecules in the TGFβ pathway, were evaluated [40]. 
SMAD4 is functionally inactivated in different types of cancer such as pancreatic 
adenocarcinomas [44], metastatic colorectal cancer [42] and small intestine 
adenocarcinomas [46]. SMAD2 has also been described as being altered in a variety of 
cancers, although to a lesser extent than SMAD4 [43, 45]. 
Western blot analyses confirmed that the loss of SMAD2 and SMAD4 protein 
expression is not commonly found in a cohort of 14 SI-NETs. Previous work done by 
the working group of Prof. Sipos revealed 100% expression of SMAD2 in 87 FFPE 
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samples by IHC; SMAD4 was only lost in three out of these 87 tumor samples. These 
findings correlate with data from Löllgen et al., who analyzed a small panel of seven 
neuroendocrine tumors of the midgut by SMAD4 immunohistochemistry and found no 
loss of SMAD4 protein expression in these samples [110]. The western blot results 
support the previous findings; indicating that SMAD2 and SMAD4 do not play a role in 
the tumorigenesis of SI-NETs.   
In 1990, DCC (deleted in colorectal cancer) was identified to be frequently deleted in 
colorectal carcinoma [47]. Meanwhile, reduced expression of DCC has been described 
in a variety of cancers [111, 112]. DCC encodes a netrin-1 receptor, which induces 
apoptosis in the absence of netrin-1 [48]. Abridged expression of DCC could result in 
less apoptosis and thus give rise to tumor progression. DCC is a 158.5 kDa 
transmembrane protein with at least 18 splice variants (7 being protein coding). Since 
no reliable anti-DCC antibodies for IHC exist, DCC expression was assessed using 
qRT-PCR of different exon boundaries and western blot assays with peptide 
competition. qRT-PCR of DCC revealed no difference in expression between the two 
cohorts (38 with and 13 samples without loss of Chr18). Western blot showed a 
loss/reduced expression of DCC in 29% (6/21) SI-NETs. The specificity of the assay 
was verified with a biological positive control (IMR-32 cell line) competition of the 
reaction with corresponding peptide and the mass spectrometry of the positive control. 
The mechanism of loss of DCC has yet to be unraveled. Possible explanations are 
alternative splicing. The DCC gene is composed of 29 exons. Exons 1-7 encode for the 
four immunoglobulin domains, exons 8-21 for the fibronectin-type III domains, and 
exons 22-29 for the intracellular domain (Figure 24).  
 
Figure 24: Domains of the DCC protein  
Ig: immunoglobulin, Fn: fibronectin-type III, TM: transmembrane domain, ICD: intracellular domain, P: conserved domains 
(www.atlasgeneticsoncology.org) 
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Alternative splicing resulting in abnormal DCC transcript has already been described in 
colon cancer [113, 114]. One splice site occurs between exon 17 and 18, which 
encodes for the region between fibronectin domain 4 and 5. qRT-PCR was performed 
to address this specific exon boundary as well as the exon boundary of exon 3 and 4, 
which encodes for Ig domains of the protein (Figure 24). Reale et al. reported that loss 
of the splicing site between two fibronectin domains leads to inactivation of DCC [114]. 
Another publication on alternative splicing of DCC in cancer found, that colon cancer 
cell lines only express the proximal (exon 2) and distal exons (exons 28-29); exons in 
the center of the gene were confirmed to be absent [113]. This finding correlated with 
loss of protein expression in the cell lines. The qRT-PCR analysis of our SI-NET 
samples revealed DCC to be low to not expressed (Cp values 33-35) with no 
expression difference between the two intron-spanning primer pairs. This marked 
reduction of mRNA expression and possibly alternatively spliced gene could therefore 
result in reduced protein expression, as was detected in 29% of our SI-NET samples, 
comparable to the findings in colon cancer. 
Another silencing mechanism of DCC, which was described in head and neck 
squamous as well as esophagus cancer, is the methylation of the DCC promoter CpG 
island [115, 116]. Further studies will shed light on the mechanisms, which lead to 
loss/reduction of protein expression in our SI-NET cohort. 
Remarkably, Francis et al. reported the highest rate (29%) of intronic alterations in the 
DCC gene out of all putative tumor suppressor candidates on Chr18, rendering this 
gene even more interesting [2].  
TCEB3C encodes for Elongin A3, a transcription elongation factor identified in 2002 
[61]. TCEB3C is a maternally imprinted gene on Chr18 [60] and hence only one 
mutational hit is required to fulfill the Knudson’s two-hit hypothesis. Edfeldt and 
colleagues were able to show that TCEB3C is epigenetically repressed in the human 
SI-NET cell line CNDT2.5 due to histone and DNA methylation. They found that 77% of 
human tumor samples with only one TCEB3C copy were completely or mostly negative 
for Elongin A3 IHC staining. However, one primary tumor, a lymph node metastasis and 
a liver metastasis with two gene copies displayed also (partly) negative staining [62]. 
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qRT-PCR of TCEB3C in 69 FFPE samples revealed significant downregulation in SI-
NET with loss of Chr18 compared to samples with two copies (p=0.01). However, no 
reduction or loss of protein expression was detected in 21 fresh frozen samples. These 
results indicate that reduced mRNA expression was not associated with a relevant loss 
of protein; however only one cryo-conserved sample with retained Chr18 status was 
available for western blot analysis. It is possible, that the evaluation of more 2xChr18 
SI-NET samples by western blot could detect a difference in protein expression 
between 1xChr18 and 2xChr18 samples. Nevertheless, all 1xChr18 SI-NETs depicted 
strong Elongin A3 expression, reducing the impact of the differential qRT-PCR findings. 
CABLES is a cell cycle regulatory protein that plays a role in proliferation and 
differentiation [53]; the encoding gene was found to be silenced in ovarian, colorectal, 
endometrial, and non-small lung cancer [54-57]. qRT-PCR of CABLES exhibited a slight 
downregulation of CABLES (p=0.03) in SI-NET samples with Chr18 loss compared to 
tumors with diploid Chr18 in our cohort of 69 FFPE samples. However, similar to the 
Elongin A3 results, all samples showed strong protein expression in western blot 
analysis, suggesting the qRT-PCR findings to be of reduced relevance for the protein 
expression in general. An interesting observation was that all SI-NET samples depicted 
an additional band at ~55 kDa in the western blot, whereas the positive control cell line 
HEK293 only depicted the normal doublet band (~67 kDa). It has been reported, that 
the CABLES gene undergoes aberrant splicing in tumors, which can result in the loss of 
the CDK-binding domain, thereby demolishing the interaction with CDKs [59]. Normally, 
CDK2 is involved in the G1-S transition and DNA replication. Its activity is inhibited by 
Wee1 tyrosine 15 phosphorylation, which is dramatically enhanced by CABLES [1]. 
Loss of the CDK-binding domain could therefore result in faster progression through the 
cell cycle, finally leading to uncontrolled cell growth and enhanced tumor formation. 
Analysis of the transcriptome and proteasome could shed light on the question if all 
samples suffered from the same aberrant splicing event and if the CDK-binding domain 
is really impaired. This will be subject of our further investigations. 
Zukerberg and colleagues reported a (partial) loss of CABLES in 92% (23/25) of SI-
NETs by IHC [58]. The loss did not correlate with grade/stage/survival data. Whether 
the loss of CABLES expression was caused by the loss of Chr18 was not evaluated in 
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this study. They also found loss of CABLES in NETs from other sites, which are not 
associated with loss of Chr18 (e.g. lung), indicating that chromosomal deletion is not the 
mechanism of CABLES inactivation. It would be interesting to test whether epigenetic 
silencing could be the reason for the frequent loss of CABLES in NETs of other origin 
than small intestine.  
PMAIP1 is a pro-apoptotic gene, whose protein functions in a p53-dependent manner 
[52]. In 2008, PMAIP1 was identified as a potential tumor suppressor in pancreatic 
cancer by comparative cDNA microarray analysis [51]. In our cohort of 69 FFPE 
samples, qRT-PCR of PMAIP1 revealed high Cp values, suggesting that PMAIP1-
mRNA is low abundant in SI-NETs irrespective of their Chr18 status. The protein 
PMAIP1 was not expressed in the eight samples investigated by western blot. This 
finding would make PMAIP1 an interesting candidate. However, due to the small 
sample size the explanatory power is slightly reduced. On the other hand, a 100% loss 
of a tumor suppressor during tumorigenesis is highly unlikely. Another explanation for 
the finding could be that PMAIP1 is not present in neuroendocrine cells at all. 
Preliminary experiments of the working group of Prof. Sipos could show that this is true 
for Maspin, which is only expressed in mucin-producing cells of the normal ileal mucosa 
and absent in the neuroendocrine cells. Unfortunately, no supportive antibody for 
PMAIP1 immunofluorescence staining was available, making the application of a double 
staining (synaptophysin and PMAIP1) unfeasible.  
In summary, the systematic search for putative tumor suppressor proteins, which could 
get lost during tumorigenesis in SI-NETs, revealed DCC as the sole promising 
candidate in 29% of SI-NETs, although the mechanism of loss remains unclear.  
The design of the project has strengths and limitations which need to be addressed to 
value the results accordingly. The strengths include the comprehensive approach of all 
Chr18-related events and the thorough examinations of the putative tumor suppressors 
at protein level. The power of the study is limited by the low number of frozen tissue 
samples (8-21); however, most of the tumor suppressors exhibited an unequivocal 
expression profile, so that it was possible to draw clear conclusions. The second 
limitation lies in the lack of high value antibodies for immunohistochemistry, making it 
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impossible to investigate high numbers of FFPE samples and to study co-localization of 
tumor suppressors in normal NE cells. 
The next step was the search for novel putative tumor suppressor candidates located 
on Chr18. SNP array analysis and exome sequencing were conducted to identify 
additional genetic events on the remaining copy of Chr18, such as LOH, which could 
lead to the inactivation of tumor suppressor genes. SNP array analysis revealed loss of 
Chr18 in six of eight analyzable tumors, one tumor depicted a mosaic pattern and one 
tumor had two copies of Chr18. In the samples with loss / mosaic status of Chr18 no 
additional loss could be detected, indicating that the second hit of a Chr18 tumor 
suppressor does not underlie a genetic mechanism. Remaining possibilities are 
epigenetic events or post-translational modifications, which could affect the protein 
structure/stability. Since partial losses of Chr9 and 12 were also detected in one primary 
tumor and one pair of primary tumor and matching metastasis, respectively, further 
studies should concentrate on potential tumor suppressors located in these areas. 
Recently, Karpathakis et al. described three different subtypes of SI-NETs, concerning 
their molecular pattern. The largest group was defined by loss of Chr18, CIMP 
negativity, and presence of CDKN1B mutation. It was associated with older age at 
onset and longer PFS, compared to the other subgroups, suggesting a less aggressive 
phenotype. In contrast, patients with multiple CNVs (Chr18 loss, gain of Chr4, 5, 20) 
had a younger age of onset in combination with a shorter PFS, indicating a more 
aggressive phenotype [96]. This subgroup is contrary to the grouping of Nilsson et al., 
where Chr18 loss seems to be exclusive of chromosomal gains [39]. Our SNP array 
analysis revealed tumors of three patients (the two primaries Tu1 and Tu7, and the 
matching metastases Tu1 Met and Tu7 Met, and Tu2) to harbor Chr18 loss and gain of 
Chr4 and 20. The two pairs of primary and metastasis also depicted gain of Chr5. So, 
these patients of our collective seem to fit in the prognostic least favorable group with 
multiple CNVs defined by Karpathakis et al. In contrast, Tu4 and Tu5 Met depicted 
Chr18 loss as sole alteration, whereas Tu3 had a mosaic pattern regarding Chr18. Our 
findings support the fact that Chr18 loss can occur as single chromosomal variation in 
SI-NETs, or appears in combination with other CN variations (gains and losses). 
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Five SI-NETs, that showed complete (n=4) or partial (n=1) loss of Chr18, were analyzed 
by exome sequencing. No SNVs or InDels in known tumor suppressor genes were 
detected. To extend this search, a data comparison with the supplementary data set of 
the study by Banck et al. [3] was conducted. Again, no relevant additional losses (SNVs 
in all six tumor suppressors investigated) were detected.  
Regarding other Chr18-related genes, three somatic mutations by exome sequencing 
that could be validated by Sanger sequencing were found. One patient carried SNVs in 
the CABYR and NFATC1 genes, whereas a 3-base pair deletion in PIEZO2 was 
present in another patient. The three remaining patients showed no genetic alterations 
in Chr18 genes. NFATC1 becomes activated by calcium flux, resulting in translocation 
from the cytoplasm to the nucleus, where it promotes de novo gene transcription. It 
seems to play a role in various cancer types, e.g. by overexpression and/or promotion 
of tumor angiogenesis [117]. NFATC1 could therefore represent an interesting 
candidate gene for tumor progression of SI-NETs, which is why it was further analyzed 
in a set of 30 SI-NET FFPE samples by Sanger sequencing of all functional gene 
regions (Dr. Laura Stoß). No additional somatic NFATC1 mutations were found in this 
cohort of tumors, suggesting that NFATC1 mutations are not a common event in SI-
NETs. Piezos are large transmembrane proteins conserved among various species. 
PIEZO2 is involved in rapidly adapting mechanically activated currents in 
somatosensory neurons [118]. It is not known, whether PIEZO2 plays a role in tumor 
progression. CABYR, a calcium-binding tyrosine phosphorylation regulated fibrous 
sheath protein, was initially reported to be testis-specific and subsequently shown to be 
present in brain tumors, pancreatic, and lung cancer [119]. CABYR is a CT 
(cancer/testis) antigen widely expressed in diverse cancer cells [120]. 42 carcinoid 
endocrine tumors of the small intestine showed no mutations in CABYR (Cosmic, 
Wellcome Trust Sanger Institute). Mutations (31) and CNVs (1225 entries) in this gene 
seem to be common in different kinds of tumors, e.g. breast, large intestine, lung, and 
pancreas (Cosmic, Wellcome Trust Sanger Institute). 
These results, in line with recent data from Banck et al. [3] and Verdugo et al. [121], 
indicate clearly, that SI-NETs do not harbor recurrent somatic mutations. Data 
comparison with Banck et al. revealed ADCY5 to be the only gene mutated in both data 
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sets. However, only the SNV found in our collective was predicted to be damaging. 
Therefore, mutations of ADCY5 seem to reflect passenger mutations, similar to all other 
mutations detected (including the PML mutations, detected in our tumor samples), with 
no driving impact on SI-NET development in general.  
In summary, the question arises as to how one can explain the effect of the Chr18 loss 
in SI-NETs. One possible mechanism is haploinsufficiency of one of the putative tumor 
suppressors. Of the six putative tumor suppressor genes, it has been shown that 
SMAD4 haploinsufficiency significantly alters TGF-β and BMP (Bone morphogenetic 
protein) signaling, and that a SMAD4 dose-dependent transcriptional regulation of 
target genes of the TGF-β and Wnt signaling pathways in a SMAD4-mutant mouse 
model exists [122]. A second possible mechanism may be explained by the study of 
Solimini et al. They were able to show that pro-proliferative genes (GO genes) are often 
enriched and anti-proliferative genes (STOP genes) are underrepresented by 
hemizygous deletions in malignant tumors [123]. In other words, multiple 
haploinsufficiencies probably contribute to proliferative fitness of cancers. This 
hypothesis may at least in part explain the significance of Chr18 loss in SI-NETs. In 
conclusion, this study on loss of putative tumor suppressor proteins on Chr18 was able 
to show, that DCC is the only tumor suppressor that is lost in 29% of SI-NETs, in 
contrast to retained expression of SMAD2, SMAD4, CABLES (aberrant splicing?), and 
Elongin A3. PMAIP1 is possibly not expressed at all in SI-NETs. This finding should be 
interpreted as a feature of neuroendocrine cells in small intestine in general, rather than 
as a complete loss of these molecules during tumorigenesis. No recurrent Chr18 
alterations could be found by exome sequencing of SI-NETs (in line with data from [2, 3, 
121]), which could identify new potential tumor suppressors. Further studies should 
concentrate on Chr18-related alterations of transcriptome or proteome signatures to 
shed light on more complex events such as potential haploinsufficiencies of tumor 
suppressors or transcriptional/posttranscriptional events such as alternative splicing of 
Chr18 transcripts. Recently, a transcriptome analysis of 33 ileal NETs defined three 
clinical relevant subgroups of tumors [124], but unfortunately differences between 
tumors with and without loss of Chr18 were not part of the analysis and therefore 
remain to be elucidated. 
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Part 2: PI3K/AKT/mTOR-pathway 
In 2013, Banck et al. published the genomic landscape of neuroendocrine tumors of the 
small intestine [3]. Apart from showing that SI-NETs are genetically stable tumors, they 
detected an accumulation of amplifications in the PI3K/AKT/mTOR pathway. 
Amplifications may lead to constant activation of this pathway, resulting in enhanced 
proliferation, cell survival and angiogenesis [66], promoting tumorigenesis. Since 
surgery is the sole curative therapy for SI-NETs and only possible in 20% of patients 
[97], new approaches are strongly needed. A series of FDA approved drugs is available 
for mutated or amplified genes involved in different pro-tumorigenic pathways in a broad 
range of tumor types. However, only few studies focused on GEP-NETs in regard of the 
use of these drugs. 
In 2009, Pitt and colleagues showed that the PI3K inhibitor LY294002 (which binds the 
p110δ catalytic subunit thereby preventing AKT1 phosphorylation), as well as small 
interfering RNA (siRNA) targeting AKT1, lead to suppression of cell growth in the 
pancreatic carcinoid cell line BON-1 [125]. 
Another group did a druggable approach by analyzing different genes/proteins on 
mutational and expression level [126]. They found 35% of SI-NETs to harbor low grade 
EGFR amplifications (aneuploid tumors with >2.47 signals/nucleus), suggesting anti-
EGFR tyrosine kinase inhibitors (TKI) and monoclonal antibodies to be potential drugs 
for GEP-NETs.  
Finally, the RADIANT-4 study showed, that advanced, non-functional neuroendocrine 
tumors of the gastrointestinal tract benefit from everolimus, a potent mTOR inhibitor, in 
regard of prolonged progression-free survival [4]. 
Therefore, the second part of my doctoral thesis focused on the PI3K/AKT/mTOR 
pathway: Six genes, namely PIK3CD, AKT1, AKT2, PDGFRα, PDGFRβ, and mTOR 
were analyzed by FISH. Low level amplifications (partially in combination with increased 
reference chromosome signals) were detectable in 4-14% in primary tumors, 9-27% in 
lymph node metastases, and 8-36% in distant metastases (Figure 16). Statistical 
analysis revealed higher frequencies of CN gains in tumors of advanced, metastatic 
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stage (p=0.028) and more invasive tumors (p=0.014). Additionally, for AKT1 (p=0.005), 
AKT2 (p=0.014), PDGFRα, and PDGFRβ (both p<0.000) significantly higher proportions 
of amplifications were found in the metastases (lymph node and distant metastases 
combined) compared to primary tumors. 
We sometimes observed co-amplification of the centromere signal with the target signal 
by FISH; the CN data from Banck et al. [3] and our SNP array results revealed the 
amplified genes to be included in huge regions which are affected in total by CN gains, 
in contrast to single gene specific amplifications. 
The frequent association of gene specific signals with CN gains of the reference 
chromosomes has already been described for AKT1 and AKT2 in lung carcinomas, 
resulting in mean ratios of 1.29 and 1.66, respectively [63]. The authors reported that 
single AKT amplifications were rare, but that polysomy seems to be a frequent 
deregulation in these tumors. However, they found a significant correlation between 
gene gains and protein overexpression.  
No significant association could be found between gains on DNA level and protein 
expression in our investigation of the PI3K/AKT/mTOR pathway. One possible 
explanation might be that the gains have no impact on single gene level but on 
chromosomal level. As described before, SI-NETs often harbor gains of a number of 
(parts of) chromosomes (e.g. Chr4, 5, 14, and 20). So, amplifications of single genes 
could be passenger effects of gains of whole chromosomes. This hypothesis is 
supported by the fact, that nearly all of the patients with PI3K/AKT/mTOR-amplified 
tumors harbored amplifications in more than one gene. Interestingly, one tumor (I105) 
exhibited loss of one gene specific signal for five out of the six genes, indicating loss of 
Chr1 (mTOR, PIK3CD), Chr4 (PDGFRα), Chr5 (PDGFRβ), and Chr14 (AKT1). AKT2, 
which is located on Chr19, was not affected. This specific rearrangement pattern 
affecting the chromosomes commonly underlying CN gains in SI-NETs, points out, that 
these tumors are driven by alterations on chromosomal level, rather than by gains of 
single genes. However, CN gains of regions in which genes of pro-tumorigenic 
pathways are located, can result in enhanced gene function, although no specific 
amplification exists. This has also been shown for CN gains of HER2 in breast cancer, 
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with normal HER2:Chr17 ratios due to Chr17 polysomy [127]. In a retrospective study it 
could be shown, that polysomy is no counter argument against trastuzumab medication. 
IHC results were of better prognosis for treatment response compared to HER2:Chr17 
ratios [128]. Other reports state that polysomy does not necessarily lead to protein 
overexpression [129]. The authors ask, if the absolute HER2 gene copy number may be 
the best predictor for trastuzumab response, irrespective of underlying polysomy or 
amplification.  
Since no significant association between CN gains and protein expression could be 
found in our cohort of SI-NETs, similar questions should be addressed. The most 
important question is if/why the extra chromosome copies could/should hamper or block 
the effect of the additional gene copies. In metastatic colorectal cancer (mCRC) a 
similar situation occurs concerning EGFR amplifications / co-amplification with Chr7, 
since “true” amplifications – defined as more than 2x EGFR signals compared to the 
CEP7 signals – are rarely seen in these tumors. Nevertheless, the EGFR amplification 
is used as predictive biomarker for response prediction of the therapy with anti-EGFR 
monoclonal antibodies, such as cetuximab, in KRAS wildtype mCRC [130]. More 
retrospective studies on effectiveness of monoclonal antibodies in cancers with gene 
amplification accompanying chromosome polysomy and the dependence of the drug 
impact on protein overexpression could help resolve the question of drug application in 
tumors with this kind of alterations.  
For head and neck squamous cell carcinoma it has been shown, that CN gain or 
amplifications of 3q26, harboring PIK3CA amongst other genes, are early and frequent 
aberrations [131]. This alteration was significantly associated with a lower differentiation 
grade and a higher tumor stage, comparable to our findings regarding CN variations in 
the PI3K/AKT/mTOR pathway and the association with more invasive and advanced, 
metastatic tumors. Suh et al. could even demonstrate, that CN gains of PIK3CA is a 
poor prognostic factor for disease-free survival in liposarcomas, in contrast to PIK3CA 
mutations [132]. 
Others found, that gene amplifications do not necessarily result in protein 
overexpression, suggesting that epigenetic events might play a role in the 
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transcriptional control of amplified genes [133]. Since we observed, that gene gains and 
protein expression were not – partly even inversely – correlated in SI-NETs, such 
mechanisms could play a role here as well. 
All these publications underline the results which were achieved by analyzing genes of 
the PI3K/AKT/mTOR pathway by FISH and protein expression of downstream 
molecules by IHC. CN gains were present in 12-24% of our cohort, revealing slightly 
higher frequencies than the ones detected by the study of Banck et al., and seem to 
define a subgroup of advanced and more invasive tumors of higher UICC-stages. Since 
especially this group is in need of new anti-cancer drugs, it would be interesting to test, 
whether monoclonal antibodies or inhibitors of these targets have an effect on tumor 
dissemination and invasiveness. Although no association between CN gains and overall 
survival could be detected, inhibition of the PI3K/AKT/mTOR pathway could slow down 
tumor cell growth and thereby tumor progression and formation of metastases. The 
usefulness of these findings for future therapeutic interventions remains to be seen. 
The analysis of the PI3K/AKT/mTOR pathway by FISH and IHC has its strength and 
limitations, which are important to have in mind for the interpretation of the results. The 
great sample size achieved by using TMAs for the analysis is an advantage, which 
results in greater power of the statistical evaluation. Therefore, the finding of a 
significant association between accumulation of CN variations and more 
developed/invasive tumor stages is a reliable result. The second strength is the 
thorough investigation of this pathway by analyzing key players by FISH and IHC. We 
therefore could rule out, that the CN gains result in overexpression of the respective 
(downstream) effector proteins. One possible explanation for this finding is, that the 
gene gains were partially accompanied by chromosome polysomy, so that the alteration 
affects not one specific gene, but a greater area on the respective chromosome. 
However, the interaction of different affected genes could give rise to altered protein 
expression not yet detected and subsequent changed signaling cascades. Another 
explanation for the missing translation of gene amplifications into protein 
overexpression might be that epigenetic events regulate the transcription of amplified 
genes.  
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One drawback of the study is the heterogeneity of tumor tissues owing to the usage of 
TMAs. Therefore, the fixation of the biopsies of different tissue blocks can vary greatly, 
so that some samples had to be excluded from the evaluation due to low sample 
quality. One disadvantage lies in the FISH analysis itself, since the evaluation is time-
consuming due to counting the gene specific and the reference chromosome signals 
separately of 30-100 cells per sample. Based on the fact, that a certain observer bias is 
also not dismissed, a second assessor is to be recommended.  
Concluding remarks 
This thesis focused on the genetic alterations in SI-NETs, since up to know only little is 
known about driver mutations giving rise to these tumors.  
We could demonstrate that the common Chr18 loss seems to result in a partial loss of 
the tumor suppressor protein DCC. Another interesting finding regarding Chr18-
associated tumor suppressors, is the fact, that CABLES depicted additional isoforms in 
the western blot analysis of SI-NETs, possibly as a result of aberrant splicing. These 
two candidates will be subject of further investigations in our lab.  
The PI3K/AKT/mTOR pathway is deregulated in 12-24% of our SI-NET samples. 
Although the gene amplifications were not reflected by protein overexpression, the 
alterations defined a subgroup of more advanced and invasive tumors. Since especially 
patients with tumors of these stages are in urgent need of new anti-cancer drugs, 
inhibitors of the PI3K/AKT/mTOR pathway should be tested in functional gastrointestinal 
NETs. 
Another outcome of this study is the possible use of Chr18 loss and CN gains as 
distinct tumor markers for SI-NETs. Unpublished data of our work group suggest the 
usefulness of these variations for distinguishing SI-NETs from appendiceal NETs (a-
NET). A- and SI-NETs are phenotypical similar tumors (sharing the same embryonic 
origin), but whereas SI-NETs show high malignant behavior, manifesting in early lymph 
node and distant metastases, a-NETs are indolent tumors and often found incidentally.  
The 5-year survival rate of a-NETs ranges between 74% and 95% [134, 135]. We 
suggest that the mortality rate of a-NETs might be overrated due to false disease 
coding and imprecise data on causes of death. Usage of Chr18 FISH in combination 
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with analysis of CN gains (by FISH or SNP array) could help to improve the data and 
making a precise diagnosis, since these alterations were not present in our cohort of 15 
a-NETs (unpublished data).  
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VII. Appendix 
 
Table 26: Clinical characteristics  
M: male, f: female, X: not assessable, NA: not available 
Case Site of primary 
tumor 
Age at 
diagnosis 
Sex Cohort T N M UICC Stage MIB-1 Grade PHH3 CEP18 Tissue type 
1 Ileum 70 m 3 3 2 1 IIIB 0.90 1 0.47 1 FFPE 
2 Ileocecal valve 51 f 2 3 1 X IIIB 0.70 1 0.09 1 FFPE 
3 Ileum 50 f 1 3 0 X IIB 0.75 1 0.01 2 FFPE 
4 Ileocecal valve 65 m 2 2 1 X IIIB 0.40 1 0.23 1 FFPE 
5 Ileum 71 m 3 3 1 1 IV 1.01 1 0.19 1 FFPE 
7 Ileum 67 m 2 2 1 X IIIB 0.46 1 0.12 1 FFPE 
8 Ileocecal valve 66 m 2 2 X X IIA 0.54 1 0.11 1 FFPE 
9 Ileocecal valve 77 f 1 3 0 X IIB 0.42 1 0.02 1 FFPE 
10 Ileum 67 m 3 3 2 1 IV 6.13 2 0.17 2 FFPE 
11 Ileum 48 m 2 3 1 X IIIB 0.21 1 0.09 2 FFPE 
13 Ileum 73 m 1 3 0 X IIB 0.59 1 0.00 2 FFPE 
14 Ileocecal valve 63 f 2 3 1 X IIIB 0.98 1 0.20 2 FFPE 
15 Jejunum 75 m 1 3 X X IIB 0.90 1 0.05 1 FFPE 
16 Ileocecal valve 45 f 2 3 1 X IIIB 1.10 1 0.11 2 FFPE 
17 Ileum 53 f 2 2 1 X IIIB 1.89 1 0.12 1 FFPE 
18 Ileum 57 f 2 1 1 X IIIB 0.88 1 0.08 1 FFPE 
19 Ileum 56 f 3 4 1 1 IV 0.37 1 0.59 2 FFPE 
20 Ileum 68 f 2 NA NA NA NA 0.60 1 0.22 1 FFPE 
21 Ileocecal valve 45 m 3 3 2 1 IV 0.24 1 0.06 1 FFPE 
22 Ileum 58 m 1 1 0 X I NA NA NA 1 FFPE 
23 Jejunum 76 f 3 3 0 1 IV 0.60 1 0.21 1 FFPE 
24 Ileum 48 f 2 3 2 X IIIB 1.09 1 0.07 1 FFPE 
25 Jejunum 63 m 2 3 1 X IIIB 1.09 1 0.53 1 FFPE 
26 Ileum 74 f 1 2m 0 X IIA 0.49 1 0.11 2 FFPE 
27 Ileum 77 m 2 3m 1 X IIIB 0.77 1 0.20 2 FFPE 
28 Ileum 44 f 2 3 1 X IIIB 1.30 1 0.06 1 FFPE 
29 Jejunum 86 m 2 4 1 X IIIB 0.78 1 0.16 2 FFPE 
30 Jejunum 66 f 2 3 1 X IIIB 0.63 1 0.14 1 FFPE + cryo 
31 Jejunum 66 m 3 3 0 1 IV 0.90 1 0.07 1 FFPE 
32 Ileum 69 m 2 3 1 X IIIB 1.02 1 0.06 2 FFPE + cryo 
33 Terminal ileum 40 m 2 3 1   IIIB 4.03 2 1.18 1 FFPE 
34 Ileum 46 w 1 1 X X I 2.78 2 0.09 2 FFPE 
38 NA 56 NA 2 NA NA NA NA 0.25 1 0.12 2 FFPE 
39 NA 60 NA 3 NA NA NA NA 0.61 1 0.41 2 FFPE 
48 NA 56 NA 2 NA NA NA NA 3.88 2 0.46 1 FFPE 
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52 Ileum 80 m 3 3 1 X IIIB 1.49 1 0.02 mosaicism FFPE 
53 Terminal ileum 29 f 1 1 0 0 I 1.07 1 0.04 1 FFPE 
54 Jejunum 60 NA 1 3 0 0 IIB 0.30 1 0.00 1 FFPE 
55 Terminal ileum 20 NA 1 3 X X IIB 0.99 1 0.09 1 FFPE 
56 Terminal ileum 46 NA 3 2 1 1 IV 0.21 1 NA 2 FFPE 
57 Ileum 58 NA 1 3 X X IIB 0.49 1 0.11 2 FFPE 
58 Small intestine 69 NA 1 1 x x I 0.82 1 0.00 mosaicism FFPE 
59 Terminal ileum 74 NA 1 1 0 X I 0.36 1 0.13 1 FFPE 
60 Small intestine 64 NA 1 3 X X IIB 1.49 1 0.10 1 FFPE 
61 Terminal ileum 54 NA 2 3 1 X IIIB 1.71 1 0.04 1 FFPE 
62 Terminal ileum 47 NA 1 1 0 X I 0.78 1 0.03 1 FFPE 
63 Small intestine 68 NA 3 3 1 1 IV 0.85 1 0.16 1 FFPE 
64 Ileum 54 NA 1 2m X X IIA 1.34 1 0.06 1 FFPE 
65 Terminal ileum 36 NA 2 2 1 X IIIB 1.60 1 0.11 1 FFPE 
66 Terminal ileum 60 NA 2 2 1 X IIIB 0.68 1 0.09 1 FFPE 
67 Terminal ileum 81 NA 2 2 1 X IIIB 1.69 1 0.48 1 FFPE 
68 Small intestine 62 NA 1 2 0 X IIA 0.42 1 0.05 2 FFPE 
89 Terminal ileum 65 f 2 2 1 X IIIB 0.78 1 0.08 1 FFPE 
91 Terminal ileum 74 m 3 4 1 1 IV 1.08 1 0.03 1 FFPE 
92 Ileum 39 m 1 2 X X IIA 0.58 1 0.09 2 FFPE 
93 Ileocecal valve 71 f 3 3 1 1 IV 1.46 1 0.16 1 FFPE 
96 Small intestine 66 NA 3 2m X 1 IV 3.43 2 0.26 1 FFPE 
97 Terminal ileum 62 NA 2 3 1 X IIIB 0.72 1 0.02 1 FFPE 
98 Ileum 75 NA 2 3 1 X IIIB 2.94 2 0.45 1 FFPE 
99 Terminal ileum 54 f 3 2 1 1 IV 2.68 2 0.16 2 FFPE 
100 Terminal ileum 65 f 2 3 1 X IIIB 0.97 1 0.05 1 FFPE 
101 Terminal ileum 65 m 1 1 X X I 1.36 1 0.08 2 FFPE 
103 Small intestine 84 f 1 4m 0 X IIIA 1.57 1 0.07 1 FFPE 
104 Terminal ileum 53 m 2 2 1 X IIIB 1.32 1 0.45 1 FFPE 
105 Small intestine 73 m 3 4 0 1 IV NA NA 0.37 1 FFPE 
106 Small intestine 38 m 3 3 1 1 IV 7.09 2 0.25 mosaicism FFPE 
107 Terminal ileum 60 f 2 3 1 X IIIB 1.71 1 0.11 1 FFPE 
109 Terminal ileum 49 NA 3 3 1 1 IV 0.27 1 0.30 1 FFPE 
110 Small intestine 87 NA 2 2 1 X IIIB 1.05 1 0.30 2 FFPE 
111 Ileum 73 NA 3 4 1 1 IV 1.26 1 0.44 mosaicism FFPE 
112 Terminal ileum 38 f 2 3 1 X IIIB 1.60 1 0.09 2 FFPE 
113 Terminal ileum 84 NA 2 4 1 X IIIB 0.84 1 0.05 mosaicism FFPE 
115 Ileum 52 NA 2 2 1 X IIIB 0.44 1 0.40 mosaicism FFPE 
116 Ileum 77 f 2 2m 1 X IIIB NA NA 0.10 1 FFPE 
117 Distal ileum 63 NA 3 2 1 1 IV 0.25 1 0.23 1 FFPE 
118 Ileum 56 f 3 4m 1 1 IV 1.19 1 0.80 1 FFPE 
119 Small intestine 77 NA 2 2m 1 X IIIB 0.70 1 0.09 mosaicism FFPE 
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120 Terminal ileum 44 NA 2 2 1 X IIIB 1.62 1 0.49 1 FFPE 
121 Ileum 64 NA 2 3m 1 X IIIB 0.94 1 0.36 1 FFPE 
122 Terminal ileum 70 NA 2 3 1 X IIIB 1.05 1 0.16 1 FFPE 
123 Distal jejunum, 
terminal ileum 
67 NA 3 2 1 1 IV 0.44 1   NA FFPE 
124 Jejunum/ileum 45 f 3 3 1 1 IV 1.85 1 0.00 1 FFPE 
125 Terminal ileum 77 m 2 3 1 X IIIB 0.03 1 1.12 NA FFPE 
126 Small intestine 72 f 2 3 1 X IIIB 0.03 1 0.10 NA FFPE 
127 Small intestine 67 f 2 3 1 X IIIB NA NA NA NA FFPE 
130 Small intestine 70 f 2 3 1 X IIIB 0.00 1 NA NA FFPE 
133 Small intestine 58 m 2 2 1 X IIIB 1.60 1 0.56 mosaicism FFPE 
134 Ileocecal valve 60 f 2 3 1 X IIIB 0.13 1 0.00 NA FFPE 
136 Terminal ileum 67 f 3 3 1 1 IV 0.18 1 0.71 NA FFPE 
137 Small intestine 73 m 3 3 1 1 IV 0.57 1 0.15 NA FFPE 
138 Small intestine 70 f 3 3 1 1 IV 1.95 1 0.54 mosaicism FFPE 
140 Ileum 46 f 2 2 1 X IIIB 1.60 1 0.35 NA FFPE 
141 Ileum 69 m 3 3 1 1 IV NA NA NA NA FFPE 
142 Small intestine 60 m 3 3 1 1 IV 0.34 1 0.00 1 FFPE 
144 Small intestine 28 m NA NA NA NA NA 7.24 2 0.04 NA FFPE 
146 Small intestine 56 m 3 3 1 1 IV 1.28 1 0.09 NA FFPE 
147 Small intestine 59 f NA NA NA NA NA 0.34 1 0.10 1 FFPE 
148 Small intestine 53 m NA NA NA NA NA NA NA NA 1 FFPE 
149 Terminal ileum 67 f 3 3 1 1 IV 0.70 1 0.10 mosaicism FFPE 
152 Ileum 73 f 3 3 1 1 IV 0.90 1 NA 1 FFPE 
153 Small intestine 47 f NA NA NA NA NA 0.08 1 0.01 1 FFPE 
156 Ileum 62 m 3 3 1 1 IV 4.82 2 0.03 1 FFPE 
157 Terminal ileum 45 m 1 1 0 x I 0.00 1 0.08 1 FFPE 
158 Small intestine 52 f 3 3 1 1 IV 1.76 1 0.06 1 FFPE 
160 Small intestine 71 f NA NA NA NA NA NA NA NA NA FFPE 
161 Ileum 42 m 3 3 1 1 IV 1.91 1 2.14 1 FFPE 
162 Small intestine 68 m 3 3 1 1 IV 1.30 1 NA 1 FFPE 
163 Jejunum 68 m 2 3 1 X IIIB 1.26 1 0.31 1 FFPE 
166 Terminal ileum 43 f 3 3 1 1 IV 1.45 1 0.82 1 FFPE 
168 Ileum 40 m 3 3 1 1 IV 0.52 1 1.19 1 FFPE 
169 Terminal ileum 44 m 3 3 1 1 IV 1.10 1 0.10 1 FFPE 
172 Small intestine 70 m 2 2 1 X IIIB 0.43 1 0.08 1 FFPE 
173 Small intestine 65 f NA NA NA NA NA 1.54 1,00 0.15 1 FFPE 
174 Small intestine 52 f NA NA NA NA NA NA NA 1.31 1 FFPE 
176 Small intestine 52 m NA NA NA NA NA 6.91 2,00 0.71 mosaicism FFPE 
177+178 Ileum 67 m 2 3 1 X IIIB 1.30 1 1.31 1 FFPE 
180 Ileum 63 m 3 2 1 1 IV 11.67 2,00 1.11 mosaicism FFPE 
183 Ileum 55 m 2 2 1 X IIIB 2.35 2 0.50 1 FFPE 
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184 Small intestine 56 f 3 3 1 1 IV 1.14 1 0.10 1 FFPE 
186 Ileum 65 m 2 3 1 X IIIB 1.01 1 0.87 1 FFPE 
188 Ileum 70 m 3 3 1 1 IV 10.65 2 0.44 1 FFPE 
189 Ileum 70 f 3 2 1 1 IV 1.79 1,00 0.78 NA FFPE 
190 Ileum 45 f 3 3 1 1 IV 1.79 1 0.78 1 FFPE 
192 Ileum 65 m 3 3 1 1 IV 0.64 1 0.18 mosaicism FFPE 
193 Ileum 43 f 1 2 0 X IIA 0.53 1 0.05 mosaicism FFPE 
194 Ileum 68 f 2 3 1 X IIIB 0.98 1 0.66 mosaicism FFPE 
195 Ileum 58 m 3 3 1 1 IV NA NA NA mosaicism FFPE 
196 Ileum 45 f 2 1 1 X IIIB 2.28 2 0.72 1 FFPE 
197 Terminal ileum 61 f 3 2 1 1 IV 1.00 1 NA mosaicism FFPE 
198 Ileum 50 f 3 3 1 1 IV 1.31 1 0.07 mosaicism FFPE 
199 Small intestine 55 f 1 3 X X I 0.49 1 0.21 mosaicism FFPE 
201 Terminal ileum 72 m 3 3 1 1 IV 1.07 1 0.22 1 FFPE 
202 Small intestine 59 m 3 3 1 1 IV 3.36 2 0.49 1 FFPE 
207 Ileum 87 m 2 3 1 X IIIB 2.39 2 0.27 1 FFPE 
254 Ileum 66 f 1 2m 0 X IIA 0.75 1 0.11 1 FFPE + cryo 
255 Terminal ileum 69 f 2 3 1 X IIIB 3.13 2 0.33 1 FFPE + cryo 
256 Unknown 74 f NA NA NA NA NA 1.27 1 0.21 1 FFPE + cryo 
257 Ileum 52 f 3 2m 1 1 IV 1.97 1 0.33 1 FFPE + cryo 
258 Ileum 26 f 1 3 X X IIB 1.94 1 0.10 1 FFPE + cryo 
259 Ileum 66 m 2 2 1 X IIIB 6.65 2 0.37 mosaicism FFPE + cryo 
260 Ileum 70 f 2 3 1 X IIIB 0.87 1 0.17 1 FFPE + cryo 
Tu1 Met Small intestine NA NA 3 1 1 1 IV NA NA NA 1 Cryo 
Tu3 Ileum 72 f 2 2 2 0 IIIB NA 1 NA mosaicism Cryo 
Tu4 Ileum 72 f 2 3 1 0 IIIB NA 1 NA 1 Cryo 
Tu7 Met Small intestine NA NA 3 4 1 1 IV NA NA NA 1 Cryo 
Tu5 Met Small intestine NA NA 2 3 1 X IIIB NA NA NA 1 Cryo 
BB1 Ileum 71 f 3 3 1 1 IV 1.00 1 NA 1 Cryo 
GR1 Duodenum 52 f 1 1 0 X I 1.00 1 NA 1 Cryo 
GR2 Jejunum 45 m 1 4 0 X I 1.00 1 NA 1 Cryo 
GR3 Duodenum 57 m 1 3 0 X I 1.00 1 NA 1 Cryo 
GR4 Ileum 85 m 2 4 1 X IIIB 1.00 1 NA 1 Cryo 
GR5 Small intestine 78 f 2 4 1 X IIIB 1.00 1 NA 1 Cryo 
MB1 Ileum 45 f 2 3 1 X IIIB NA 1 NA 1 Cryo 
MB2 Ileum 44 f 3 3 1 1 IV NA 1 NA 1 Cryo 
MB3 Ileum 69 m 2 2 1 0 IIIB NA 1 NA 1 Cryo 
MB4 Ileum 64 f 3 3 1 1 IV NA 1 NA 1 Cryo 
MB5 Ileum 47 m 2 2 1 0 IIIB NA 1 NA 1 Cryo 
MB6 Ileum 74 f 3 3 1 1 IV NA 1 NA 1 Cryo 
MB7 Ileum 49 m 3 3 1 1 IV NA 1 NA 1 Cryo 
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Table 27: Expression of immunohistochemical markers  
P: Primary tumor, LN: lymph node metastasis, DM: distant metastasis, neg: negative, pos: positive, NA: not available; 
samples in grey were excluded from further analyses. 
Case P, LN, DM Synaptophysin 
(0-3) 
SSTR2 (0-3) CDX2 (-: neg, (+): 
weak pos, +: pos) 
Serotonin (0-3) 
I001 P 3 3 (+) 3 
I001 LN 3 3 + 3 
I002 P 2 1+ NA 0 
I002 LN 3 2 + 2 
I003 P 3 3 + 1 
I004 P 3 1+ NA 3 
I005 DM 3 0 + 1 
I005 P 2 3 + 2 
I005 LN 3 1+ + 2 
I007 P 3 NA NA 3 
I008 P 1 3 - 3 
I009 P 3 3 + 3 
I010 P 2 1+ NA 1 
I010 LN 2 3 + 2 
I011 P 2 3 + 3 
I013 P 2 3 + 3 
I014 P 3 0 - 2 
I015 P 2 3 + 1 
I016 P 3 2+ + 3 
I016 LN 3 3 + 3 
I017 LN 2 3 + 3 
I017 Normal liver P 0 NA - 0 
I018 P 3 3 + 3 
I018 LN 3 3 + 3 
I019 P 2 0 + 3 
I019 LN 3 2+ + 3 
I020 No tumor LN 0 NA - - 
I020 P 1 3 + 3 
I021 P 2 3 + 3 
I022 P 2 0 + 3 
I023 No tumor P 0 NA - 0 
I024 LN 3 3 + 1 
I024 P 2 3 + 2 
I025 P 2 3 + 3 
I026 P 2 3 + 3 
I027 LN 3 0 + 0 
I027 Normal liver P 0 NA - 0 
I028 P 3 1+ + 3 
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I029 LN 3 3 + 2 
I029 P 3 2+ + 3 
I030 LN 2 0 NA 1 
I030 P 3 3 + 3 
I031 P 2 1+ + 1 
I031 DM 3 3 + 3 
I032 LN 3 0 + 0 
I032 P 3 3 + 3 
I033 P 3 3 + 3 
I034 P 2 3 + 3 
I038 LN 3 1 + 1 
I038 P 2 3 NA 2 
I039 LN 3 1 + 0 
I039 P 1 2+ + 3 
I048 P 2 3 + 0 
I048 LN 3 0 + 1 
I052 P 2 3 + 3 
I053 P 2 3 + 3 
I054 P 1 NA + 0 
I055 P 3 3 + 2 
I056 LN 3 3 + 1 
I056 P 3 2 + 2 
I057 P 2 3 + 3 
I058 P NA 3 + 1 
I059 P 1 3 + 3 
I060 P 2 1 + 3 (focal) 
I061 LN 0 NA + 1 
I061 P 2 3 + 3 
I062 P 2 0 + 1 
I063 LN 3 2 + 2 
I063 DM 3 0 + 2 
I063 P 2 2 + 3 
I064 P 2 3 + 3 
I065 P 1 3 + 3 
I065 LN 2 2+ + 3 
I066 P 2 1 + 3 
I067 P 3 2 + 3 
I068 P 2 3 + 3 
I089 P 0 0 + 2 
I089 LN 3 1+ + 3 
I091 DM 3 0 + 0 
I091 LN 2 1 + 2 
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I091 P 1 1+ + 3 
I092 Detached from 
slide 
P NA NA - 3 
I093 LN 3 3 + 1 
I093 P 3 3 + 3 
I093 DM 3 2+ + 3 
I095 P 2 3 + 1 
I096 P 3 3 + 3 
I097 LN 3 1+ + 2 
I097 P 3 0 + 3 
I098 P 1 3 + 3 
I098 LN 2 0 - 3 
I099 P 1 3 + 3 
I099 LN 1 3 + 3 
I099 DM 1 3 + 3 
I100 P 2 3 + 3 
I100 LN 1 0 - 3 
I101 P 2 3 + 3 
I103 P 2 2 + 3 
I104 LN 0 NA + 0 
I104 P 1 3 + 3 
I105 P 0 0 - 0 
I105 DM 0 0 - 0 
I106 P 3 3 + 3 
I106 DM 3 3 + 3 
I107 LN 2 2+ + 3 
I107 No tumor P 0 NA + 0 
I109 P 2 3 + 3 
I109 LN 2 1+ + 3 
I110 P 2 3 + 1 
I111 P 2 0 + 3 
I112 P 2 1+ NA 0 
I112 LN 2 0 + 2 
I113 P 2 0 + 1 
I113 LN 3 0 + 3 
I115 P 1 0 + 3 
I116 P 0 0 - 0 
I117 P 3 3 + 3 
I117 DM 3 3 + 3 
I118 LN 3 2+ + 1 
I118 P 3 3 + 3 
I119 P 2 3 + 2 
I120 P 2 3 + 3 
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I121 LN 3 3 + 0 
I121 P 3 1+ + 3 
I122 P 1 3 + 3 
I123 LN 2 3 + 1 
I123  P 1 3 + 1 
I124 LN 2 3 + 3 
I124  P 1 0 + 3 
I125 P 1 2+ - 0 
I125 LN 0 0 - 1 
I126 LN 1 1 - 0 
I126 P 1 3 (+) 3 
I127 LN 3 3 + 0 
I130 LN 1 0 - 1 
I130 P 1 0 - 1 
I133 LN 2 3 + 3 
I133 P 3 0 (+) 3 
I134 P 2 0 NA 1 
I136 LN 2 0 NA 0 
I136 P 1 1+ - 3 
I137 LN 1 0 + 3 
I137 P 1 3 + 3 
I138 LN 2 3 + 0 
I138 P 2 3 + 1 
I140 P 2 3 + 3 
I141 LN 1 3 + 3 
I141 P 1 3 + 3 
I142 LN 3 2 + 0 
I142 P 2 3 + 1 
I144 LN 0 0 - 0 
I144 P 0 0 - 0 
I146 LN 2 0 + 0 
I146 P 1 3 + 2 
I147 P 2 0 + 1 
I148 LN 2 3 + 2 
I149 LN 1 NA + 0 
I149 DM 1 0 - 2 
I152 P 2 0 + 2 
I153 P 3 3 - 0 
I153 DM 1 NA + 2 
I156 DM 2 2+ + 3 
I157 P 0 3 + 3 
I158 DM 3 3 NA 0 
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I158 LN 2 1 NA 0 
I158 P 3 3 + 1 
I160 P 3 3 + 3 
I161 P 2 0 + 2 
I161 LN 1 3 (+) 3 
I162 P 3 2+ + 2 
I162 LN 3 2 NA 3 
I163 LN 3 3 + 1 
I163 P 3 3 + 2 
I166 LN 3 NA - - 
I166 P 3 1+ + 3 
I168 LN 3 0 + 0 
I168 P 2 2+ + 1 
I169 P 3 2 + 1 (focal) 
I169 DM 2 2 + 2 
I172 LN NA 0 + 1 
I172 P 2 2 + 1 
I173 LN 3 0 (+) 1 
I173 P 3 1+ + 3 
I174 LN 3 1+ + 0 
I176 LN 3 1+ (+) 1 
I178 P 3 3 + 3 
I178 No tumor LN 0 NA - 0 
I180 P 2 3 + 3 
I180 LN 3 3 + 3 
I183 LN 3 3 + 3 
I183 P 2 3 + 3 
I184 P 1 0 (+) 3 
I186 LN 2 0 + 1 
I186 P 2 0 + 3 
I188 P 3 3 + 3 
I189 P 2 1 + 0 
I189 LN 2 3 + 1 
I190 LN 3 1+ + 2 
I190 P 2 3 + 3 
I192 P 3 0 + 0 
I192 LN 3 1 + 2 
I193 P 3 3 + 3 
I194 P 3 0 + 3 
I195 LN 3 0 + 0 
I195 P 3 3 + 3 
I196 LN 3 3 + 2 
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I196 P 2 3 + 3 
I197 LN 3 1+ + 2 
I198 LN 3 2 + 1 
I198 DM 3 2 + 1 
I198 P 3 3 + 3 
I199 P 2 3 + 3 
I201 P 2 0 + 2 
I202 LN 3 2+ + 3 
I202 P 2 3 + 3 
I207 LN 2 1 + 3 
I207 P 2 3 + 3 
 
Table 28: Quality data of exome sequencing 
A) Mean coverage on target of the five SI-NETs and the corresponding normal tissues, B) Underrepresented bases (coverage 
<10 /<30)  
Tu: tumor, Met: metastasis, N: corresponding normal tissue 
A) Tu1 Met Tu3 Tu4 Tu7 Met Tu5 Met 
Mean coverage on 
target: 
96.17 92.49 87.17 79.93 133.92 
  N1 N3 N4 N7 N1 
Mean coverage on 
target: 
126.81 119.16 129.69 142.97 129.02 
 
B) Tu1 Met Tu3 Tu4 Tu7 Met Tu5 Met 
Underrepresented bases [%] bases [%] bases [%] bases [%] bases [%] 
Cov<10 639522
3 
12.
44 
613814
5 
11.
94 
642205
9 
12.
50 
700623
9 
13.
63 
425223
8 
8.2
7 
Cov<30 138064
02 
26.
86 
136980
51 
26.
65 
144975
42 
28.
21 
156398
55 
30.
43 
973426
8 
18.
94 
  N1 N3 N4 N7 N1 
Underrepresented bases [%] bases [%] bases [%] bases [%] bases [%] 
Cov<10 509667
4 
9.9
2 
532104
4 
10.
35 
505631
9 
9.8
4 
478242
3 
9.3
0 
488369
4 
9.5
0 
Cov<30 114283
00 
22.
24 
119144
43 
23.
18 
111089
16 
21.
61 
102220
34 
19.
89 
111267
32 
21.
65 
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Table 29: Alterations of the five SI-NET samples identified by exome sequencing  
The numbers in parenthesis are alterations without rs-numbers (common SNPs). Ess.: essential 
Sam-
ple 
Total 3‘ 5‘ Down-
stream 
Inter-
genic 
Intro-
nic 
Synonymous 
coding 
Up-
stream 
Within non-
coding gene 
Ess. Splice site / 
Splice site 
1 443 
(315) 
18 
(12) 
13 
(9) 
2 16 (8) 181 
(123) 
52 (36) 7 (5) 22 (15) 6 (4) / 8 (6) 
2 451 
(301) 
19 
(15) 
13 
(5) 
9 (7) 16 (11) 201 
(132) 
49 (35) 12 (7) 25 (9) 1 (-)/ 6 (3) 
3 479 
(315) 
26 
(19) 
6 
(4) 
7 (4) 26 (11) 188 
(131) 
40 (28) 11 (7) 33 (12) - (1) / 12 (8) 
4 510 
(343) 
26 
(19) 
7 
(5) 
4 (3) 28 (14) 209 
(147) 
52 (29) 10 (5) 36 (16) 4 (3) / 12 (8) 
5 321 
(189) 
15 
(9) 
5 
(1) 
11 (8) 34 128 
(77) 
24 (11) 12 (8) 21 (10) 2 (-)/ 14 (13) 
 
Table 30: Counts and ratio of FISH signals in samples with CN alterations  
P: primary tumor, LN: lymph node metastasis, DM: distant metastasis 
A) PIK3CD 
Samples P 
PIK3C
D 
Ratio 
Count 
gene 
signal P 
PIK3CD 
Count 
referen
ce 
signal P 
PIK3CD 
LN 
PIK3CD 
Ratio 
Count 
gene 
signal 
LN 
PIK3CD 
Count 
referen
ce 
signal 
LN 
PIK3CD 
DM 
PIK3CD 
Ratio 
Count 
gene 
signal 
DM 
PIK3CD 
Count 
referen
ce 
signal 
DM 
PIK3CD 
I001       1.25 75 60       
I002                   
I003                   
I004                   
I005 1.16 74 64             
I007                   
I008 1.28 37 29             
I009                   
I010                   
I011                   
I013                   
I014                   
I015                   
I016                   
I017       1.26 43 34       
I018 1.23 69 56             
I019                   
I020                   
I021                   
I024                   
I025                   
I026                   
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I027                   
I028                   
I029       1.38 88 64       
I030                   
I031                   
I033 1.43 83 58             
I034                   
I038                   
I039       1.04 77 74       
I048                   
I052                   
I053                   
I055                   
I056                   
I059                   
I060                   
I061                   
I062                   
I063                   
I064                   
I065                   
I066                   
I068                   
I089                   
I091                   
I093                   
I095                   
I096                   
I097                   
I098                   
I099                   
I100                   
I101                   
I103                   
I104                   
I106             1.44     
I107       1.25           
I109                   
I110                   
I112                   
I113                   
I117                   
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I118       1.25 85 68       
I120                   
I121       1.58 104 66       
I122                   
I123       1.29 81 63       
I124                   
I127                   
I133                   
I138       1.23 81 66       
I141                   
I142 1.20 12 10             
I144                   
I146                   
I147                   
I148                   
I149       1.40 88 63 1.56 103 66 
I152                   
I153 1.44 92 46             
I156                   
I157                   
I158                   
I160                   
I161 1.00 30 30             
I162       1.48 72 63       
I163                   
I166                   
I168 1.16 73 63             
I169                   
I172                   
I173                   
I174       1.63 104 64       
I176                   
I178                   
I180                   
I183                   
I184 1.38 88 64             
I186                   
I188                   
I189                   
I190                   
I192                   
I193                   
150 
 
I194                   
I195                   
I196                   
I197                   
I198                   
I199                   
I201                   
I202 1.36 90 66             
I207 1.26 77 61             
 
B) AKT1 
Samples P AKT1 
Ratio 
Count 
gene 
signal 
P AKT1 
Count 
reference 
signal P 
AKT1 
LN 
AKT1 
Ratio 
Count 
gene 
signal 
LN 
AKT1 
Count 
reference 
signal LN 
AKT1 
DM 
AKT1 
Ratio 
Count 
gene 
signal 
DM 
AKT1 
Count 
reference 
signal 
DM AKT1 
I001                   
I002                   
I003                   
I004                   
I005                   
I007                   
I008 1.57 119 76             
I009                   
I010                   
I011                   
I013                   
I014                   
I015                   
I016 1.25 79 63             
I017                   
I018                   
I019                   
I020 1.39 89 64             
I021                   
I024                   
I025                   
I026                   
I027                   
I028                   
I029                   
I030                   
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I031                   
I033                   
I034                   
I038                   
I039       1.54 106 69       
I048                   
I052 1.29 85 66             
I053                   
I055                   
I056                   
I059                   
I060                   
I061                   
I062                   
I063                   
I064                   
I065                   
I066                   
I068                   
I089                   
I091                   
I093                   
I095                   
I096                   
I097                   
I098                   
I099                   
I100                   
I101                   
I103                   
I104                   
I106 1.24 78 63       1.21 82 68 
I107                   
I109                   
I110                   
I112                   
I113                   
I117             1.22 83 68 
I118       1.19 83 70       
I120                   
I121                   
I122                   
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I123       1.21 76 63       
I124                   
I127                   
I133                   
I138       1.31 109 83       
I141                   
I142                   
I144                   
I146                   
I147                   
I148                   
I149                   
I152                   
I153                   
I156                   
I157                   
I158             1.21 85 70 
I160 1.61 108 67             
I161                   
I162       1.34 95 71       
I163                   
I166                   
I168       1.14 75 66       
I169                   
I172                   
I173                   
I174                   
I176                   
I178                   
I180 1.29 88 68 1.41 103 73       
I183                   
I184                   
I186                   
I188 1.28 88 69             
I189       1.30 87 67       
I190                   
I192 1.05 80 76 1.31 89 68       
I193                   
I194                   
I195 1.37 89 65 1.21 85 70       
I196                   
I197       1.60 88 55       
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I198                   
I199                   
I201                   
I202                   
I207                   
 
 
C) AKT2 
Samples P AKT2 
Ratio 
Count 
gene 
signal 
P AKT2 
Count 
reference 
signal P 
AKT2 
LN 
AKT2 
Ratio 
Count 
gene 
signal 
LN 
AKT2 
Count 
reference 
signal LN 
AKT2 
DM 
AKT2 
Ratio 
Count 
gene 
signal 
DM 
AKT2 
Count 
reference 
signal 
DM AKT2 
I001                   
I002                   
I003 1.11 78 70             
I004                   
I005                   
I007                   
I008 1.26 49 39             
I009                   
I010                   
I011                   
I013                   
I014                   
I015                   
I016                   
I017                   
I018                   
I019                   
I020                   
I021                   
I024                   
I025                   
I026                   
I027                   
I028                   
I029                   
I030                   
I031                   
I033                   
I034                   
I038                   
154 
 
I039                   
I048                   
I052                   
I053                   
I055                   
I056                   
I059                   
I060                   
I061                   
I062                   
I063                   
I064                   
I065                   
I066                   
I068                   
I089                   
I091                   
I093                   
I095                   
I096                   
I097                   
I098                   
I099                   
I100                   
I101                   
I103                   
I104                   
I106 1.08 86 80       1.05 81 77 
I107                   
I109                   
I110                   
I112                   
I113                   
I117                   
I118 1.07 87 81 1.23 70 57       
I120                   
I121                   
I122                   
I123       1.23 70 57       
I124                   
I127                   
I133                   
155 
 
I138       1.14 83 73       
I141                   
I142                   
I144                   
I146                   
I147                   
I148                   
I149                   
I152                   
I153                   
I156                   
I157                   
I158                   
I160                   
I161                   
I162       1.37 89 65       
I163                   
I166                   
I168       1.23 79 64       
I169                   
I172                   
I173                   
I174       1.26 81 64       
I176                   
I178                   
I180                   
I183                   
I184                   
I186                   
I188 1.00 78 78             
I189       1.17 81 69       
I190                   
I192 1.34 39 29 1.11 78 70       
I193                   
I194                   
I195       1.05 67 64       
I196                   
I197                   
I198       1.12 83 74 1.33 96 72 
I199                   
I201                   
I202 1.21 88 73             
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I207                   
 
D) PDGFRα 
Samples P 
PDGF
Rα 
Ratio 
Count 
gene 
signal P 
PDGFR
α 
Count 
referenc
e signal 
P 
PDGFRα 
LN 
PDGFR
α Ratio 
Count 
gene 
signal 
LN 
PDGFR
α 
Count 
referenc
e signal 
LN 
PDGFRα 
DM 
PDGFR
α Ratio 
Count 
gene 
signal 
DM 
PDGFR
α 
Count 
referenc
e signal 
DM 
PDGFRα 
I001       1.15 78 68 1.20 89 74 
I002                   
I003                   
I004                   
I005                   
I007                   
I008                   
I009                   
I010                   
I011                   
I013                   
I014                   
I015                   
I016                   
I017                   
I018                   
I019                   
I020                   
I021                   
I024                   
I025                   
I026                   
I027                   
I028                   
I029                   
I030                   
I031                   
I033                   
I034                   
I038                   
I039                   
I048                   
I052                   
157 
 
I053                   
I055                   
I056                   
I059                   
I060                   
I061                   
I062                   
I063                   
I064                   
I065                   
I066                   
I068                   
I089                   
I091                   
I093                   
I095                   
I096                   
I097                   
I098                   
I099                   
I100                   
I101                   
I103                   
I104                   
I106                   
I107                   
I109                   
I110                   
I112                   
I113                   
I117                   
I118                   
I120                   
I121       1.11 84 76       
I122                   
I123                   
I124                   
I127                   
I133                   
I138       1.29 93 72       
I141                   
I142                   
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I144                   
I146                   
I147                   
I148                   
I149             1.07 88 82 
I152                   
I153                   
I156                   
I157                   
I158             1.06 75 71 
I160                   
I161                   
I162       1.39 100 72       
I163                   
I166                   
I168       1.16 80 69       
I169                   
I172                   
I173                   
I174                   
I176                   
I178                   
I180                   
I183                   
I184                   
I186                   
I188                   
I189                   
I190 1.09 87.00 80 1.03 90 87       
I192       1.07           
I193                   
I194                   
I195 1.10 80.00 73 1.14 89 78       
I196                   
I197                   
I198                   
I199                   
I201                   
I202                   
I207                   
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E) PDGFRβ 
Samples  Count 
signal P 
PDGFRβ 
Count 
signal LN 
PDGFRβ 
Count 
signal DM 
PDGFRβ 
I001   75   
I002       
I003 93     
I004       
I005       
I007       
I008 81     
I009       
I010 79 81   
I011       
I013       
I014 68     
I015 9     
I016       
I017       
I018       
I019       
I020       
I021       
I024       
I025       
I026       
I027       
I028       
I029       
I030       
I031     80 
I033       
I034       
I038       
I039   90   
I048       
I052 84     
I053       
I055       
I056       
I059       
160 
 
I060       
I061       
I062       
I063       
I064       
I065       
I066       
I068       
I089       
I091       
I093       
I095       
I096       
I097 68     
I098       
I099       
I100       
I101       
I103 77     
I104 9     
I106       
I107       
I109       
I110       
I112 73 74   
I113       
I117     78 
I118       
I120       
I121       
I122       
I123       
I124       
I127       
I133   80   
I138 71 91   
I141       
I142 68 70   
I144       
I146   75   
I147       
I148       
161 
 
I149   96 113 
I152       
I153 71     
I156       
I157       
I158   85 90 
I160       
I161       
I162   79   
I163       
I166 79 77   
I168       
I169       
I172 63     
I173 76 82   
I174   73   
I176   82   
I178   9   
I180 80     
I183       
I184       
I186     9 
I188       
I189   69   
I190 79 78   
I192 94 85   
I193       
I194       
I195 66 78   
I196       
I197       
I198     79 
I199       
I201       
I202 84 69   
I207       
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F) mTOR 
Samples P 
mTOR 
Ratio 
Count 
gene 
signal 
P 
mTOR 
Count 
reference 
signal P 
mTOR 
LN 
mTOR 
Ratio 
Count 
gene 
signal 
LN 
mTOR 
Count 
reference 
signal LN 
mTOR 
DM 
mTOR 
Ratio 
Count 
gene 
signal 
DM 
mTOR 
Count 
reference 
signal 
DM 
mTOR 
I001                   
I002                   
I003                   
I004                   
I005 1.22 95 78             
I007                   
I008 1.18 91 77             
I009 1.23 74 60             
I010                   
I011                   
I013 1.31 81 62             
I014 1.27 85 67             
I015                   
I016                   
I017                   
I018                   
I019                   
I020                   
I021                   
I024                   
I025                   
I026                   
I027                   
I028                   
I029 1.08 66 61 1.43 90 63       
I030                   
I031                   
I033                   
I034                   
I038                   
I039                   
I048                   
I052 1.19 86 72             
I053                   
I055                   
I056                   
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I059                   
I060                   
I061                   
I062                   
I063                   
I064                   
I065                   
I066                   
I068                   
I089                   
I091                   
I093                   
I095                   
I096                   
I097                   
I098                   
I099                   
I100       -           
I101                   
I103                   
I104                   
I106 1.19 94 79             
I107                   
I109                   
I110                   
I112                   
I113                   
I117                   
I118 1.36 90 66             
I120                   
I121 1.04 76 73 1.46 99 68       
I122                   
I123                   
I124                   
I127                   
I133                   
I138       1.23 81 66       
I141                   
I142                   
I144                   
I146                   
I147                   
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I148                   
I149             1.39 96 69 
I152                   
I153 1.15 84 73             
I156                   
I157                   
I158                   
I160                   
I161                   
I162       1.19 96 81       
I163                   
I166                   
I168                   
I169                   
I172       -           
I173 1.50 73 64             
I174       1.21 74 61       
I176                   
I178                   
I180                   
I183                   
I184 1.30 86 66             
I186                   
I188                   
I189                   
I190 1.00 60 60             
I192                   
I193                   
I194                   
I195                   
I196                   
I197                   
I198                   
I199                   
I201                   
I202 1.58 89 62             
I207                   
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Table 31: Statistical analysis of the association between gains in the PI3K/AKT/mTOR pathway and subsequent protein expression and activation. 
CN: copy number, P: primary tumor, LN: lymph node metastasis, DM: distant metastasis. 
Protein expression p-mTOR any 0-3 vs. 
4-12 
p-mTOR any 0-6 vs. 
7-12 
p-S6 any 0-3 vs. 4-
12 
p-S6 any 0-6 vs. 7-
12 
p-4E-BP1 any 0-3 
vs. 4-12 
p-4E-BP1 any 0-6 
vs. 7-12 
any 0-3 vs. 4-12 
Gene CN variation               
P AKT1 0.463 0.856 0.602 0.602 0.382 0.28 0.408 
LN AKT1 0.263 0.671 0.271 0.271 0.225 0.581 0.436 
DM AKT1 1 - 0.252 0.252 0.188 0.569 0.279 
any AKT1 0.199 0.908 0.363 0.363 0.489 0.097 0.709 
P AKT2 0.197 0.932 0.735 0.735 0.211 0.814 0.24 
LN AKT2 0.063 0.813 0.565 0.565 0.326 0.708 0.209 
DM AKT2 0.153 - 0.335 0.335 0.585 0.87 0.104 
any AKT2 0.003* 0.261 0.362 0.362 0.794 0.156 0.113 
P PDGFRα 0.253 0.92 0.732 0.732 0.051 0.783 0.434 
LN PDGFRα 0.22 0.754 0.468 0.468 0.32 0.522 0.847 
DM PDGFRα 0.067 - 0.19 0.19 0.028* 0.64 0.166 
any PDGFRα 0.419 0.342 0.129 0.129 0.087 0.765 0.751 
P PDGFRβ 0.605 0.394 0.909 0.909 0.056 0.694 0.223 
LN PDGFRβ 0.491 0.31 0.437 0.437 0.343 0.983 0.682 
DM PDGFRβ 0.928 - 0.803 0.803 0.36 0.439 0.923 
any PDGFRβ 0.446 0.144 0.35 0.35 0.352 0.273 0.19 
P mTOR 0.483 0.602 0.928 0.928 0.413 0.397 0.451 
LN mTOR 0.46 0.876 0.758 0.758 0.648 0.74 0.395 
DM mTOR 0.165 - 0.377 0.377 0.14 0.73 0.64 
any mTOR 0.961 0.889 0.693 0.693 0.953 0.766 0.418 
P PIK3CD 0.841 0.224 0.254 0.254 0.685 0.4 0.349 
LN PIK3CD 0.093 0.645 0.046 0.046 0.593 0.542 0.678 
DM PIK3CD 0.028* - 0.715 0.715 0.715 - 0.4 
any PIK3CD 0.15 0.836 0.793 0.793 0.703 0.114 0.481 
any gain in 0.058 0.965 0.409 0.409 0.036 0.094 0.094 
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pathway (no vs. 
gain) 
any gain in 
pathway (no vs. 1x 
vs multiple) 
0.217 0.149 0.693 0.693 0.075 0.218 0.2 
any gain in 
pathway (no vs. 1x 
vs. 2x vs. 3x+) 
0.089 0.283 0.36 0.36 0.142 0.344 0.285 
any gain in 
pathway (no vs. 1x 
vs. 2x vs. 3x vs. 
4x+) 
0.161 0.432 0.519 0.519 0.227 0.358 0.408 
any gain in 
pathway (no vs. 1x 
vs. 2x vs. 3x vs. 4x 
vs. 5x) 
0.127 0.577 0.609 0.609 0.159 0.497 0.382 
lower vs. higher 
gains (0-2 vs. >3) 
0.128 0.218 0.874 0.874 0.415 0.483 0.439 
 
